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CHAPTER 1
Review of the Literature
1.1

The toxicity of arsenic
Arsenic (As) is a toxic metalloid that displays some of the properties of both

metals and nonmetals. Arsenic has two biologically important oxidation states, As(V)
and As(III). Arsenate is also called arsenic acid (H3AsO4). And arsenite is called
arsenous acid (H3AsO3) or arsenic trioxide (As2O3). Arsenic is widely distributed in the
whole biosphere, which our life is dependent on. Human are exposed to arsenic by
drinking water or eating food contaminated with arsenic. Antimony (Sb) is another toxic
metalloid in the same group as arsenic in the period table. They share similar chemical
properties. Chronic exposure to arsenic is related to skin lesions, neurological effects,
high blood pressure, diabetes mellitus, diseases of the respiratory system,
cardiovascular disease, and cancers typically involving the skin, lung, and bladder
(Rahman et al., 2009).
1.1.1 Ubiquitous existence of arsenic in the environment
Arsenic is widely distributed throughout the earth’s crust at an average
concentration of 2-3 mg/kg; arsenopyrite (FeAsS) is the most abundant arseniccontaining mineral (Cullen and Reimer, 1989; Peters et al., 1996). Natural processes
like weathering of rocks and volcanic emissions, and human activities such as
combustion of fossil fuels, mining, smelting of ores or the application of arsenical
pesticides, herbicides and wood preservatives, are the main sources which contribute to
arsenic contamination in the environment.
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Weathering of rocks leads to mobilization of the soluble oxoanions, arsenite and
arsenate, and these are the dominant forms of arsenic in fresh water and in seawater.
The concentrations of arsenic in fresh water vary between 1 to 100 μg/L or even more.
The concentration of arsenic in the world’s oceans is at ~1-2 μg/L (Francesconi, 2005).
Arsenic in ground water is largely the result of minerals dissolving from weathered rocks
and soils. High concentrations of arsenic in ground water became a problem in recent
years, due to the shortage of usable surface water. The use of deep tubewells for water
supply in the Ganges Delta causes serious arsenic poisoning to large numbers of
people in India (Kim et al., 2002). Arsenic contamination of ground water is prevalent in
many countries throughout the world including India, Bangladesh, Thailand, Taiwan,
and Mainland China.
Anthropomorphic sources include arsenical-containing fungicides, pesticides and
herbicides, insecticides, rodenticides, wood-preservatives, animal feeds, paints, dyes,
and semiconductors. Lead arsenate was used to control the codling moth from the
1800s to the 1940s (when DDT became available). CCA (chromated copper arsenate)
is the best known of the arsenical wood preservatives. The treated wood has a
characteristic greenish tint. This wood has been widely used in decks and play
structures. Arsenic is still being used in lawn and turf herbicides. Products with names
like All-In-One Weed Killer, Crabgrass Killer, and Liquid Edger contain various arsenic
compounds. Conventional poultry farmers often feed chickens roxarsone, one of many
drugs approved by the Food and Drug Administration for the purpose to kill microbes
but actually containing arsenic. Arsenic helps remove impurities during glass making. It
is also used as a colorant in fireworks and a doping material in semiconductor
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manufacturing. In the end, all of these arsenics will end up somewhere, usually in
topsoil and water, where arsenic could be enriched by crops and enters the food chain.
Arsenic will accumulate in crops if the crops are irrigated with arsenic
contaminated water or grown in the soils contaminated by arsenic from herbicide or
insecticide. As one of the most popular crops in the world, rice is of particular concern
(Williams et al., 2005). Flooded soils, in which paddy rice is cultivated, lead to rapid
mobilization of arsenite (As(III)), which becomes available for rice to take up (Xu et al.,
2008). Among the cereals, rice accumulates relatively high proportions of arsenic in its
edible parts. Rice grain contains arsenic that range from 0.08 to 0.20 mg/kg if grown on
non-contaminated soils (Zavala and Duxbury, 2008). It could be as high as 2.0 mg/kg if
rice is grown in contaminated areas (Tripathi et al., 2007).
Arsenic contamination of drinking water is a serious environmental problem
worldwide because of the large number of contaminated sites that have been identified
and the large number of people at risk (Chappell et al., 1997). An estimated 100 million
people in more than 70 countries are at risk of exposure to unacceptable arsenic levels
in either well water or ground water. This has become a major public health issue in the
developing world, primarily Bangladesh and surrounding countries, where many
thousands of individuals are suffering from precancerous arsenic-related disease. In
2001, the US Environmental Protection Agency lowered the Maximum Contaminant
Level (MCL) in drinking water from 50 μg/L to 10 μg/L. The World Health Organization
(WHO) standard is also 10 μg/L. There are many locations in the United States where
groundwater contains arsenic concentrations in excess of the new standard of 10 μg/L
<http://water.usgs.gov/nawqa/trace/arsenic/>.
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As a consequence of its environmental pervasiveness, exposure and health
effects, arsenic ranks first on the United States Government’s Comprehensive
Environmental Response, Compensation, and Liability (Superfund) Act Priority List of
Hazardous Substances. <http://www.atsdr.cdc.gov/cercla/05list.html>
1.1.2 Health effect of arsenic
Humans are exposed to arsenic mainly through either oral or inhalation routes.
Oral exposure occurs via consumption of contaminated water, food and drugs.
Occupational exposure occurs mainly through inhalation via semiconductor and glass
manufacturing, or power generation by the burning of arsenic-contaminated coal (Yager
and Wiencke, 1993). Large dose of arsenic exposure will cause acute toxicity including
gastrointestinal discomfort, vomiting, diarrhea, bloody urine, anuria, shock, convulsions,
coma, and death. The toxicity of arsenic is related to the chemical form and its oxidative
state. Dimethyl arsenate (DMAs(V)) and methylarsenate (MAs(V)) are less toxic, than
As(V). The sequence is as the following, DMAs(V),MAs(V)<As(V)<As(III)<MAs(III)
(Hughes, 2002). General noncarcinogenic symptoms of chronic arsenic poisoning in
humans are weakness, loss of appetite and energy, loss of hair, hoarseness of voice,
loss of weight, and mental disorders (Hindmarsh and McCurdy, 1986). Following
absorption of trivalent or pentavalent arsenic compounds, arsenic is initially
accumulated in the liver, kidney, lung, spleen, aorta, and skin. One of the hallmarks of
chronic toxicity in humans from oral exposure to arsenic are skin lesions, which are
characterized by hyperpigmentation, hyperkeratosis, and hypopigmentation (Cebrian et
al., 1983). In Taiwan, Blackfoot Disease, a peripheral vasoocclusive disease which
leads to gangrene of the extremities, is also observed in individuals chronically exposed
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to arsenic in their drinking water (Tseng, 1977). Other targets include nervous system
(peripheral neuropathy) (Valentine et al., 1982), and vascular system (Wu et al., 1989).
Inorganic arsenic is classified by the International Agency for Research on
Cancer (Higginson and DeVita, 1980) and the U.S. Environmental Protection Agency
(EPA, 1988) as a human carcinogen. Epidemiological studies have revealed an
association between arsenic concentrations in drinking water and increased incidences
of skin cancers (including squamous cell carcinomas and multiple basal cell
carcinomas), as well as cancers of the liver, bladder, respiratory and gastrointestinal
tracts (Chen et al., 1985; Chen et al., 1986; Smith et al., 1992).

In the past few

decades, arsenic exposure has attracted great interest, due to occupational disease of
lung cancer among copper smelter workers, and the connection with increased risk of
skin, lung and bladder cancers.
1.1.3 Medical application of arsenic
Although arsenic is toxic, few things in this world are completely evil. Arsenic
compounds have also been used to treat diseases like trypanosomiasis and
promyelocytic leukemia. Roughly a century ago, arsenic formed the structural
centerpiece of arsphenamine, known as Salvarsan or Compound 606, this molecule
was the first wonder drug: the cure for syphilis. Arsphenamine was soon followed by
neoarsphenamine, which was water-soluble and easier to administer (Sneader, 1985).
These drugs were used for syphilis chemotherapy for forty years, until the advent of
penicillin rendered them obsolete.
In the realm of inorganic arsenic, arsenic trioxide (As2O3), solubilized as the
arsenite salt of an alkali metal, is a prominent medicinal compound. In the 18th century,
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Dr. Thomas Fowler developed a therapeutic agent known as Fowlers solution by
combining arsenic trioxide with potassium bicarbonate (Scheindlin, 2005). Throughout
the 19th century Fowler’s Solution was deemed a useful alternative to quinine for
malaria, and there were also claims of beneficial effects in syphilis and sleeping
sickness. It was also sporadically tried for the treatment of leukemia and found effective
for inducing remission in chronic myelogenous leukemia (CML). In the early 1970s,
some Chinese physicians, analyzing a number of traditional preparations used in
treating cancer, found As2O3 to be a common component of these products. They
proceeded to test the compound in a variety of cancers, and obtained remission rates of
90% in relapsed acute promyelocytic leukemia (APL) (Niu et al., 1999). Recent studies
show that arsenic directly targets to cysteine residues in zinc fingers within PMLRARalpha and PML. Arsenic binding induces PML oligomerization, which increases its
interaction with the small ubiquitin-like protein modifier (SUMO)-conjugating enzyme
UBC9, resulting in enhanced SUMOylation and degradation (Zhang et al., 2010).
Further research on anticancer activity of arsenic is still going on. Preliminary results
have been reported on various diseases such as multiple myeloma (MM), acute
lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (Verstovsek and
Estrov, 2004).
There are also organic arsenic derivatives under development. Organic
phenylarsenic acid (PAA) compounds with potent in vitro activity against human acute
lymphoblastic leukemia cells showed 50% inhibition of cell growth (Liu et al., 2003). Sdimethylarsino-glutathione has been identified as a lead compound among more than
100 derivatives and is currently being developed for clinical use by ZIOPHARM
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Oncology, Inc. A Phase II trial is nearing completion in patients with primary liver cancer
and advanced myeloma, a Phase II trial is ongoing in patients with lymphomas, and a
Phase I oral trial is in progress.
1.1.4 Mechanisms of arsenic toxicity
Arsenic occurs predominantly in inorganic form as arsenate (As(V)) and arsenite
(As(III)). Pentavalent Arsenate is an analogue of phosphate and thus interferes with
essential cellular processes such as oxidative phosphorylation and ATP synthesis. For
example, arsenate reacts in vitro with glucose to form glucose-6-arsenate, which
resembles glucose-6-phosphate, can inhibit hexokinase (Lagunas, 1980). At both the
substrate and mitochondrial level, arsenolysis diminishes in vitro formation of ATP by
the replacement of phosphate with arsenate in the enzymatic reactions. Depletion of
ATP by arsenate has been observed in cellular systems (Gresser, 1981). ATP levels
are reduced in rabbit (Delnomdedieu et al., 1994b) and human erythrocytes (Winski and
Carter, 1998) after in vitro exposure to arsenate.
The toxicity of trivalent arsenite is due to its propensity to bind to sulfhydryl
groups, with consequent detrimental effects on general protein functioning. A main
target is pyruvate dehydrogenase (PDH), which is a multi subunit complex that requires
the cofactor lipoic acid, a dithiol, for enzymatic activity. Arsenite inhibits PDH (Szinicz
and Forth, 1988), perhaps by binding to the lipoic acid moiety. Lipoate is needed in the
formation of acetyl-CoA from pyruvate and in the formation of succinyl-CoA from alphaketoglutarate. Therefore, arsenic blocks the Krebs Cycle and interrupts oxidative
phosphorylation, resulting in a marked depletion of cellular ATP and eventually death of
the metabolizing cell. Other targets include numerous other cellular enzymes, which are
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involved in cellular glucose uptake, gluconeogenesis, fatty acid oxidation and production
of glutathione. The binding of arsenite to the critical sulfhydryl groups in these enzymes,
interferes the normal protein function and lead to toxicity.
Reactive oxygen species can be induced by arsenite that can eventually alter the
redox status of the cell and present a stressful and toxic situation and induce large
deletion mutations in hamster-human hybrid cells (Hei et al., 1998). Many mechanism of
arsenic carcinogenicity have been proposed, including genotoxicity, cell proliferation,
altered DNA repair and DNA methylated oxidative stress, co-carcinogenesis, and tumor
promotion (Hughes, 2002). DMAs has the potential to promote rat urinary bladder
carcinogenesis and one of the mechanisms involved is its stimulation of cell proliferation
in the urinary bladder epithelium (Wanibuchi et al., 1996). A significant dose-dependent
decrease in activity of a DNA repair enzyme, poly-(ADP-ribose)polymerase by arsenite
was observed (Yager and Wiencke, 1997).
1.2

Arsenic detoxification
In response to the ubiquity of arsenic in the environment and to counteract the

deleterious effects of arsenic, nearly every organism, from E. coli to human, evolved
resistance strategies, including arsenite oxidation or methylation into less toxic species,
as well as active extrusion of arsenite from the cell (Rosen, 2002).
1.2.1 Arsenic uptake systems
In solution at neutral pH, arsenic acid exists as the arsenate oxyanion. Since
arsenate is very similar with phosphate, the phosphate transporters are usually hijacked
to catalyze the arsenate uptake. In the prokaryote E. coli, there are two phosphate
transporters, Pit and Pst (Rosenberg et al., 1977). Both catalyze arsenate uptake, but
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the Pit system appears to be the predominant system for arsenate (Willsky and Malamy,
1980). Similarly, in the eukaryote Saccharomyces cerevisiae several phosphate
transporters, such as PHO84 (Bun-Ya et al., 1992), PHO86 and PHO87 (Bun-ya et al.,
1996), participate in arsenate uptake. Specific arsenate transporters have been
identified in plant that are believed to mediate a large part of the observed arsenate
influx and these include the A. thaliana Pht1;1 and 1;4 high and medium affinity
phosphate uptake systems (Shin et al., 2004). Human AQP9 expressed in Xenopus
laevis oocytes increased the uptake of MAs(V) and DMAs(V), two major pentavalent
arsenic cellular metabolites (McDermott et al., 2010).
The pKa of arsenous acid is 9.2. At neutral pH, it is present in solution primarily
as neutral As(OH) 3 (Ramirez-Solis et al., 2004), which might be considered an inorganic
equivalent of glycerol. Recently, arsenite uptake was found through aquaglyceroporins
in bacteria, yeast and mammalian cells. A screen of a random mutagenesis E. coli
library turned up that mutation in GlpF leads to resistance to Sb(III) (Sanders et al.,
1997). The chemical properties of Sb(III) and As(III) are very close, and, even though
the mutant did not exhibit increased arsenite resistance, GlpF was shown to increase
As(III) uptake if it is overexpressed in E. coli (Meng et al., 2004). S. cerevisiae cells with
FPS1 gene deleted are more sensitive to arsenite, indicating that the glycerol channel
Fps1p mediates uptake of arsenite and antimonite (Wysocki et al., 2001). Xenopus
laevis oocytes microinjected with either mouse AQP7 or rat AQP9 cRNA exhibited
increased transport of As(III), which suggests that AQP9 and AQP7 may be major
routes of arsenite uptake into mammalian cells (Liu et al., 2002). The ability of the four
known human members of the aquaglyceroporin family, hAQP3, hAQP7, hAQP9, and
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hAQP10, to facilitate As(OH)3 movement in Xenopus oocytes was also examined. The
order of effectiveness as an As(III) transporter was found to be hAQP9 > hAQP7, with
little or no transport by hAQP3 or hAQP10 (Liu et al., 2004b). AQP9 was also shown to
be able to transport MAs(III) (Liu et al., 2006b). In S. cerevisiae cells, hexose
permeases are found to be involved in arsenite uptake (Liu et al., 2004a). Human and
rat GLUT1 catalyzed uptake of both As(OH)3 and CH3As(OH)2 in oocytes (Liu et al.,
2006a). Plants take up arsenite significantly if they are grown in reducing environments
such as paddy-grown rice and aquatic species. It was hypothesized that plants also
take up arsenite through aquaporins (Meharg and Jardine, 2003), although the
molecular identity of the proteins that participate in uptake, efflux, compartmentation
and long-distance transport of As(III) is largely unknown. Heterologous expression of
NIPs, a subfamily of plant aquaporins, in yeast, confirmed the arsenite transport
capacity of AtNIP7;1 and OsNIP2;1, but in addition showed that all group II NIPs are
capable of arsenite transport (Bienert et al., 2008).
1.2.2 Arsenic metabolism
After arsenic is taken up into the cells, usually it is metabolized intentionally or
adventitiously by reduction, oxidative methylation and glutathione conjugation, and then
it is pumped out of the cell or sequestered in intracellular organelles.
When the pentavalent oxyanion arsenate is taken up, it is reduced to As(III) prior
to extrusion or sequestration. Three independently evolved families of arsenate
reductase enzymes have been recognized (Mukhopadhyay et al., 2002). The product of
arsC, the last gene of the ars operon of E. coli plasmid R773 is an arsenate reductase,
which belongs to the first family. R773 ArsC uses glutaredoxin as the reducing agent
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and only has one cysteine residue participating in the reaction. The crystal structure of
the 16-kDa R773 ArsC has been reported with bound substrate (arsenate) and product
(arsenite) (Martin et al., 2001). A second family of arsenate reductases also widely
distributed in bacteria is represented by the arsC gene product of Staphylococcus
aureus plasmid pI258 (Ji and Silver, 1992). The pI258 enzyme uses thioredoxin as the
source of reducing potential (Ji et al., 1994) and has two intramolecular cysteine
residues that participate in the catalytic cycle (Messens et al., 1999). The crystal
structure of the pI258 ArsC has been solved and this enzyme is related to low
molecular-weight protein tyrosine phosphatases and exhibits low-level phosphatase
activity (Zegers et al., 2001). The third family of arsenate reductases is related to the
superfamily of protein phosphatases that includes CDC25a, a cell cycle phosphatase.
Yeast Acr2p and Leishmania LmACR2 both belong to this family. Acr2p has a single
active site cysteine residue and uses glutaredoxin and glutathione as reductants
(Mukhopadhyay et al., 2000). LmACR2 is a bifunctional protein with both protein
tyrosine phosphatase activity and pentavalent antimony reduction activity. It’s proposed
that the physiological function of LmACR2 is to dephosphorylate phosphotyrosine
residues in leishmanial proteins but not to reduce the pentavalent antimony for
detoxification (Zhou et al., 2006). Specific arsenate reductases have been identified in
many plant species including Arabidopsis (Dhankher et al., 2006), P. vittata (Ellis et al.,
2006), and rice (Duan et al., 2007). Many plant arsenate reductases are also
bifunctional and show tyrosine phosphatase activity. They are homologous to the
human cell-cycle dual-specificity phosphatase CDC25.
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Metabolic conversion of inorganic arsenic into methylated products is a multistep
process that yields mono-, di-, and trimethylated arsenicals. The methylation is
proposed to occur by a series of reductions of pentavalent to trivalent arsenicals
coupled to oxidative methylations (Challenger, 1945). In recent years, it has become
apparent that formation of methylated metabolites of inorganic arsenic is not necessarily
a detoxification process, since intermediates and products formed in this pathway may
be more reactive and toxic than inorganic arsenic. Toxicity of the arsenic metabolites is
DMAs(III),MAs(III)>As(III)>As(V)>DMAs(V),MAs(V)>TMAsO (Akter et al., 2005). But the
final major pentavalent products, DMAs(V) and TMAsO are approximately a hundredfold and a thousand-fold less toxic than As(III), respectively (Hirano et al., 2004).
Arsenic methylation by fungi and other eukaryotes has been well documented (Bentley
and Chasteen, 2002) . In rat liver, a novel SAM-dependent pathway has been
discovered that involves a 42-kDa methyltransferase (designated cyt19) linked to
thioredoxin-thioredoxin reductase system (Thomas et al., 2004; Zakharyan et al., 1995).
Only recently its homolog, ArsM, has been identified in 125 bacteria and 16 archaea,
and was characterized in Rhodopseudomonas palustris. ArsM not only conferred
arsenic resistance, but also generates trimethyl arsine gas (TMAs(III)). Reduced
glutathione was used as the electron donor (Qin et al., 2006). Cyanidioschyzon sp.
isolate 5508 oxidized As(III) to As(V), reduced As(V) to As(III), and methylated As(III) to
form TMAsO and DMAs(V). Two arsenic methyltransferase genes, CmarsM7 and
CmarsM8, were cloned from this organism and demonstrated to confer resistance to
As(III) in an arsenite hypersensitive strain of Escherichia coli. The two recombinant
CmArsMs were purified and shown to transform As(III) into MAs(V), DMAs(V), TMAsO,
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and TMAs(III) gas, with an optimum temperature around 60-700C (Qin et al., 2009).
Since ArsM homologues are widespread in nature, arsenic methylation by microbes is
proposed to have an important impact on the global arsenic cycle.
1.2.3 Extrusion systems
There are two basic mechanisms of arsenite extrusion. One is carrier-mediated
efflux via an arsenite carrier protein, and the other by an arsenite-translocating ATPase
(Dey and Rosen, 1995). The most common mechanism of arsenite resistance is efflux
from cells catalyzed by members of two different and unrelated families of permeases,
ArsB and Acr3.
Majority of bacteria use ArsB, which is found in most ars operons, to extrude
arsenite. By itself, ArsB is a secondary efflux protein coupled to the protonmotive force
and confers a moderate level of arsenite resistance (Kuroda et al., 1997). ArsB
transports As(III) but has higher affinity for Sb(III). ArsB is an antiporter that catalyzes
the exchange of trivalent metalloid for protons, coupling arsenite efflux to the
electrochemical proton gradient (Meng et al., 2004). When ArsA is co-expressed with
ArsB, an ArsAB complex is formed that is obligatorily coupled to ATP. ArsB associates
with the ArsA ATPase to form a pump that confers high level resistance. ArsB is unique
in that it exhibits a dual mode of energy coupling depending on the subunit composition
(Dey and Rosen, 1995). Some bacteria have three-gene arsRBC operons and extrude
arsenite by ArsB alone, while others have five-gene arsRDABC operons and use the
ArsAB pump (Rosen, 1999). It has been proposed that the five-gene operons arose by
insertion of the arsDA genes into a three-gene operon (Rosen, 1999, 2002). Recently,
ArsD was shown to be an arsenic chaperone. ArsD sequesters the free arsenite in the
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cell cytosol, delivers it to the ArsAB pump for extrusion thus confers higher resistance to
arsenite than ArsAB pump alone (Lin et al., 2006).
The Acr3 family includes members found in bacteria, archaea and fungi.
Unfortunately, many members of the Acr3 family have been given the name ArsB even
though they exhibit almost no sequence similarity to ArsB. The first identified member is
from in the SKIN element of B. subtilis (Sato and Kobayashi, 1998). S. cerevisiae Acr3p
confers arsenite resistance (Ghosh et al., 1999; Wysocki et al., 1997). Yeast Acr3p
favors As(III) as substrate rather than Sb(III). C. glutamicum ATCC 13032 has been
shown to have three genes for Acr3 homologues, each of which contribute to the high
level of arsenite resistance in this organism (Ordonez et al., 2005). Expression of C.
glutamicum or Alkaliphilus metalliredigens acr3 genes in an arsenite-hypersensitive
strain of E. coli in which all ars genes were deleted confers resistance to As(III). This
heterologously expressed Acr3 catalyzes efflux of arsenite from E. coli.

It exhibits

significant differences from R773 ArsB. While ArsB exchanges As(III) with protons,
Acr3 does not, but how it is coupled to the proton-motive force is unknown at this point.
Like the yeast Acr3p, the C. glutamicum Acr3 is also more specific for As(III) than Sb(III),
in contrast to ArsB, which has higher affinity for Sb(III) than As(III) (Fu et al., 2009).
In eukaryotic cells, arsenite resistance is mainly conferred by members of the
MRP (multidrug resistance-associated protein) group of the ABC superfamily of
transport ATPases (Cole et al., 1994; Deeley et al., 2006), which physiologically
catalyze export of GS-conjugates such as leukotriene C4 (LTC4) (Leier et al., 1994).
MRP1-catalyzed export of glutathione from cells was increased by arsenite, suggesting
that MRP1 functions as an As(GS)3 carrier (Zaman et al., 1995). In the liver MRP2
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extrudes arsenic glutathione complexes into bile and may be a major route of arsenic
detoxification in humans (Kala et al., 2000). PgpA, another MRP homolog, was also
demonstrated to transports As(GS)3 in Leishmania (Legare et al., 2001). In S.
cerevisiae, an MRP homolog, Ycf1p, has been shown to transport As(GS)3 into the
vacuole and confers arsenite resistance in yeast (Ghosh et al., 1999).
1.3

ArsA and ArsD from E. coli R773 plasmid
In bacteria, the genes for arsenic detoxification are usually encoded by arsenic

resistance (ars) operons. Nearly every sequenced bacterial genome contains an ars
operon. Many ars operons have only three genes, arsRBC, where ArsR is an As(III)responsive transcriptional repressor, ArsB is a As(OH)3/H+ antiporter that extrudes
As(III), conferring resistance (Meng et al., 2004), and ArsC is an arsenate reductase
that converts As(V) to As(III), the substrate of ArsB, hence extending the range of
resistance to include As(V) (Mukhopadhyay and Rosen, 2002). Some ars operons have
two additional genes, arsD and arsA, such as the arsRDABC operon in E. coli plasmid
R773, and cells expressing the arsRDABC operon are more resistant to As(V) and
As(III) than those expressing arsRBC operons because ArsA forms a complex with
ArsB that catalyzes ATP-driven As(III)/Sb(III) efflux. While ArsD exhibits weak repressor
activity (Chen and Rosen, 1997; Wu and Rosen, 1993), its primary function has recently
been shown to be as an arsenic metallochaperone that delivers As(III) to the ArsA
ATPase (Lin et al., 2006). Interaction with ArsD increases the affinity of ArsA for As(III),
producing increased efflux and resistance at environmental concentrations of arsenic.
1.3.1 Co-existence of ArsA and ArsD in ars operons
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Nearly every sequenced bacterial genome contains an ars operon. Although the
majority is three-gene arsRBC operons, to date, there are more than fifty bacterial and
archaeal arsenic resistance operons and gene clusters that contain arsA and arsD
genes. It is striking that arsA and arsD genes are always found together in ars operons.
The order of the genes in those operons may differ from each other, but the arsD gene
nearly always precedes an arsA gene. The linkage of these two genes suggests first,
that ArsD and ArsA co-evolved before their association with ArsB, second that the
arsDA genes moved laterally into an ars operon as a unit and third, that ArsD has a
biochemical function related to ArsA in arsenic detoxification.
1.3.2 ArsA ATPase
The 583-residue ArsA ATPase is a member of a family of ATPases that probably
arose from GTPases (Leipe et al., 2002). It is normally bound to ArsB (Dey et al., 1994),
but, in the absence of ArsB, ArsA is found in the cytosol and can be purified as a
soluble protein. ArsA has two halves, A1 and A2, that are connected by a 25-residue
linker (Li and Rosen, 2000). The crystal structure of the enzyme has been determined
(Zhou et al., 2000).Three types of domains can be resolved. First, there are two
nucleotide-binding domains (NBDs). The NBDs are folded structures that both contain
residues from both A1 and A2. A metalloid binding domain (MBD) that binds three
As(III) or Sb(III) is located about 20 Å from the NBDs. This is an allosteric site at the
opposite end of the protein from the NBDs (Figure 1-1). Of the three Sb(III), one is
connected to Cys113 and Cys422 (MBS1), a second to Cys172 and His453 (MBS2),
and the third to His148 and Ser420 (MBS3) (Zhou et al., 2000). Each metalloid is bound
by two ArsA residues. The highest affinity site is composed of Cys-113 and Cys-422
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(Ruan et al., 2006), and a third cysteine, Cys-172, can participate in high affinity binding
(Ruan et al., 2008). Binding of As(III) or Sb(III) brings the two halves of ArsA together,
activating ATP hydrolysis. Connecting the single MBD to the two NBDs are two
signature

sequences

that

serve

as

signal

transduction

domains

(STDs),

D142TAPTGH148TIRLL in A1 (STD1) and D447TAPTGH453TLLLL in A2 (STD2), that
corresponds to the Switch II region of many other nucleotide binding proteins and have
been proposed to be involved in transmission of the energy of ATP hydrolysis to
metalloid transport (Zhou and Rosen, 1997). In the ArsA structure these sequences are
seen as extended stretches of residues physically linking the NBDs through Asp142 and
Asp447 at the N-terminal end to the MBD through His148 and His453. Asp142 and
Asp447 are Mg2+ ligands in NBD1 and NBD2, respectively, and His148 and His453 are
Sb(III) ligands in the MBD (Zhou et al., 2000). This physical connection between the
domains allows ATP hydrolysis at the NBDs to alter the affinity for As(III), and,
reciprocally, allows metalloid binding at the MBD to alter the affinity for and rate of
hydrolysis of ATP.
Specific spectroscopic probes, single tryptophan residues, were introduced into
strategic locations in ArsA. The fluorescent properties of these tryptophan residues
change in response to nucleotide binding, hydrolysis and/or conformational changes in
domains. The intrinsic fluorescence of Trp159 has allowed real time monitoring of the
conformation of ArsA during the individual steps of the catalytic cycle and has allowed
modeling of the reaction cycle (Walmsley et al., 1999, 2001). The results suggest that
the rate-limiting step in the overall reaction in the absence of metalloid activation is the
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isomerization of a longlived conformation of the enzyme, and that binding of metalloid
overcomes this rate-limiting step, increasing the rate of hydrolysis.
In the crystal structure NBD1 is occluded and has ADP bound. NBD2 is more
open, and ATP can be exchanged into the site (Zhou et al., 2000). This gives the
appearance of an alternation of sites, and alternating site mechanisms are found in
other transport ATPases. There is good evidence to suggest non-equivalence of the two
sites. NBD1 hydrolyzes ATP in the absence of activation while NBD2 does not (Kaur,
1999). For this reason, basal hydrolysis has been termed unisite catalysis. In the
presence of metalloid, both sites hydrolyze ATP and participate in multisite catalysis.
Two single tryptophan residues, Trp141 and Trp446, had been used to study either
NBD1 or NBD2. Trp141 is adjacent to NBD1 and to the N-terminal Asp142 of the A1
signature sequences. Trp446 is in the equivalent position in NBD2, next to Asp447 of
the A2 signature sequence. The fluorescent properties of these two mutants allow
measurement of the rate of hydrolysis in each site singly. The fluorescent properties of
Trp141 clearly show that NBD1 hydrolyzes ATP during unisite catalysis (Zhou and
Rosen, 1997). In contrast, Trp446 fluorescence indicates that NBD2 is catalytically
inactive until metalloid is bound, that is, only under multisite conditions (Zhou et al.,
2002). Although the two NBDs are not equivalent in all respects, the existing data
cannot yet distinguish between different functions for the two or alternating sites
catalysis.
1.3.3 Evidence for physical interaction between ArsD and ArsA
Yeast two-hybrid analysis demonstrates that ArsD and ArsA physically and
specifically interact (Lin et al., 2006). Among the four soluble proteins encoded by the

19

R773 arsRDABC operon, ArsA was found to interact with ArsD but not with the ArsR
repressor or the ArsC arsenate reductase; ArsD interacted with ArsA and with itself,
which would be expected since ArsD is a homodimer (Chen and Rosen, 1997), but not
with ArsR or ArsC; ArsR, which is a homodimer, also interacts with itself, but not with
the other proteins. Since there is no arsenic or antimony in yeast cells, ArsD and ArsA
must interact in the absence of metalloid. However, when Cys12, Cys13 or Cys18, the
residues in ArsD that form the metalloid binding site (described in more detail below),
were mutated to serines, the serine-substituted ArsD mutants neither activate ArsA
ATPase activity nor bind Sb(III) in this mutated site (Y.F. Lin and B.P. Rosen,
unpublished), consistent with the idea that it is the metalloid-bound form of ArsD that
activates ArsA. These data suggest that ArsD interacts with ArsA with high affinity when
metalloid is bound but with low affinity in the absence of metalloid such as in the yeast
cytosol in the two-hybrid assays.
Direct physical interaction between ArsD and ArsA was observed by chemical
crosslinking with dibromobimane (dBBr), a fluorogenic, homobifunctional thiol-specific
crosslinking reagent that becomes highly fluorescent when its two alkylating groups
react with cysteine residues within 3 to 6 Å of each other (Kosower et al., 1980). When
the mixture of ArsD and ArsA was reacted with dBBr, a crosslinked species was
detected that reacted with both anti-ArsA and anti-ArsD antibodies. MgATP is required
for the formation of ArsD-ArsA crosslinked product. These results suggest first that ArsD
and ArsA interact at their cysteine-rich metalloid binding sites and second that ArsD
interacts with nucleotide-bound form of ArsA.
1.3.4 Cell biology of ArsD function
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That arsD and arsA genes are nearly always found together in ars operons
implies co-evolution for a common function, most likely arsenic detoxification. Cells coexpressing arsDAB were more resistant to high concentrations of As(III) compared to
cells expressing only arsAB, consistent with interaction of ArsD with ArsA increasing the
efficiency of the ArsAB pump (Lin et al., 2006). The concentration of arsenic in such
growth experiments is usually in the millimolar range, which might be found in a volcanic
area such as Yellowstone National Park, but such concentrations are much greater than
would be found under most environmental conditions. To examine whether the
presence of a functional arsD gene conferred an growth advantage to cells at lower
levels of arsenic, two batches of cells of an E. coli strain in which the chromosomal ars
operon had been deleted were mixed together and grown at equal amount in the
presence of 10 μM sodium arsenite, a concentration present in many deep tube wells in
Bangladesh. One batch of cells had a plasmid with only the arsAB genes, and the other
had the arsDAB genes. After a little more than a week, the cells with arsDAB had
largely replaced those with only arsAB, demonstrating that ArsD provides a competitive
advantage for growth in soil or water with moderate amounts of arsenic contamination.
Examination of As(III) accumulation in intact cells revealed that ArsD enhances
the ability of the pump to extrude As(III) and reduces the intracellular arsenic
concentration to subtoxic levels. Cells expressing only arsB were able to lower the
intracellular level of As(III) compared to a strain with no ars, reflecting the ability of ArsB
to catalyze As(OH)3/H+ exchange (Meng et al., 2004). When arsA and arsB were coexpressed, the cells have more efficient As(III) extrusion than with arsB alone (Dey and
Rosen, 1995). When arsD was co-expressed with arsAB, the cells exhibited a further
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reduction in As(III) accumulation (Lin et al., 2006). These lines of evidence support the
idea that ArsD increases the efficiency of the ArsAB pump. The competitive advantage
provided by direct interaction of ArsD with ArsA provides a driving force for the coevolution of the two genes.
1.3.5 Biochemistry of ArsD function
The hallmark of metallochaperones is delivery of metal ions directly to target
proteins (Rosenzweig, 2002). The ability of ArsD to transfer Sb(III) to ArsA was shown
by mixing Sb(III)-loaded ArsD with ArsA, separating the two proteins and determining
how much Sb(III) was bound to ArsA. In the presence (but not the absence) of
magnesium and a nucleotide, ArsA was able to extract Sb(III) from ArsD.
Metalloid transfer studies of the transfer of As(III) or Sb(III) from ArsD to ArsA are
consistent with a mechanism in which this metallochaperone accelerates the rate of
transfer to its partner. However, for ArsD and ArsA, this transfer process is
thermodynamically unfavorable because ArsD has higher affinity for metalloid than does
ArsA. However, if the metalloid bound to the ArsAB pump is pumped out of the cell,
mass action will provide the directionality of the reaction. This suggests that ArsD might
not only serve a role in protecting the cell from free metalloid but also in loading ArsA for
metalloid extrusion. Indeed, because ArsD has higher affinity for metalloid than ArsA, it
can ‘scavenge’ the cytosol for free metalloid for delivery to ArsA, allowing the ArsAB
pump to confer resistance at significantly lower concentrations of As(III). The Km of
ArsB as a secondary carrier is 0.14 mM (Kuroda et al., 1997), but natural waters range
in concentration of total inorganic arsenic from 7 nM to 70 µM, and concentrations of
arsenic in drinking water in worst arsenic-contaminated wells in West Bengal and
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Bangladesh are approximately 40 µM (Smedley and Kinniburgh, 2002). By lowering the
concentration of substrate at which the pump functions efficiently, ArsD and ArsA
provide cells with a mechanism to respond to environmental concentrations of metalloid.
ArsD not only delivers metalloids to ArsA but also enhances its ATPase activity
at low metalloid concentrations. In the presence of ArsD, the apparent affinity of ArsA
for As(III) is largely increased but the Vmax remains unchanged in ATPase reactions (Lin
et al., 2006). ArsD makes the enzyme more effective at low concentrations of metalloid,
a property expected for a metallochaperone. As(III) or Sb(III) activates the ATPase
activity of ArsA, so that the increase in affinity of ArsA for metalloids in the presence of
ArsD can simply be attributed to the higher affinity of ArsD in the ArsD-ArsA complex,
that is, ArsD allows for activation of ArsA ATPase at lower metalloid concentrations.
This explains how cells expressing arsDAB can rapidly replace cells expressing only
arsAB at a subtoxic concentration of As(III).
In summary, the increase in ArsA efficiency resulting from interaction with ArsD
leads in vitro to augmented activity of the ArsAB extrusion pump, to greater resistance
in organisms with the arsDAB genes, and finally to increased fitness for growth in the
low but ubiquitous levels of environmental arsenic.
1.3.6 Metalloid binding sites in ArsD
R773 ArsD has three vicinal cysteine pairs, Cys12-Cys13, Cys112-Cys113 and
Cys119-Cys120. Alignment of the primary sequence of homologues of R733 ArsD
indicates that the cysteine pair Cys12-Cys13 and a single additional cysteine, Cys18
are conserved in homologues. Two other cysteine pairs, Cys112-Cys113 and Cys119Cys120, are found in some homologues but not others. A series of cysteine mutants

23

and truncations of ArsD were constructed, purified and studied for the metalloid binding
(Lin et al., 2007a). Mutants or truncations with only a single vicinal cysteine pair can still
bind to a phenylarsine oxide affinity column, which indicates indirectly that each
cysteine pair can form an independent metalloid binding site (Li et al., 2001). In more
recent experiments, binding of Sb(III) was measured directly (Lin et al., 2007a). Wildtype R773 ArsD binds three Sb(III) per monomer. If two of the three cysteine pairs were
changed to alanine or serine residues, or if the C-terminal vicinal pairs were removed by
construction of truncated versions, variants with only a single vicinal pair were found to
bind one Sb(III) per monomer, showing directly that each cysteine pair forms an
independent metalloid binding site. If the conserved cysteine Cys18 was mutated, the
mutant with the only first cysteine pair, Cys12-Cys13, was unable to bind Sb(III). This
suggests that the cysteine pair Cys12-Cys13 and Cys18 form a 3-coordinate thiolate
metalloid binding site, which has been termed MBS1. The metalloid binding sites
formed by cysteine pairs Cys112-Cys113 and Cys119-Cys120 are designated MBS2
and MBS3, respectively. All three binding sites have similar affinity to Sb(III),
approximately 1 μM.
A truncated ArsD lacking both MBS2 and MBS3 (ArsD1-109), still interacted with
ArsA in the yeast-two-hybrid assay and had the same stimulatory effect on ArsA
ATPase activity as wild-type ArsD (Lin et al., 2007a). In contrast, an ArsD derivative
lacking MBS1 but retaining MBS2 (ArsD1-118,C12A/C13A) was unable to interact with ArsA
in yeast-two-hybrid assay and did not stimulate ArsA activity. These results suggest that
MBS1, but not MBS2 or MBS3, participate in metalloid transfer to ArsA and in activation
of ArsA ATPase activity. Cells expressing a mutated arsD1-118, C112A/C113A gene, which
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encodes an ArsD derivative having only MBS1, in trans with arsAB accumulated As(III)
to nearly the same extent as those expressing wild type arsDAB. These cells also have
a modest reduction in arsenite resistance compared to cells expressing wild type
arsDAB. However, the cells expressing other ArsD mutants lacking MBS1 (arsDC12/C13A
or arsDC18A) accumulate slightly more As(III) than cells with only arsAB and were no
more resistant to As(III) than cells with only arsAB. These in vivo results strongly
support the hypothesis that MBS1 (Cys12, Cys13 and Cys18), but not MBS2 or MBS3,
is required for metallochaperone activity.
1.3.7 Proposed mechanism of metalloid transfer from ArsD to ArsA
The fact that the MBSs in ArsA and MBS1 in ArsD appear to be involved in
interaction suggests that metalloid binding sites in both proteins are brought into close
proximity, allowing transfer of metalloid directly from the binding site on ArsD to the
binding site on ArsA.

It is plausible that this interaction destabilizes the metalloid

binding sites on ArsD, reducing its affinity, while stabilizing the metalloid binding sites on
ArsA by occluding the metalloid within the complex, thus enabling transfer of metalloid
to ArsA. In this manner, the thermodynamically unfavorable process of transferring the
metalloid from a high to a low-affinity site could be overcome, although, as mentioned
above, this might not be a concern if the transferred metalloid is rapidly extruded from
the cell. While the details of metalloid transfer from ArsD to ArsA are unknown at this
time, the mechanism of transfer of copper from the metallochaperone CCS to the
superoxide dismutase SOD1 is instructive (Lamb et al., 2001; Torres et al., 2001). The
cysteine residues of CCS project into the active site of SOD1. By doing so, Cu(I)
bridges the donating cysteine residues of CCS and the receiving histidine residues,
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stabilizing the heterodimer and facilitating metal transfer. In effect, transfer of copper
between the Atx1 and Ccc2p is ‘catalyzed’ by the metallochaperone. We propose a
similar mechanism of As(III) transfer from ArsD to ArsA in which there is a step-wise
exchange of sulfur ligands from ArsD cysteines to ArsA cysteines (Figure. 2-12). The
MBS1 (metalloid binding site 1) of ArsD and MBSs of ArsA come close to each other,
then the As(III) bound by ArsD will be released by one cysteine of ArsD and coordinated
by the cysteine of ArsA to form an As(III) intermediated complex. Through step by step
change of the thiol-ligands of As(III) from ArsD to ArsA, finally As(III) is coordinated by
the three cysteines from ArsA.
1.4

Other metallochaperones
Arsenic is a non-essential element in any organism. ArsD functions to sequester

toxic arsenic and deliver it to the extrusion pump. Similar metal-chaperones have been
found for essential but toxic metals such as copper and iron. They sequester free metal
in cells and specifically deliver to target proteins. Though copper and iron are essential,
both Cu(I) and Fe(II) could undergo Fenton or Fenton-like chemistry to generate highly
toxic hydroxyl radical. Accumulation of free Cu(I) and Fe(II) is detrimental to the cell. On
one hand, the metal-chaperone could sequester the metal and keep the concentration
of free metal at very low concentration. On the other hand, the chaperones specifically
deliver metal to the target proteins, which could be the enzyme requiring the metal as
cofactor, the extrusion pump or the metal-storage protein.
Metal-chaperones deliver metals to the target proteins. Usually without a metal,
the chaperone protein does not interact with the target protein or does so very weakly.
In the presence of metal, the interaction is strengthened. After the metal is delivered,
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the chaperone protein dissociates from the target protein, and a new cycle starts. For
this cycle to be efficient, the chaperone-target interaction should be transient and weak.
This is one reason that it’s difficult to study how chaperone proteins interact with their
target proteins.
1.4.1 Copper chaperones
Copper chaperone has been found from prokaryotic cells to eukaryotic cells. In
vitro, most copper enzymes easily acquire their metal without the help of any auxiliary
proteins.

However, in living cells such as yeast, the cytoplasmic free copper

concentration is estimated to be less than 10-18 M since SOD1 cannot get Cu(I) even
though the total copper concentration is very high. Almost no free copper exist in the
cells, and copper chaperone proteins are required for the maturation of the enzyme
(Rae et al., 1999).
Enterococcus hirae has a copYZAB operon encoding proteins involved in copper
homeostasis. CopA and CopB are P-type ATPase pumps, importing and exporting
copper, respectively. CopY is a operon repressor in the absence of Cu(I). CopZ is
required for delivery of Cu(I) to CopY to activate transcription of the operon (Odermatt
and Solioz, 1995). Through gel-filtration, Cu(I)-CopZ transfer Cu(I) to CopY. But these
two proteins do not come off the gel-filtration column as a complex (Cobine et al., 1999).
The interaction between CopZ and CopY was suggested to be mediated by charged
residues. MNKr2, a homolog of CopZ, the second copper binding site of human Menkes
ATPase, can be engineered to gain the function similar of CopZ to transfer Cu(I) to
CopY through changing the different charged residues (Cobine et al., 2002), suggesting
CopZ and CopY interact through these charged residues. Surface Plasmon Resonance
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show that CopZ specifically interacts with CopA immobilized on the chip. Cu(I)
increased the affinity of interaction between CopZ and CopA 15-fold by decreasing the
dissociation rate of the two proteins. Mutation of Cys to Ser of the N-terminal copper
binding motif CXXC of CopA abolishes the modulation of interaction affinity by Cu(I), but
the mutant still binds to CopZ as well as wild-type CopA in the absence of Cu(I)
(Multhaup et al., 2001). Recent studies show that N-terminal copper binding site of
CopA may only serve as a regulatory site, while CopZ is able to directly transfer Cu(I) to
TM-MBS, the transmembrane copper binding site (Gonzalez-Guerrero and Arguello,
2008).
CopZ homologues are Atx1 in yeast and HAH1 in human. Ccc2 in yeast and
Menkes (ATP7A) and Wilson (ATP7B) ATPase in humans are CopA homologues that
also have several copies of CopZ-like copper binding motif in their N-termini. These
MBDs (metal binding domain) have been proposed to accept Cu(I) from chaperone
proteins. Atx1 interacts with the N-terminal MBD of Ccc2 in the yeast two-hybrid system
(Pufahl et al., 1997). The transfer from Atx1 to the MBD of Ccc2 is reversible, which
suggests the transfer from Atx1 to Ccc2 is not due to higher affinity for Cu(I). But Atx1
can protect Cu(I) from other copper scavengers in the cell such as glutathione, and
directly bring Cu(I) to the target protein through protein-protein interaction (Huffman and
O'Halloran, 2000). The binding interface between Atx1 and the first MBD of Ccc2 has
been characterized by NMR. By following the
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N and 1H chemical shifts, a new species

is detected. This species is in fast exchange with the parent species on the NMR time
scale. Nuclear relaxation data are consistent with the formation of an adduct (Arnesano
et al., 2001). Based on NMR chemical shift mapping information, a structure model of
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the transient complex was proposed through in silico docking. The model shows that the
interaction is mainly of an electrostatic nature with hydrogen bonds stabilizing the
complex (Arnesano et al., 2004). Coupling site-directed mutagenesis and NMR study,
the contribution of copper and cysteine residues of the binding site was studied. The
copper is essential for the weak and transient metal-mediated interaction (Banci et al.,
2006). Recently, a new target protein, copper amine oxidase Cao1 is also shown to
accept Cu(I) from Atx1. And these two proteins were shown to interact with each other
in yeast two-hybrid system (Peter et al., 2008).
Hah1 compensates for the function of Atx1 in atx1Δ yeast (Hung et al., 1998).
Coimmunoprecipitation experiments revealed that HAH1 interacts with both the Wilson
(ATP7B) and Menkes (ATP7A) proteins and that this interaction depends on available
copper. This provides a mechanism for the function of HAH1 as a copper chaperone in
mammalian cells to transfer to ATP7A and ATP7B (Hamza et al., 1999). Yeast twohybrid experiments show copper-dependent interaction between HAH1 and the 2nd or
4th MBD of ATP7B (van Dongen et al., 2004), also with 2-6 MBD of ATP7A (Larin et al.,
1999). The interaction between HAH1, and the second or the fifth soluble domains of
ATP7A (MNK2 and MNK5, respectively), was investigated in solution using
heteronuclear NMR. The copper-transfer properties of MNK2 and MNK5 are similar,
and differ significantly from those previously observed for the yeast homologous
system. No stable adduct is formed between either of the MNK domains and HAH1. The
copper(I) transfer reaction is slow on the time scale of the NMR chemical shift, and the
equilibrium is significantly shifted towards the formation of copper(I)-MNK2/MNK5
(Banci et al., 2005). NMR titration show the formation of an adduct by Cu(I)-HAH1 with
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WLN4 that is in fast exchange on the NMR time scale with the isolated protein species
as confirmed by

15

N relaxation data. A similar interaction is also observed between

Cu(I)-HAH1 and WLN2; however, the relative amount of the adduct in the protein
mixture is lower. In both cases the interaction interface can not be mapped by NMR
(Achila et al., 2006).
Another example of a copper chaperone is the chaperone protein involved in the
maturation of superoxide dismutase (SOD1). In Saccharomyces cerevisiae, it’s LYS7
and in human it’s CCS. They are responsible for the delivery of copper to copper/zinc
superoxide dismutase (Culotta et al., 1997). Interaction of the yeast copper chaperone
yCCS in complex with its partner protein, superoxide dismutase (SOD1), has been
elucidated crystallographically using a mutant SOD1 (Lamb et al., 2001). In this mutant
SOD1, His48, one of the ligand for copper was mutated to Phe. yCCS, and this mutant
SOD1 form a stable complex (Lamb et al., 2000).
1.4.2 Iron chaperones
Frataxin, the protein lacked in the neurological disease Friedreich's ataxia,
functions as a mitochondrial iron chaperone for iron-sulfur cluster and heme
biosynthesis. Frataxin interacted with aconitase in a citrate-dependent fashion, reduced
the level of oxidant-induced inactivation, and converted inactive [3Fe-4S]1+ enzyme to
the active [4Fe-4S]2+ form of the protein. Thus, frataxin is an iron chaperone protein that
protects the aconitase [4Fe-4S]2+ cluster from disassembly and promotes enzyme
reactivation (Bulteau et al., 2004). Yeast frataxin was shown to interact with
ferrochelatase by NMR (He et al., 2004). This model was proposed based on the
structural information to show the channel of iron transfer from frataxin to ferrochelatase
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for the heme synthesis (Bencze et al., 2007). Yeast frataxin Yfh1 binds to the central
Fe/S-cluster (ISC)-assembly complex, which is composed of the scaffold protein Isu1
and the cysteine desulphurase Nfs1. Association between Yfh1 and Isu1/Nfs1 was
markedly increased by ferrous iron, but did not depend on ISCs on Isu1. Functional
analyses in vivo showed an involvement of Yfh1 in de novo ISC synthesis on Isu1
(Gerber et al., 2003). The iron-bound form of ISU is viable for assembly of holo ISU,
either by subsequent addition of sulfide or by NifS-mediated sulfur delivery. Without
sulfur delivery, isothermal titration calorimetry (ITC) shows that holo human frataxin
forms a complex with ISU with sub-micromolar binding affinities, while apo frataxin does
not bind to ISU, suggesting an important role for iron in cross-linking the two proteins
and/or stabilizing the structure of frataxin that is recognized by ISU (Yoon and Cowan,
2003). In Drosophila, holo frataxin also forms a complex with ISU that can be trapped
without the sulfide delivery and can be detected by ITC (Kondapalli et al., 2008).
Ferritins are the main iron storage proteins found in animals, plants, and bacteria.
The capacity to store iron in ferritin is essential for life in mammals. Human ferritins
expressed in yeast contain little iron. Human poly (rC)-binding protein 1 (PCBP1)
increased the amount of iron loaded into ferritin when expressed in yeast.
Coimmunoprecipitation shows PCBP1 binding to ferritin. In vitro, PCBP1 binds iron and
facilitates iron loading into ferritin (Shi et al., 2008).
1.5

Summary
Arsenic is widely distributed throughout the earth’s crust and is brought into water

and soils due to natural weathering process and human activities. Severe health effects
have been observed in populations exposed to arsenic, which include cancer,
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cardiovascular disease, peripheral neuropathies and diabetes mellitus. Because of the
prevalence of arsenic in the environment, nearly every organism, from E. coli to humans,
has genes for arsenic detoxification.
The ArsAB pump in E. coli, encoded by the ars operon of plasmid R773, confers
resistance to arsenicals and antimonials. ArsA is the catalytic subunit of the pump that
hydrolyzes ATP in the presence of arsenite or antimonite. ArsB is a membrane protein
containing arsenite-conducting pathway. ArsA forms complex with ArsB, therefore ATP
hydrolysis is coupled to extrusion of As(III) or Sb(III) through ArsB. Upon
overexpression, ArsA exists primarily as a soluble protein in the cytosol. Purified ArsA
is an As(III)/Sb(III)-stimulated ATPase.
ArsD is an arsenite chaperone for ArsA. ArsD sequesters free As(III) in the cell
and then delivers to ArsA. ArsD increases the apparent affinity of ArsA for As(III) by
about 60 fold from 1.2mM to 20μM (Lin et al., 2006). This effect is more significant at
‘physiological’ concentration of As(III) in the cell. There is no data of the maximum
concentration of free As(III) inside the cells, at which the cells can tolerate. Most likely it
is less than 50μM suggested by measuring growth of E. coli cells, lacking arsenic
resistance operon, with addition of As(III) in the medium. 50μM As(III) inhibits cell
growth. The free As(III) inside the cell should not be higher than outside of the cell
(Hung-Chi Yang, Barry Rosen, unpublished). By increasing affinity of ArsA for As(III),
ArsD also increased ArsA ATPase activity at the ‘physiological’ concentration of As(III).
Therefore, ArsAB pump efficiency is increased and less As(III) will be accumulated in
the cells. On the other hand, since ArsD is a protein with higher affinity for As(III), there
is less chance for free As(III) to bind to other proteins interfering their function after the
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formation of ArsD-As(III) complex. So ArsD also confers the cell with the advantage of
low availability of free As(III), therefore decreasing the deleterious effect of free As(III).
ArsD has been shown to transfer Sb(III) to ArsA in the presence of Mg2+ and ATP.
ArsD and ArsA can be crosslinked by dibromobimane, a homofunctional cysteine
crosslinker with arm length about 6Å. The N-terminal metal binding site of ArsD, formed
by Cys12, Cys13 and Cys18, is required for the metallochaperone function. From ArsA
crystal structure, three cysteine residues, Cys113, Cys172 and Cys422 are found to
near each other and involved in As(III) binding. Since both ArsD and ArsA use cysteine
residues as ligands for As(III), all these results suggest that ArsD interacts with ArsA
through their arsenic binding sites. However, the interaction detail is not known yet and
the process of arsenic transfer is also not known. I approached the answers from three
directions in chapters 2, 3 and 4. In chapter 2, the binding affinity of ArsD for As(III) was
determined, and ATP hydrolysis was shown to be required for As(IIII) transfer from ArsD
to ArsA. The results suggest that ATP hydrolysis changes ArsA to a conformation with
higher affinity for As(III), and As(III) is transferred at this step. In chapter 3, the relation
between ArsD dimerization and metallo-chaperone function was studied. In chapter 4,
yeast two-hybrid analysis was used to select mutations affecting the interaction between
ArsD and ArsA, which shed light on the interface between ArsD and ArsA.
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CHAPTER 2
Arsenic binding and transfer by the ArsD As(III) metallochaperone
2.1

Introduction
In bacteria and archaea various ars operons encode ArsAB ATPases that pump

the trivalent metalloids As(III) or Sb(III) out of cells. In these operons, an arsD gene is
almost always adjacent to the arsA gene, suggesting a related function. Most transition
and heavy metal ions do not exist as free ions in the cytosol but are sequestered by a
variety of proteins variously called metal ion chaperones, scaffolds or intracellular
carriers (Field et al., 2002). ArsD was recently shown to be a chaperone for transfer of
cytosolic As(III) to the 583-residue ArsA ATPase, the catalytic subunit of the efflux pump
(Lin et al., 2006; Lin et al., 2007a). ArsD is a 120-residue protein with three conserved
cysteine residues, Cys12, Cys13 and Cys18 required for chaperone activity (Lin et al.,
2007a). ArsA exhibits a low, basal rate of ATPase activity in the absence of As(III) or
Sb(III) and a higher, activated rate in their presence. ArsA has a high affinity metalloid
binding site composed of Cys113 and Cys422 (Ruan et al., 2006), and a third residue,
Cys172, that participates in high affinity binding and activation of ATP hydrolysis (Ruan
et al., 2008). In analogy with the mechanism of copper transfer from chaperones to
copper pumps or enzymes (Boal and Rosenzweig, 2009), we previously proposed a
step-wise transfer from the cysteines of ArsD to the cysteines of ArsA (Lin et al.,
2007b). ArsD increases the affinity of ArsA for As(III), permitting detoxification of
environmental concentrations of arsenic.
In this study the properties of As(III) binding by ArsD and subsequent transfer to
ArsA were examined. X-ray absorption spectroscopy was used to show that As(III) is
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coordinated with three sulfur atoms, consistent with Cys12, Cys13 and Cys18 forming
the As(III) binding site. Assays with single-tryptophan derivatives of ArsA have been
informative about As(III) or Sb(III) binding properties and catalysis (Walmsley et al.,
1999, 2001; Zhou et al., 2001; Zhou and Rosen, 1997; Zhou et al., 2002), so an assay
using intrinsic protein fluorescence was developed as a probe of metalloid binding to
ArsD. Two single tryptophan derivative of ArsD were constructed by changing either
Thr15 or Val17 to tryptophan in a tryptophan-free background. Both exhibited quenching
of fluorescence upon binding of As(III) or Sb(III), from which the apparent affinity for
metalloid could be estimated. Since it is likely that cytosolic As(III) is bound to reduced
glutathione (GSH), the effect of GSH on binding to ArsD was examined. GSH greatly
increased the rate of binding As(III) to ArsD, suggesting that ArsD accepts metalloid
from the As(GS)3 complex. In contrast, GSH did not affect the As(III)-stimulated ArsA
ATPase activity, suggesting that As(III) is directly transferred from ArsD to ArsA, as
opposed to release from ArsD, binding to GSH and then interaction of ArsA with the
As(GS)3 complex. To differentiate between these two possibilities, the effect of the
As(III) chelator dimercaptosuccinic acid (DMSA) was examined. The chelator did not
affect transfer, indicating channeling of As(III) from ArsD to ArsA. Transfer occurs only
under conditions where ArsA hydrolyzes ATP, suggesting that ArsD transfer As(III) to
an ArsA conformation transiently formed during catalysis and not simply to the closed
conformation that ArsA adopts when As(III) and MgATP are bound (Zhou et al., 2001).
2.2

Materials and Methods

2.2.1 Strains, plasmids and media
E. coli cells were grown in Luria-Bertani (LB) medium (Sambrook et al., 1989) at
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37°C. Ampicillin (100 µg/ml) or kanamycin (40 µg/ml) was added as required. E. coli
strain JM109 [recA1 supE44 endA1 hsdR17 gyrA96 relA1 thiΔ(lac-proAB) F’ (traD36
proAB+ lacIq lacZΔM15)] was used for molecular cloning. E. coli strain BL21(DE3) [FompT hsdSB (rB-mB-) gal dcm (DE3 [lacI lacUV5-T7 gene1 ind1 Sam7 nin5]) was used
for protein expression and purification. ArsA with a C-terminal 6-histidine tag was
expressed from plasmid pAlter-dAhB (Li and Rosen, 2000). ArsD contains three vicinal
cysteine pairs, of which the last two are not required for chaperone activity, so the last
11 residues containing those two cysteine pairs were removed, creating the ArsD1-109
truncation. N-terminal MBP-fused ArsD1-109 (henceforth designated MBP-ArsD109) was
expressed from plasmid pMAL-ArsD109 (Lin et al., 2007a). ArsD1-109 with an N-terminal
six-histidine tag (henceforth designated as wild type ArsD109) was expressed from
plasmid pET28a-ArsD109. The codons for the two native ArsD tryptophan residues,
Trp35 and Trp97, were mutated to tyrosine codons by site directed mutagenesis in
plasmid pET28a-ArsD109, generating pET28a-ArsD109W35/97Y. In this plasmid Thr15
and Val17 codons were mutated to tryptophan codons, generating pET28aArsD109T15W and pET28a-ArsD109V17W, respectively. The codon for Cys12, Cys13 and
Cys18 was individually mutated to glycine codons in pET28a-ArsD109, generating
pET28a-ArsD109C12G, pET28a-ArsD109C13G and pET28a-ArsD109C18G, respectively.
The codons for Cys12, Cys13 and Cys18 were mutated to glycine codons in pET28aArsD109T15W, generating pET28a-ArsD109C12G,T15W, pET28a-ArsD109C13G,T15W and
pET28a-ArsD109C18G,T15W. Growth in liquid culture was estimated from the absorbance
at 600 nm. The strains and plasmids are listed in Table 2-1.
2.2.2 DNA manipulation and mutagenesis
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Plasmid extraction, DNA restriction endonuclease analysis, ligation and other
general molecular biological procedures were performed as described (Sambrook et al.,
1989). Transformation of E. coli cells was carried out using a BIO-RAD MicroPluser
(BIO-RAD, Hercules, CA). DNA purification kits were obtained from QIAGEN (Valencia,
CA). Either a Qiaprep Spin Miniprep kit or a Qiaquick gel extraction kit (QIAGEN) was
used to prepare plasmid DNA for restriction enzyme digestion, sequencing, and
recovering DNA fragments from agarose gels. The sequence of new plasmid constructs
was confirmed by DNA sequencing of the entire gene. Site-directed mutagenesis was
performed using Quick-change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA)
and confirmed by sequencing. DNA sequencing was performed using a CEQ2000 DNA
sequencer (Beckman Coulter, Brea, CA). The primers used are listed in Table 2-2.
2.2.3 Protein expression and purification
Cells bearing the indicated plasmids were grown in LB medium overnight at 37°C
and then diluted 50-fold into 1 L of the same medium. Proteins were expressed by
induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6-0.8 for 3 hrs.
MBP-ArsD109 was purified from E. coli strain BL21(DE3) bearing plasmid pMALArsD109 as described (Lin et al., 2006). Cells were harvested by centrifugation and
washed once with a buffer containing 50 mM MOPS, pH 7.5, 0.5 M NaCl, 5 mM DTT
and 10 mM 2-mercaptoethanol (Buffer A). The cells were suspended in 5 ml of Buffer A
per gram of wet cells and lysed by a single passage through a French press at 20,000
psi.

Diisopropyl fluorophosphate (DIFP) (Sigma) was added at 2.5 μl/g wet cells

immediately following French press. Unbroken cells and membranes were removed by
centrifugation at 150,000 x g for 1 hr at 4oC. The supernatant was loaded to 10 ml
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amylose column (New England Biolabs, Ipswich, MA) pre-equilibrated with Buffer A.
Unbound proteins were washed by 200 ml of buffer A, and MBP-ArsD109 was eluted
with Buffer B (50 mM MOPS, pH 7.5, 0.5 M NaCl, 5 mM DTT, 10mM maltose and 10
mM 2-mercaptoethanol), followed by addition of 0.25 mM EDTA and 5 mM DTT to each
fraction. MBP-ArsD109 containing fractions were identified by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), pooled, concentrated by Amicon
Ultra-15 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore), mixed with 10%
glycerol, aliquoted and stored at -80oC until used. ArsA with a six histidine tag at the Cterminus was purified from cells of strain BL21(DE3) expressing pAlter-1-dAhB plasmid,
as described (Zhou and Rosen, 1997). Basically similar procedure was used as
purification of MBP-ArsD109, but with different buffer and column. Probond Ni-column
(Invitrogen) was used. Buffer A(50 mM MOPS, pH 7.5, 0.5 M NaCl, 30 mM Imidazole
and 10 mM 2-mercaptoethanol) and Buffer B(50 mM MOPS, pH 7.5, 0.5 M NaCl, 300
mM Imidazole and 10 mM 2-mercaptoethanol) were used. ArsD and its derivatives with
a six histidine tag at the N-terminus were purified similarly. Purified proteins were stored
at -80°C until use, and their concentrations were determined according to the method of
Bradford (Bradford, 1976) or from the absorption at 280 nm (Gill and von Hippel, 1989).
2.2.4 Circular dichroism measurements
Circular dichroism (CD) spectra from 190 to 260 nm were acquired with a
spectrometer from Olis Inc. (Bogart, GA) at 20 °C using a 0.2-cm path-length cell at
1.75-nm intervals. Three scans were averaged for each spectrum. ArsDs were assayed
at 10 μM in 10 mM potassium phosphate buffer, pH 7.5.
2.2.5 X-ray absorption spectroscopy (XAS)
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XAS samples were prepared in 50 mM MOPS, 0.5 M NaCl and 30% glycerol, pH
7.5. For wild-type ArsD109, 4 mM protein was incubated with 3.2 mM sodium arsenite
for 1 hr on ice, and unbound As(III) was removed with a Bio-Gel P-6 column. For C12G,
C13G and C18G, 4mM protein was incubated with 1 mM As(III) for 1hr. A higher
protein:ligand ratio was used since unbound As(III) was not removed by gel filtration
due to weak binding by the mutant proteins. Solution samples were loaded in Lucite
cells, wrapped in Kapton tape and flash frozen in liquid nitrogen.
XAS data were collected at the Stanford Synchrotron Radiation Laboratory
(SSRL) on beamline 9-3, equipped with Si[220] double crystal monochromator equipped
with a harmonic rejection mirror.

Samples were maintained at 10 K using Oxford

Instruments continuous-flow liquid helium cryostats. Protein fluorescence excitation
spectra were collected using a 30-element Ge solid-state array detector. A germanium
filter (0.6 mM in width) and solar slits were placed between the cryostat and detector to
filter scattering fluorescence not associated with protein bound arsenic signals. XAS
spectra were acquired in 5 eV steps in the pre-edge region (11,625-11,825 eV), 0.25 eV
steps in the edge region (11,850-11,900 eV) and 0.05 Å-1 increments in the extended xray absorption fine structure (EXAFS) region out to a k range of 13 Å-1. The data were
integrated from 2 to 20 s in a k-weighted manner in the EXAFS region for a total scan
length of 45 min. X-ray energies were calibrated using an arsenic foil absorption
spectrum collected simultaneously with the protein data. The first inflection point for the
arsenic foil edge was assigned to 11,867 eV. Each fluorescence channel of each scan
was examined for spectral anomalies prior to averaging and spectra were closely
monitored for photodegradation. The data represent an average of 6 to 7 scans.

39

XAS data were processed using the Macintosh OS X version of the EXAFSPAK
software suite (available on the World Wide Web) integrated with the Feff v7 software
(Ankudinov and Rehr, 1997) for theoretical model generation. Data reduction followed a
previously published protocol for a spectral resolution in bond lengths of 0.13 Å
(Lieberman et al., 2006). EXAFS fitting analysis was performed on raw/unfiltered data.
Protein EXAFS data were fit using single scattering Feff v7 theoretical models,
calculated for carbon, oxygen, sulfur and copper coordination to simulate arsenic-ligand
environments, with values for the scale factors (Sc) and E0 calibrated by fitting
crystallographically characterized arsenic model compounds. Criteria for judging the
best-fit EXAFS simulations utilized both the lowest mean square deviation between data
and fit, corrected for the number of degrees of freedom (F’), and reasonable DebyeWaller factors (σ2 < 0.006 Å2).
2.2.6 Fluorescence measurements
Fluorescence measurements were conducted with a QuantaMaster™ UV VIS
QM-4 Steady State Spectrofluorometer (Photon Technology International, Birmingham,
NJ) at room temperature. For time based measurements, the excitation wavelength
was 295 nm, and the emission wavelength was 345 nm. Emission scans were acquired
between 310 and 390 nm. As(III) or Sb(III) was added as sodium arsenite or potassium
antimonyl tartrate, respectively, at the indicated concentrations to a cuvette containing 2
ml of 1 μM ArsD in a buffer consisting of 50 mM MOPS-KOH, pH 7.5, 0.25 mM EDTA.
GSH was added to the indicated concentrations. Additions were made from
concentrated solutions, and fluorescence was corrected for dilution. To examine the
effect of pH, buffers containing 50 mM sodium acetate, pH 4.0, 50 mM sodium acetate,
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pH 5.0, 50 mM MES, pH 6.0, 50 mM MOPS, pH 7.0, 50 mM Tris, pH 8.0 or 50 mM
CHES, pH 9.0, were used.
2.2.7 ATPase activity assays
ATPase activity was estimated using a couple assay (Vogel and Steinhart, 1976),
as described (Hsu and Rosen, 1989). ArsA was added at a final concentration of 0.3 μM
into an assay mixture containing 5 mM ATP, 1.25 mM phosphoenolpyruvate, 0.25 mM
NADH, 10 units of pyruvate kinase and lactate dehydrogenase with or without the
indicated concentrations of potassium antimonyl tartrate or sodium arsenite, in the
buffer containing 50 mM MOPS-KOH, pH 7.5, 0.25 mM EDTA. ArsD was added at the
indicated concentrations. The mixture was pre-warmed to 37°C, and the reaction was
initiated by addition of 2.5 mM MgCl2 and measured at 340 nm. The linear steady state
rate of ATP hydrolysis was used to calculate specific activity. The reaction volume was
0.2 ml each in 96-well microplates, and the reactions were monitored by microplate
reader SPECTRA max 340PC (Molecular Devices). GSH or DMSA was added as
indicated.
2.2.8 Metalloid transfer assays
Transfer assays were performed as described (Lin et al., 2007b) except that
purified MBP-ArsD109 was used in place of cytosol fractions containing MBP-ArsD109.
A 0.5 ml amylose column pre-equilibrated with 4 ml of buffer consisting of 50 mM
MOPS-KOH, 0.5 mM NaCl, pH 7.5 (column buffer) was used. Purified MBP-ArsD109
was dialyzed against column buffer supplemented with 5 mM β-mercaptoethanol and
0.5 mM dithiolthreitol and loaded to the column, which was then washed with 1 ml of
column buffer. Next 0.5 ml of 1 mM sodium arsenite was added to the column, which
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was then washed with 4 ml of column buffer. BSA or purified ArsA (0.5 ml of 20 μM of
either protein) was applied to the columns with 5 mM MgATP, MgADP or MgATPγS, as
indicated. The column was eluted with 1 ml of column buffer supplemented with the
appropriate nucleotide and then 2 ml of column buffer. Finally the column was eluted
with 1.5 ml of 10 mM maltose. Ten fractions of 0.5 ml were collected and analyzed by
sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) (Laemmli,
1970). For assays conducted at 4ºC, everything was pre-cooled to 4ºC for 30 min. The
protein concentration of each fraction was determined according to the method of
Bradford (Bradford, 1976). The arsenic concentration was quantified by inductively
coupled plasma mass spectroscopy (ICP-MS).
2.3

Results

2.3.1 Cys12, Cys13 and Cys18 form a three-coordinate As(III) binding site in
ArsD
R773 ArsD has three cysteine pairs, Cys12-Cys13, Cys112-Cys113 and Cys119Cys120, plus an additional cysteine at residue 18. However, only cysteine residues 12,
13 and 18 are conserved in known homologues, and truncation of the last two vicinal
pairs had no effect on ArsD chaperone activity, and this variant, with a N-terminal sixhistidine tag was used as the wild type ArsD109 for further analysis (Lin et al., 2007a).
(It should be pointed out that six-histidine tags do not bind As(III) (Qin et al., 2007)).
The nature of the binding site was investigated in structural detail using XAS using wild
type and mutant ArsD109s lacking individual cysteine residues (C12G, C13G and
C18G). XANES analysis indicated arsenic in both the wild type and mutant proteins is
As(III) (Figure 2-1). The observed value for the first inflection point energy is 11868 eV,
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consistent with observed values for As(III) in protein and model systems (Ramirez-Solis
et al., 2004). XANES spectra for wild type ArsD109 are unique from those observed for
the three mutant proteins, indicating the distinctive structural environment that
coordinates As(III) in the wild type sample is different from that seen in the mutant
samples. On the other hand, the structural environment of each mutant sample is
closely related to the other mutant samples.
The EXAFS fitting results are most consistent with trivalent arsenic being
maintained in a 3-coordinate all-sulfur structural environment in wild type ArsD109
(Figure 2-2). This environment is different in the mutants. The structural environment for
the wild type protein is dominated by a symmetric three sulfur coordination environment
to the As(III) at an average bond length of 2.24 Å. Addition of a small oxygen/nitrogen
scattering contribution to the As-S3 fits for the wild type suggests a possible low
percentage partial dissociation of the bound metalloid (Table 2-3). There was no sulfur
ligation in any of the three cysteine mutants. EXAFS analysis of C18G suggests an
average nearest neighbor coordination environment constructed of three As-O
interactions at 1.79 Å. In the remaining two mutants, the data are best fit with two
independent As-O/N environments constructed of two oxygen ligands at 1.79 Å and a
third oxygen/nitrogen ligand interaction between 2.13 and 2.16 Å. The most likely
explanation for these results is that As(III) is bound to the thiolates of Cys12, Cys13 and
Cys18 in the wild type, but that, in the mutants, binding to the two remaining cysteines is
weak, and most of the arsenic is present as As(OH)3 .
2.3.2 Tryptophan fluorescence reports trivalent metalloid binding by ArsD
Previous assays to quantify arsenic binding by wild type and mutant ArsDs used

43

ICP-MS (Lin et al., 2006; Lin et al., 2007a). To develop a real-time assay for arsenic
binding, single tryptophan derivatives of ArsD109 were constructed. ArsD has two
native tryptophan residues, Trp35 and Trp97. Trp35 does not respond to As(III), but the
fluorescence of Trp97 is quenched when As(III) binds to the vicinal pair, Cys112Cys113 but not to the Cys12-Cys13-Cys18 As(III) binding site (Li et al., 2001; Li et al.,
2002).

A tryptophan-free derivative lacking the last two vicinal cysteine pairs was

constructed (W35/97Y). Two derivatives with single tryptophan residues near the As(III)
binding site were then constructed by changing Thr15 or Val17 to tryptophan.
Introduction of either tryptophan residue had no apparent effect on ArsD structure or
function. The overall secondary structure of these two mutants, T15W and V17W, were
similar to wild-type ArsD109, as determined by circular dichroism (Figure 2-3A), and
both stimulated ArsA ATPase activity nearly as well as wild-type ArsD109 (Figure 2-3B;
data not shown for V17W). Tryptophan-free W35/97Y showed very low background
fluorescence (Figure 2-4A). Both single tryptophan derivatives exhibited considerable
intrinsic protein fluorescence compared with W35/97Y, with emission maxima of
approximately 340 nm compared with an emission maximum of approximately 355 nm
for free tryptophan in solution. Denaturation of the proteins with guanidine red shifted
the emission maxima to approximately 352 nm. The fluorescence of either T15W or
V17W was quenched approximately 50% by addition of high concentrations of As(III) or
Sb(III) (Figure 2-4B).
In the absence of added thiols, the rate of fluorescence quenching, presumably
proportional to the rate of As(III) binding, was very slow, requiring more than 0.5 hr to
attain a steady-state level of fluorescence when 1 μM protein was mixed with 5 μM
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As(III) (Figure 2-5A). From the As(III) concentration dependence of fluorescence
quenching, apparent binding constants for the two single tryptophan proteins could be
calculated from the relationship kobs = koff + kon*[As(III)] (Tamerler et al., 2006), where
kobs is the rate of quenching fitted with SigmaPlot 9.0 (Figure 2-5B). For V17W, koff was
calculated as (4 ± 2) x 10-4 s-1, and kon was calculated as (2 ± 0.06) x 10-4 s-1.μM-1. From
the ratio koff/kon = kd, a binding affinity of 2 ± 1 μM was calculated. For T15W, koff was
estimated as (3 ± 1) x 10-4 s-1, and kon as (2 ± 0.05) x 10-4 s-1.μM-1, and kd = 1.5 ± 0.5
μM. Thus, the values for the two single tryptophan derivatives are in agreement.
2.3.3 Effect of cysteine substitutions on As(III) binding
Substitutions of the three cysteines in ArsD were previously result in loss of
Sb(III) binding ability by gel filtration assays (Lin et al., 2007a). As noted above, no
sulfur ligation was observed with any of the three cysteines mutants in the EXAFS
experiments. However, neither EXAFS nor binding assays by gel filtration are as
sensitive as fluorescence assays and cannot measure low affinity binding. As(III)
binding parameters were estimated from quenching of T15W fluorescence of each
cysteine mutant (Figure 2-5B). C18G/T15W, which retains the Cys12 and Cys13 vicinal
pair, has kon = (5 ± 0.1) x 10-5 s-1.μM-1, koff = (1.4 ± 0.1) x 10-3 s-1 and kd = 28 ± 3 μM.
C12G/T15W, which retains Cys13 and Cys18, has kon = (5 ± 0.1) x 10-5 s-1.μM-1, koff =
(2.4 ± 0.1) x 10-3 s-1 and kd = 48 ± 3 μM. C13G/T15W, which retains Cys12 and Cys18,
has kon = (4 ± 0.2) x 10-5 s-1.μM-1, koff = (2.7 ± 0.1) x 10-3 s-1 and kd = 68 ± 6 μM. Thus,
the affinity of each of the three cysteine mutants decreased by 20-fold or more
compared with the parental protein containing Cys12, Cys13 and Cys18.
2.3.4 Reduced glutathione increases the rate of binding of As(III) to ArsD but not
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ArsA In vivo
As(III) is nearly completely complexed with GSH (Delnomdedieu et al., 1994a).
As GSH is the major intracellular thiol in E. coli, cytosolic As(III) would be expected to
be primarily in the form of As(GS)3 (Apontoweil and Berends, 1975). For that reason,
the effect of 5 mM GSH on the rate of binding of 50 μM sodium arsenite to 1 μM V17W
was examined over a pH range of 4.0 to 9.0 (Figure 2-6). The rate of fluorescence
quenching increased with increasing pH with or without GSH. In the absence of GSH,
the rate of fluorescence quenching was about 10-fold faster at pH 9 than at pH 7.
Addition of GSH accelerated the rate by 10-fold at pH 7.5, and the rate was too fast to
measure accurately at pH 8 or higher. The pH dependence in the absence of GSH
indicates binding of As(III) by thiolates of the three ArsD cysteines but could also reflect
dissociation of As(OH)3 to As(OH)2-1 (pKa of 9.23). Acceleration by GSH is consistent
with binding of As(III) by thiolates of GS-1 (pKa of 8.7), which is highly pH dependent
(Yehiayan et al., 2009), consistent with intermolecular transfer of metalloid from As(GS)3
to ArsD.
The effect of GSH was investigated in more detail. In the absence of GSH,
fluorescence of V17W decreased very slowly when 50 μM sodium arsenite was added
at pH 7.5 (Figure 2-7A). Addition of 0.2 mM GSH had little effect, but 5 mM GSH
increased the rate substantially. Addition of 5 mM of either β-mercaptoethanol or Lcysteine also increased the rate of quenching with As(III) (Figure 2-7B). While ArsD
might be able to accept As(III) from complexes with other monothiols, but only GSH is
present intracellularly in concentrations high enough to be involved physiologically. In
contrast, 2.5 μM potassium antimonyl tartrate rapidly quenched fluorescence in the
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absence of added monothiols (Figure 2-7B), consistent with the fact that ArsD has
higher affinity for Sb(III) than As(III) (Li et al., 2002). Addition of 5 mM tris(2carboxyethyl)phosphine (TCEP), which is a stronger reductant than GSH but is not a
monothiol, did not increase the rate of quenching (Figure 2-7A), indicating that the effect
of GSH is not simply to protect either ArsD or As(III) from oxidation. Since formation of
As(GS)3 is slow at pH 7.5 (Yehiayan et al., 2009), 4 mM sodium arsenite was preincubated with 16 mM GSH for 10 min to allow for formation of the complex. When
preformed As(GS)3 was added at 50 μM, the rate of quenching was too fast to quantify
(Figure 2-7A), supporting our hypothesis that As(GS)3 is a direct donor of metalloid to
ArsD.
To examine whether GSH also facilitates As(III) binding to ArsA, the stimulation
of ArsA activity by As(III) was determined in the presence or absence of GSH (Figure 28). ArsA exhibited an apparently affinity of around 0.6 mM for As(III) with or without
GSH. These results indicate that ArsA accepts either free As(III) or from As(GS)3 with
low affinity, but As(GS)3 does not replace ArsD as an intracellular metallochaperone for
high affinity As(III) binding.
To see the effect of glutathione on the cooperation of ArsD and ArsA, the change
of apparent affinity of ArsA for As(III) by ArsD was determined in the absence and
presence of 5 mM glutathione. 3 μM ArsD increases apparent affinity of ArsA to about
34 μM in the absence of glutathione and 5 μM in the presence of glutathione (Figure 29A). To study in more detail, the change of apparent affinity of ArsA for As(III) by
different concentrations of ArsD was determined. 0.3 μM ArsA was used in the assay. In
the absence of glutathione, when ArsD concentration was increased from 0.3 μM to 3
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μM, the apparent affinity was increased from 0.6 mM to a plateau of 30 μM. In the
presence of 5mM glutathione, when ArsD concentration was increased from 0.3μM to
3μM, the apparent affinity was increased from 0.6 mM to a plateau of 5 μM, six fold less
comparing in the absence of glutathione (Figure 2-9B). From another aspect, in the
presence of glutathione, less ArsD is required to stimulate ArsA ATPase activity to the
same extent. To exclude the possibility that the effect of glutathione is due to prevention
of ArsA and ArsD from oxidation, 5mM TCEP was added in the buffer and it show
almost no effect on the cooperation of ArsA and ArsD (Figure 2-9B). These results
suggests that glutathione increases the binding rate of As(III) to ArsD, therefore
increasing the transferring rate of As(III) from ArsD to ArsA and stimulating ArsA
ATPase activity at low concentration of As(III) when As(III) binding is the rate-limiting
step in ArsA ATP hydrolysis cycle.
2.3.5 ArsD transfers As(III) directly to ArsA
From the results of yeast two-hybrid analysis, it is clear that ArsD and ArsA
physically interact (Lin et al., 2006). How is As(III) transferred during this interaction?
One possibility is that the metalloid dissociates from ArsD and re-associates with ArsA.
A second possibility is that there is direct transfer from the thiols of ArsD to the thiols of
ArsA in a step-wise fashion (Lin et al., 2007a), similar to the mechanism of copper
transfer from the yeast Atx1p chaperone to the Ccc2p copper efflux pump (Pufahl et al.,
1997).
Metabolic trapping is often applied to examine for channeling (Anderson, 1999;
Kwok et al., 2006). To differentiate between channeling and a dissociation/reassociation mechanism, the As(III) chelator DMSA was added to the reaction. DMSA

48

has an apparent affinity of approximately 20 μM for As(III) (Spuches et al., 2005), which
is between the ArsD and ArsA affinities. Direct transfer of As(III) from ArsD to ArsA
would be expected to be insensitive to DMSA. In contrast, if As(III) dissociates from
ArsD before binding to ArsA, an excess of DMSA should prevent transfer. Using the
stimulation of ArsA ATPase by the ArsD-As(III) complex, the effect of DMSA was
examined (Figure 2-10). DMSA did not affect the basal activity of ArsA, but the As(III)stimulated rate of ArsA activity was inhibited by DMSA. In that experiment ArsA + As(III)
was titrated with DMSA, and the stimulated ATPase activity returned to basal level at
higher concentrations of DMSA. When ArsD was preincubated with As(III) and then
added to ArsA, the rate of ATP hydrolysis was stimulated, reflecting the chaperone
activity of ArsD. Titration of that mixture with DMSA resulted in an initial decrease in
activity as free As(III) was chelated, but the activity plateaued at a level corresponding
to the activated rate. Since ArsD has higher affinity for As(III) than DMSA, it is able to
retain and transfer metalloid even at higher concentrations of DMSA. These results are
consistent with direct transfer of As(III) from ArsD to ArsA.
2.3.6 Transfer of As(III) from ArsD to ArsA requires catalysis
We have previously shown that ArsD transfers Sb(III) to ArsA in the presence of
MgATP (Lin et al., 2007a). Here transfer of As(III) from ArsD to ArsA was compared
under catalytic and noncatalytic conditions. Purified MBP-ArsD109 was bound to an
amylose column. Sufficient As(III) was added to the column to saturate ArsD, following
which free As(III) was washed off.

Next either ArsA or BSA pre-incubated with

nucleotides was passed through the column. When ArsA pre-incubated with MgATP
was passed through the column at room temperature, conditions under which ArsA
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hydrolyzes ATP, nearly all of the As(III) eluted in the ArsA-containing fractions, with
almost none in the MBP-ArsD109-containing fractions (Figure 2-11A and B). In contrast,
when BSA preincubated with MgATP was passed through the column, almost none of
the As(III) eluted in the BSA-containing fractions, but eluted in the MBP-ArsD109containing fractions (Figure 2-11C).
When MgADP was used instead of MgATP, As(III) eluted with MBP-ArsD109 and
not with ArsA (Figure 2-11D). Similarly, the MgATP-γ-S, a nonhydrolyzable nucleotide,
did not promote transfer (Figure 2-11E). When the reaction with MgATP and column
elution were at 40 C, where ArsA hydrolyzes ATP very slowly, almost no As(III) eluted
with ArsA but remained bound to MBP-ArsD109 (Figure 2-11F). These data
demonstrate that ATP hydrolysis is required for As(III) transfer from ArsD to ArsA.
2.4

Discussion
In vivo results quite clearly demonstrate that ArsD is an As(III)/Sb(III) chaperone

that transfers metalloid to the ArsA ATPase (Lin et al., 2006; Lin et al., 2007a), but the
molecular details of the process are lacking. In this study the questions of the nature of
the metalloid binding site in ArsD and requirements for the transfer reaction were
addressed.
From genetic analysis and conservation of residues in homologues, it seemed
likely that the metalloid binding site in ArsD involved the three conserved cysteines,
residues 12, 13 and 18. Here the EXAFS data with wild type ArsD unambiguously
demonstrate that the binding site is a three-coordinate sulfur-containing site, similar in
nature but not sequence to the ArsA As(III) binding site (Bhattacharjee et al., 1995) and
the three convergently evolved sites of three different ArsR repressors (Ordóñez et al.,
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2008; Qin et al., 2007; Shi et al., 1996). This suggests that a common type of As(III)
binding site in proteins is composed of three cysteine residues, with similar As-S bond
distances of 2.24 Å and probably similar geometries.
While EXAFS is useful for determining the environment surrounding the bound
metalloid, a more complete analysis requires quantitative measurements of As(III)
binding. Previous assays using gel filtration yield stoichiometries, but it is difficult to
extract more detailed information from analysis conducted after the reaction is complete.
Changes in intrinsic protein fluorescence can provide real-time information about ligand
binding or catalysis. Full length ArsD has three vicinal cysteines pairs, Cys12-Cys13,
Cys112-Cys113 and Cys119-Cys120, and two tryptophan residues, Trp35 and Trp97.
Trp97 fluorescence reports binding of Sb(III) or As(III) to the vicinal Cys112-Cys113 pair
(Li et al., 2001; Li et al., 2002). However, only the N-terminal Cys12-Cys13 pair is
involved in chaperone activity; the C-terminal pairs are dispensable and not present in
the constructs used for this study. For that reason, the two endogenous tryptophan
residues were altered by site-directed mutagenesis, and new tryptophan residues
introduced singly at positions 15 and 17, near the Cys12-Cys13-Cys18 As(III) binding
site. Fluorescence of either single tryptophan derivative was blue-shifted approximately
14 nm compared with free tryptophan. The fluorescence was red-shifted and decreased
by denaturation with guanidine. These results indicate that the two tryptophan residues
are in a less aqueous environment compared with free tryptophan.

These two

tryptophans are located between the three cysteines that form the As(III) binding site.
Both single tryptophan derivates of ArsD exhibited substantial quenching of protein
fluorescence upon addition of either As(III) or Sb(III), consistent with the region of ArsD
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containing the metalloid binding site undergoing a conformational change when the site
is filled.
However, the rate of quenching with As(III) was slower than might be expected
for a simple binding reaction. If in vivo binding to ArsD was slower than the transfer to
ArsA, then free arsenite might accumulate in the cytosol, negating the value of a
chaperone.

As(III) likely forms a As(GS)3 complex with cytosolic GSH, the major

reduced thiol in E. coli, where it can accumulate to concentrations as high as 10 mM
(Apontoweil and Berends, 1975; Fahey and Sundquist, 1991). However, ArsA accepts
metalloid from As(GS)3 no faster than it binds free As(III), so, even though GSH might
serve as an As(III) buffer, it does not aid in detoxification via the ArsAB pump. In
contrast, ArsD accepts metalloid from As(GS)3 faster than can be determined with our
instrumentation. These considerations lead us to propose that the physiological donor to
ArsD is As(GS)3 (Figure 2-12). As arsenite enters E. coli cells via the aquaglyceroporin
GlpF as As(OH)3, the high concentration of GSH would by mass action rapidly drive
exchange of hydroxyls for thiols.
The next series of steps is proposed to involve the step-wise transfer of As(III)
from ArsD thiolates to ArsA thiolates. The lack of effect of the As(III) chelator DMSA on
the transfer reaction indicates that transfer is direct channeling from one protein to the
other, rather than dissociation from ArsD and re-association with ArsA. The transfer
reaction itself apparently requires ArsA to be undergoing catalysis. As(III) is not
transferred from ArsD to ArsA in the presence of MgADP or MgATP-γ-S, but only in the
presence of MgATP, and then only at a temperature at which hydrolysis occurs. During
the catalytic cycle ArsA undergoes a series of conformational changes in which the A1
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and A2 halves are open relative to each other to a tightly closed conformation in which
the product MgADP is trapped (Zhou et al., 2000, 2001). In our model, ArsD would
interact with one of the transitional conformations, with transfer of As(III) integral to
formation of the closed conformation. Further details of the transfer reaction will require
structural information about ArsD and the ArsD-ArsA complex.
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CHAPTER 3
Correlation between ArsD dimerization and metallochaperone function
3.1

Introduction
In vivo results demonstrate that ArsD is an As(III)/Sb(III) chaperone that transfers

metalloid to the ArsA ATPase (Lin et al., 2006). ArsD and ArsA interact with each other
by yeast two-hybrid analysis. ArsD transfers As(III) to ArsA in the presence of Mg2+ and
ATP. Channeling of arsenic from ArsD to ArsA protected As(III) from chelation by the
chelator dimercaptosuccinic acid (DMSA). ArsA (Zhou et al., 2000) and ArsD (Ye et al.,
2010). Structures have been solved by crystallization. But the details of interaction
between ArsD and ArsA are still unknown. Non-tagged wild-type ArsD has been shown
to be a homodimer by Sephacryl S-200 chromatography (Chen and Rosen, 1997). ArsD
is also a dimer in the crystal structure. In this section, the question, whether ArsD
dimerization is required for its function is studied.
The residues in dimerization interface observed in the ArsD crystal structure
were mutated by site-directed mutagenesis. The dimerization status of the mutants was
analyzed by gel-filtration chromatography. The activity of the mutants was also
examined.
In addition, we did random mutagenesis of the arsD gene by error-prone PCR
induced with Mn2+ (Cadwell and Joyce, 1992). Then ArsD mutants that lose interaction
with wild-type ArsD was selected by reverse yeast two-hybrid analysis. The yeast twohybrid system is a genetic system engineered to study protein-protein interactions
(Fields and Song, 1989). Yeast two-hybrid analysis takes advantage of the properties of
yeast transcriptional factor such as GAL4. GAL4 is a transcriptional activator required
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for expression of genes encoding enzymes for utilizing galactose. It consists of two
separate and essential domains. One is the N-terminal DNA binding domain (BD). The
other is the C-terminal activation domain (AD). The BD binds to a small DNA element
(UAS, upstream activation sequence), usually in the promoter region of the activated
genes. The AD recruits the transcriptase to initiate transcription. By expressing a bait
protein fused with BD and prey protein fused with AD separately from different
plasmids, a functional GAL4 transcriptional activator can be reconstituted through their
interaction. A reporter gene was engineered in the yeast chromosome as a marker for
selection. When the two proteins interact, the reporter gene will be expressed. Usually
the yeast two-hybrid system uses a nutritional synthetic gene such as his3, a histidine
synthesis gene, as reporter gene. So only when two proteins interact with each other
can the yeast cells grow on medium lacking histidine. New systems are also
constructed using a toxic gene such as ura3 as a reporter gene. ura3 encodes orotidine
5-phosphate decarboxylase. It can metabolize 5-FOA (5-fluoroorotic acid) to 5fluorouridine, an analog of uridine, inhibiting cell growth. Therefore it can be used to
select for the mutants with weaker interaction or no interaction by growing the yeast
cells on the plate with 5-FOA.
3.2

Materials and Methods

3.2.1 Strains, plasmids and media
E. coli cells were grown in Luria-Bertani (LB) medium (Sambrook et al., 1989) at
37°C. Ampicillin (100 µg/ml) or kanamycin (40 µg/ml) was added as required. E. coli
strain JM109 [recA1 supE44 endA1 hsdR17 gyrA96 relA1 thiΔ(lac-proAB) F’ (traD36
proAB+ lacIq lacZΔM15)] was used for molecular cloning. E. coli strain BL21(DE3) [F-
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ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI lacUV5-T7 gene1 ind1 Sam7 nin5]) was used
for protein expression and purification. ArsA with a C-terminal 6-histidine tag was
expressed from plasmid pAlter-dAhB (Li and Rosen, 2000). N-terminal MBP-fused
ArsD1-109 (henceforth designated MBP-ArsD109) was expressed from plasmid pMALArsD109 (Lin et al., 2007a). ArsD1-109 with an N-terminal six-histidine tag (henceforth
designated as wild type His6-ArsD109) was expressed from plasmid pET28a-ArsD109.
Site-directed mutagenesis was done on plasmid pET28a-ArsD109 to get the mutant
ArsD109S68A/R87A/R96A. Plasmid pGBT9 and pACT2 were used as S. cerevisiae/E. coli
shuttle vectors for yeast two-hybrid assay (Lin et al., 2007b).
AH109

(MATa,

trp1-901,

leu2-3,

112,

ura3-52,

S. cerevisiae strain

his3-200,

gal4∆,

gal80∆,

LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UAS-MEL1TATAlacZ) (Clontech, Mountain View, CA) and MAV203 (MATα; leu2-3,112; trp1-901;
his3Δ200;

ade2-101;

cyh2R;

can1R;

HIS3UASGAL1::HIS3@LYS2; SPAL10::URA)

gal4Δ;

gal80Δ;

GAL1::lacZ;

(Invitrogen, Carlsbad, CA) were used for

yeast two-hybrid assay. Yeast cells were grown in complete yeast extract-peptonedextrose (YPD) or minimal synthetic dextrose (SD) media with the appropriate
supplements at 30°C (Adams et al., 1998). Growth in liquid culture was estimated from
the absorbance at 600 nm. The strains and plasmids are listed in Table 3-1.
3.2.2 DNA manipulation and mutagenesis
Plasmid extraction, DNA restriction endonuclease analysis, ligation and other
general molecular biological procedures were performed as described (Sambrook et al.,
1989). Transformation of E. coli cells was carried out using a BIO-RAD MicroPluser
(BIO-RAD, Hercules, CA). Transformation of Yeast cells was performed using Fast
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Yeast Transformation™ kit from G-Biosciences (Maryland Heights, MO). DNA
purification kits were obtained from QIAGEN (Valencia, CA). Either a Qiaprep Spin
Miniprep kit or a Qiaquick gel extraction kit (QIAGEN) was used to prepare plasmid
DNA for restriction enzyme digestion, sequencing, and recovering DNA fragments from
agarose gels. Zymoprep II™ Yeast Plasmid Miniprep (Zymo Research, Orange, CA)
was used to extract plasmid from yeast cells. The sequence of new plasmid constructs
was confirmed by DNA sequencing of the entire gene. Site-directed mutagenesis was
performed using Quick-change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA)
and confirmed by sequencing. DNA sequencing was performed using a CEQ2000 DNA
sequencer (Beckman Coulter, Brea, CA). The primers used are listed in Table 3-2.
3.2.3 Protein expression and purification
Cells bearing the indicated plasmids were grown in LB medium overnight at 37°C
and then diluted 50-fold into 1 L of the same medium. Proteins were expressed by
induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6-0.8 for 3 hrs.
MBP-ArsD109 was purified from E. coli strain BL21(DE3) bearing plasmid pMALArsD109 as described (Lin et al., 2006). ArsA with a six histidine tag at the C-terminus
was purified from cells of strain BL21(DE3) expressing pAlter-1-dAhB plasmid, as
described (Zhou and Rosen, 1997). ArsD and its derivatives with a six histidine tag at
the N-terminus were purified similarly. Purified proteins were stored at -80°C until use,
and their concentrations were determined according to the method of Bradford
(Bradford, 1976) or from the absorption at 280 nm (Gill and von Hippel, 1989).
3.2.4 Gel-filtration chromatography
A 1.5cm diameter column filled with 165ml home-packed Superdex-75 (GE
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Healthcare) gel-filtration column was used to analyze His6-ArsD109 truncation and
ArsD109 derivatives on a Bio-rad Biological LP chromatography system. 1.5mg
ovalbumin, 1.5mg carbonic anhydrase and 1.5mg ribonuclease were used as internal
standard. 2mg His6-ArsD109 or His6-ArsD109 mutants and protein standards in 1ml
buffer were loaded onto the column pre-equilibrated with column buffer (50mM MOPS,
200mM NaCl, 5mM 2-mercaptoethanol and 2mM DTT, pH 7.5). A 1.5cm diameter
column filled with 165ml home-packed Sephacryl-200 (GE Healthcare) gel-filtration
column was used to analyze MBP-ArsD109 on a Bio-rad Biological LP chromatography
system. 1.5mg aldolase, 1.5mg conalbumin, and 1.5mg ovalbumine were used as
internal standard. 2.4mg MBP-ArsD109 and protein standards in 1ml buffer were loaded
onto the column pre-equilibrated with same column buffer as above. Then the column
was washed with 200ml of column buffer. Elutions were collected as 1.5ml each
fraction. Fractions were analyzed by 16% SDS-PAGE for His6-ArsD109 and 12% SDSPAGE for MBP-ArsD109. Standard proteins are from Gel Filtration LMW Calibration Kit
and Gel Filtration HMW Calibration Kit (GE Healthcare).
3.2.5 ATPase activity assays
ATPase activity was estimated using a couple assay (Vogel and Steinhart, 1976),
as described (Hsu and Rosen, 1989). ArsA was added at a final concentration of 0.3 μM
into an assay mixture containing 5 mM ATP, 1.25 mM phosphoenolpyruvate, 0.25 mM
NADH, 10 units of pyruvate kinase and lactate dehydrogenase with or without the
indicated concentrations of potassium antimonyl tartrate or sodium arsenite, in the
buffer containing 50 mM MOPS-KOH, pH 7.5, 0.25 mM EDTA. ArsD was added at the
indicated concentrations. The mixture was pre-warmed to 37°C, and the reaction was
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initiated by addition of 2.5 mM MgCl2 and measured at 340 nm. The linear steady state
rate of ATP hydrolysis was used to calculate specific activity. The reaction volume was
0.2 ml each in 96-well microplates, and the reactions were monitored by microplate
reader SPECTRA max 340PC (Molecular Devices).
3.2.6 Generation of a random mutated library of PCR fragments
Random mutagenesis of ArsD was performed using ep-PCR (Cadwell and Joyce,
1992) by employing biased nucleotide composition of the PCR buffer, high
concentration of Mg2+ and addition of Mn2+. The ep-PCR reaction mixture (50 μl)
contained 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 7 mM MgCl2, 0.2 mM each of dATP
and dGTP, 1 mM each of dCTP and dTTP, 25 pmol each of the oligonucleotide primers,
80 ng of template DNA, 2.5 U of Taq DNA polymerase (Invitrogen). pGBT9-D plasmid
DNA was used as template. Primer pGBT9-s (TAA AGA TGC CGT CAC AGA TAG ATT
G) and pGBT9-a (ACC TGA CCT ACA GGA AAG AGT TAC T) were used as primer,
and 0.5 mM Mn2+ was added. PCR condition was 1× 96 °C for 3 min, 30× 94 ° for 30 s,
1×55 °C for 30 s, 1×72 °C for 100s, and, finally, 1× 72 °C for 10 min. The ep PCR
product was analyzed by agarose gel, extracted from gel and quantified by absorption
at 260nm.
3.2.7 Yeast two-hybrid analysis
Two yeast stains, AH109 (Fields and Song, 1989) and MAV203 (Vidal et al.,
1996), were used. Both are GAL4-based yeast two-hybrid system. Yeast cells are cotransformed with ars gene-fused pGBT9-X (BD-X) and pACT2-Y (AD-Y) plasmids.
pGBT9 was modified to pGBT9-k by inserting kanamycin resistant gene for easier
selection of the mutants. Primers pET28a-3600-AatII (CTA TGA CGT CCA ACC CGG
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TAA GAC ACG ACT TAT C) and pET28a-5300-AatII (CTA TGA CGT CCG CCC GCT
CCT TTC GCT TTC TTC C) were used to amplify kanamycin resistant gene from
pET28a by PCR. Then the PCR product was analyzed by agarose gel, extracted from
gel and digested by AatII. pGBT9 was also digested with AatII. Then digested PCR
fragment and vector are ligated and transformed into JM109. The cells were plated on
the LB plate with kanamycin to select for the vector, pGBT9-k, which shows kanamycin
resistance. For unknown reason, pGBT9-k loses ampicillin resistance.
MAV203 was firstly used to select for ArsD mutants that lose the capability of
dimerization with wild-type ArsD. The ep-PCR fragment was mixed with pGBT9-k vector
linearized by EcoRI and BamHI, and co-transformed with pACT2-D into MAV203 and
selected on the SD-L-W plate supplemented with 0.2% 5-FOA (5-Fluoroorotic Acid)
(Fermentas, Burlington, Ontario). The PCR fragment will be ligated into the vector in
vivo through homology recombination (Hua et al., 1997). The colonies were pooled and
colony-PCR was done with primer pGBT-s and pGBT9-a. PCR product was purified by
agarose gel-extraction, mixed with pGBT9-k vector linearized by EcoRI and BamHI, and
co-transformed with pACT2-A into AH109 and selected on the SD-L-W-H plates lacking
histidine. To determine protein-protein interaction by growth of series of dilutions, the
transformed cells were cultured overnight in SD medium at 30°C and then washed,
suspended and adjusted to an absorbance of 1 at A600nm in 20 mM Tris-HCl pH 7.5.
Portions of the cell suspensions (1 μl) were inoculated in serial 10-fold dilutions on SD
agar plates lacking histidine or with 3-AT at indicated concentration. The plates were
incubated at 30°C for 3 days.
3.2.8 Sequencing of ArsD mutant genes in yeast colonies
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Each yeast colony was grown in corresponding liquid SD medium. The plasmids
were isolated from yeast by Zymoprep II™ Yeast Plasmid Miniprep Kit (Zymo Research
Cop. Orange, CA), transformed to E. coli JM109 and grown on LB plate with kanamycin.
Then the plasmids were extracted from E. coli JM109 and sequenced with the GAL4-BD
sequencing primer (GAG TAG TAA CAA AGG TCA A).
3.3

Results

3.3.1 Dimerization equilibria of MBP-ArsD109 and His6-ArsD109
Non-tagged wild-type ArsD has been shown to be a homodimer by Sephacryl S200 chromatography (Chen and Rosen, 1997). In my studies, both N-terminal MBP
(maltose binding protein) tagged ArsD and N-terminal six-histidine-tagged ArsD were
used. Both MBP-ArsD109 and His6-ArsD109 could stimulate ArsA ATPase activity.
ArsA exhibits apparent affinity for As(III) of approximately 0.5 mM. Both MBP-ArsD109
and His6-ArsD109 increased ArsA the apparent affinity for As(III) to around 10 μM
(Figure 3-1). However, these two different ArsD derivatives showed different
dimerization equilibria by gel-filtration chromatography. The apparent molecule weight
of MBP-ArsD109 monomer is 56 kDa. It elutes out between standard conalbumin (75
kDa) and ovalbumin (43 kDa) and is more likely a monomer (Figure 3-2A). The
molecule weight of His6-ArsD109 is predicted to be 16 kDa for a monomer and 32 kDa
for a dimer. It elutes out before standard carbonic anhydrase (29 kDa) and so is more
likely a dimer (Figure 3-2B). Since dimerization is concentration dependent, both MBPArsD109 and His6-ArsD109 could be in equilibrium between monomer and dimer. This
leads to the question whether ArsD interacts with ArsA as a dimer or a monomer. It is
also possible that both dimer and monomer are able to interact with ArsA.
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3.3.2 Mutations at the putative dimerization interface shift ArsD to a monomer
We attempted to make monomeric ArsD by mutating residues located at the
major dimerization interface observed in the crystal structure to test whether it is still
active. Whether the crystallographic ArsD dimer represents the solution dimer is not
know, but the observed dimer has an extensive interface between two subunits mainly
contributed by the 4th β-sheet and 3rd and 4th α-helix. In the crystallographic dimer, a
total surface area of 1,338 Å2 is buried between the two ArsD monomers. This
represents 11.5% of the total solvent-accessible surface. The dimer is mainly held
together by hydrogen bonds. Notably, there are at least 10 hydrogen bonds, and the
donors from one monomer and the acceptor from the other are less than 3.2 Å apart.
The hydrogen bond and salt bridge was shown in Figure 3-3. The amide and carbonyl
groups of Ala85 from one monomer make hydrogen bonds to the carbonyl and amide of
Ala85 from the other monomer, respectively. The hydroxyl of the Ser68 side chain from
one monomer is hydrogen bonded to the carbonyl of Val83 from the other monomer.
The carbonyl of Gly86 from one monomer makes hydrogen bonds to the side chain
amides of Arg96 from the other monomer. The carbonyl of Gly86 from one monomer
also makes hydrogen bonds to the side chain amides of Arg87 from the other monomer.
Arg96 and Glu71 form salt-bridge.
The side chains of Ser68, Arg87 and Arg96 are predicted to contribute hydrogen
bonds and a salt bridge. A triple mutant was made by mutating these three residues to
alanines. Eight hydrogen bonds should be eliminated if no new bonds are formed. This
triple mutant His6-ArsD109S68A/R87A/R96A is predicted to have molecular weight of 16 kDa
for a monomer and 32 kDa for a dimer, similar to the wild-type His6-ArsD109. In gel-
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filtration chromatography, this mutant elutes after carbonic anhydrase (29 KDa) (Figure
3-4A) and so is most likely in an equilibrium between dimer and monomer, compared
with wild-type His6-ArsD109, which elutes before carbonic anhydrase (Figure 3-2B).
Thus the dimerization equilibrium of this mutant is shifted toward the monomer. This
suggests that Ser68, Arg87 and Arg96 are involved in dimerization in the solution, and
that the dimer interface in the crystal structure is similar to that in solution.
We further mutated four other residues, Glu81, Thr82, Val83 and Met84 to
alanine residues, creating His6-ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A. These seven
mutations totally changed the 4th β-sheet, which is predicted to be involved in
dimerization. In gel-filtration chromatography, this mutant elutes between carbonic
anhydrase (29 kDa) and ribonuclease (13 kDa), suggesting that it is in equilibrium
between monomer and dimer (Figure 3-4B). However, it does not totally correspond to a
monomer size, making interpretation difficult.
The mutant ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A stimulated ArsA ATPase
activity as well as the wild type. Both of wild type His6-ArsD109 and this mutant
increased the apparent affinity of ArsA for As(III) to around 10 μM (Figure 3-4C),
suggesting that dimerization may be not required for the ArsD metallochaperone
function. However, since the mutants are in monomer-dimer equilibrium, this conclusion
is not firm.
3.3.3 Generating an ArsD mutant with weaker dimerization
Since we were unable to change ArsD entirely to a monomeric form by sitedirected mutagenesis, we use yeast random mutagenesis coupled with the yeast twohybrid system to select for ArsD mutants that show weaker dimerization. Yeast strain
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MAV203 has ura3 reporter gene that encodes an enzyme metabolizing 5-FOA (5fluoroorotic acid) to 5-fluorouridine, an analog of uridine, inhibiting cell growth. Therefore
MAV203 can be used to select for mutants with weaker interaction or no interaction as a
result of ability to grow on plates with 5-FOA (Vidal et al., 1996). ArsD have been shown
to dimerize by GAL4 yeast two-hybrid analysis with yeast strain AH109 (Lin et al.,
2007b). We confirmed that ArsD also dimerizes in MAV203 and determined that
MAV203 co-transformed with pACT2-D (encoding wild type AD-ArsD) and pGBT9-D
(encoding wild type BD-ArsD) cannot grow on SD-L-W plates with 0.2 % 5-FOA. So we
used 0.2 % 5-FOA to select for ArsD mutants that cannot interact with wild type ArsD or
interacts more weakly.
Using a pair of primers homologous to regions on pGBT9-D (encoding BD-ArsD)
flanking the inserted arsD gene, error-prone PCR was performed on ArsD as described
under ‘Materials and Methods’. The purified PCR product was mixed with pGBT9-k
vector linearized by EcoRI and BamHI, and co-transformed with pACT2-D (encoding
wild type AD-ArsD) into MAV203 and selected on SD-L-W plates with 0.2 % 5-FOA. 240
colonies could grow on 5-FOA plates, 8% of the 3000 clones that grew on plates without
5-FOA. Presumably these colonies might contain not only ArsD mutants interacting
more weakly with wild type ArsD, but also truncated ArsD mutants, non folding ArsD
mutants, or even empty pGBT9 vector. Since ArsD interacts with ArsA in yeast strain
AH109 (Lin et al., 2007b), we further screened the mutants for their ability to still interact
with ArsA. If they retained the ability to interact with ArsA, they should fold normally. We
pooled the resulting 240 colonies and used the same primer, homologous to regions on
pGBT9-D flanking the inserted arsD gene for colony PCR. Then the purified PCR
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products were mixed with vector plasmid pGBT9-k linearized by EcoRI and BamHI. The
mixture was co-transformed with pACT2-A (encoding AD-ArsA) into AH109, and
colonies were selected on SD-L-W-H plates. 55 colonies grew on SD-L-W-H plates,
0.8% compared with 6500 colonies on the SD-L-W plates. 24 colonies were picked and
sequenced. Finally, we isolated two ArsD mutants that showed no interaction with wild
type ArsD but retained interaction with ArsA (Figure 3-5A). These two mutants are
ArsDL36H, I43F,G86E and ArsDG86E.
Only the G86E mutation was found in both mutants. Gly86 sits in the dimerization
interface (Figure 3-3C), suggesting this mutant might be a monomer. His6-ArsD109G86E
was constructed by site-directed mutagenesis. The protein was expressed, purified and
analyzed by gel-filtration chromatography. His6-ArsD109G86E eluted between carbonic
anhydrase (29 KDa) and ribonuclease (13 KDa), suggesting an equilibrium between
monomer and dimer (Figure 3-5B). Compared with wild-type His6-ArsD109, which
elutes before carbonic anhydrase (Figure 3-2B), mutant His6-ArsD109G86E was shifted
toward monomer, consistent with yeast two-hybrid analysis.
The ability of mutant ArsD109G86E to stimulate ArsA ATPase activity was
examined. His6-ArsD109G86E increased the apparent affinity of ArsA for As(III) to around
10 μM (Figure 3-6), again suggesting dimerization may be not required for the ArsD
metallochaperone function.
3.4

Discussion
In vivo results demonstrate that ArsD is an As(III)/Sb(III) chaperone that transfers

metalloid to the ArsA ATPase (Lin et al., 2006; Lin et al., 2007a), but the molecular
details of the process are lacking. Structural information about ArsD and the ArsD-ArsA
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complex is needed to understand the details. ArsD has been shown to be a dimer in
crystal structure. In this study the correlation between ArsD dimerization and
metallochaperone function was studied.
Non-tagged wild-type E. coli R773 ArsD has been shown to be a homodimer by
Sephacryl S-200 chromatography (Chen and Rosen, 1997). ArsD is also a dimer in the
crystal structure (Ye et al., 2010). ArsD constructs with either an N-terminal maltose
binding protein (MBP) tag or an N-terminal His6 tag were used in this study. They were
both active but behaved differently in gel-filtration chromatography. The monomer-dimer
equilibrium of MBP-ArsD109 is toward monomer, while the equilibrium of His6-ArsD109
is toward dimer.

These results could mean that either monomer or dimer of ArsD

interact with ArsA, so further analysis was required.
The crystallographic dimerization interface of ArsD involves a series of hydrogen
bonds and one salt bridge, with the side chains of Ser68, Arg87 and Arg96 participating.
As a consequence of mutating these residues to alanines, there was a shift in the
equilibrium toward the monomer direction, but each mutant was still active in terms of
metallochaperone activity. Using the yeast two-hybrid assay to select and screen
mutants with reduced interaction with wild-type ArsD but retaining interaction with ArsA,
the mutation G86E was found to decrease ArsD dimerization. Gly86 is located in the
dimerization interface in the crystal structure. Gel-filtration chromatography confirmed
that the equilibrium of His6-ArsD109G86E is shifted toward monomer direction, and this
mutant retains ability to stimulate ArsA ATPase activity. All these results suggest that
the dimerization region observed in the crystal structure also exists in solution, and that
dimerization is not strictly required for ArsD metallochaperone function.
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Recently the crystal structure of another ArsD homolog from Bacteroides
vulgatus ATCC 8482 was deposited in the Protein Data Base (pdb: 3KTB; Kim,
Y., Tesar, C., Feldmann, B., Joachimiak, A., Midwest Center for Structural
Genomics (MCSG), unpublished). E. coli R773 ArsD is clearly a dimer (Figure 3-7A).
However, Bacteroides vulgatus ATCC 8482 ArsD has four molecules in the
crystallographic unit (Figure 3-7C). In all four molecules, Cys13 and Cys18 form intrasubunit disulfide bonds. Each two of the subunits form an inter-subunit disulfide bond
with Cys12 from each subunit. Then two dimers form a tetramer noncovalently. 3KTB
and R773 ArsDs can be superimposed with an RMSD of 1.0 Å (Figure 3-7B).
Although Bacteroides vulgatus ATCC 8482 ArsD is a tetramer in crystal
structure, it is not known the aggregation status in the solution. But the structure
definitely suggests different subunit contact positions. The cysteine residues position of
Bacteroides vulgatus ATCC 8482 ArsD is very consistent with our previous result of
cysteine crosslinking by dibromobimane that Cys12, Cys13 and Cys18 from one subunit
are close to the cysteine residues from another subunit (Lin et al., 2007a). So it is also
possible R773 ArsD may have more than one site of contact between subunits, one at
the interface shown in R773 ArsD crystal structure and another one is close to the
cysteines. This may be one reason that no mutant is totally monomeric ArsD.
Very recently a new ArsD mutant, P52L, which exhibits increased affinity for wild
type ArsD was isolated using random mutagenesis and a modified yeast two-hybrid
assay (unpublished data). In the standard assay cells of histidine-requiring yeast are
screened for interaction between proteins by the ability to grow in the absence of
histidine. 3-Aminotriazole (3-AT) is a HIS3 competitive inhibitor that prevents growth.
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The two proteins fused to AD and BD should interact stronger to support the yeast cell
growth on the plates with 3-AT. Yeast cells co-transformed with BD-ArsD P52L (mutant
ArsD fused to BD) and AD-ArsD (wild-type ArsD fused to AD) grow in the presence of
60 mM 3-AT (Figure 3-8). Interestingly, the yeast two-hybrid results suggest that P52L
loses interaction with ArsA (Figure 3-8). This may indicate that there is another
dimerization interface that involves Pro52 (Figure 3-9A and B). The crystal structure
suggests that a hydrophobic patch may be involved in interaction between subunits in
neighboring asymmetric units, including Leu48, Phe52, Met53, Phe55, Val56, Val61,
Ile66 and Ala70, which may form an extensive hydrophobic interface (Figure 3-9C and
D). Residues Leu48, Pro52, Met53 and Val56 are close to an adjacent subunit,
contributing to this crystallographic dimerization interface. Although the side chains of
residues Phe55, Val61 and Ile66 point inward, they are less than 5Å from corresponding
residues in the adjacent subunit, close enough to form an intra-subunit hydrophobic
core. They may be important for maintaining the angles between the α2 and α3 helixes
and may contribute to dimerization as well (Figure 3-9E). This hypothesis can explain
why mutations in the previous dimerization interface do not result in strict monomer.
This idea will be tested by future students in the lab.
In addition, ultra-centrifugation will be used to analyze the aggregation status of
ArsD in the solution and to obtain the associating constant of ArsD. In summary, it is still
unclear whether ArsD is a monomer or dimer when it interacts with ArsA.

68

CHAPTER 4
Mapping ArsA-ArsD interaction interface by genetic analysis
4.1

Introduction
ArsD is an As(III)/Sb(III) chaperone that transfers metalloid to the ArsA ATPase

(Lin et al., 2006). ArsD transfers As(III) to ArsA in the presence of Mg2+ and ATP.
Correspondingly, ArsD can be crosslinked with ArsA in the presence of Mg2+ and ATP,
by the homofunctional cysteine crosslinker dibromobimane. ArsA structure has been
solved by crystallization (Zhou et al., 2000). Cys113, Cys172 and Cys422 are close to
each other and involved in metal binding (Ruan et al., 2006, 2008). ArsD structure has
been recently solved (Ye et al., 2010). Though the metal binding site is missing in the
structure, biochemical results suggest that Cys12, Cys13 and Cys18 form a three-sulfur
coordinated metal binding site important for transferring As(III) to ArsA (Lin et al.,
2007a). According to this, we proposed a model for the metal transfer similar as the
model shown in Figure 2-12 (Lin et al., 2007a), that ArsA and ArsD interact at their
metal binding sites, then As(III) is transferred through ligand-exchange between
cysteine residues of ArsA and ArsD. Consistent with this model, As(III) is protected from
sequestration by As(III) chelator, DMSA, during transfer from ArsD to ArsA, suggests
that ArsA-ArsD interaction forms a channel for As(III) transferring from MBS of ArsD to
MBS of ArsA. However, a detail of interaction between ArsD and ArsA is still unknown.
Copper chaperone has been found from prokaryotic cells to eukaryotic cells.
They are most well studied metallochaperone protein. The study of interaction between
copper chaperone proteins and their targets are summarized in Table 4-1. So far, no cocrystallization of the wild-type chaperone proteins and their targets has been successful.
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Through gel-filtration, Cu(I)-CopZ transfer Cu(I) to CopY. But these two protein do not
come off the gel-filtration column as a complex (Cobine et al., 1999). Similar to this,
ArsD transfers As(III) to ArsA but they do not form stable complex. The interaction
between HAH1, and the second or the fifth soluble domains of ATP7A (MNK2 and
MNK5, respectively), was investigated in solution using heteronuclear NMR. No stable
adduct is formed between either of the MNK domains and HAH1 (Banci et al., 2005).
NMR titration shows the formation of an adduct by Cu(I)-HAH1 with WLN4 that is in fast
exchange on the NMR time scale with the isolated protein species as confirmed by

15

N

relaxation data. A similar interaction is also observed between Cu(I)-HAH1 and WLN2;
however, the relative amount of the adduct in the protein mixture is lower. In both cases
the interaction interface can not be mapped by NMR (Achila et al., 2006). All these
results suggest that the interaction between copper chaperone proteins and their targets
is weak and transient. Maybe this is a common nature for all metallochaperone proteins
since their roles are to escort the metal to the target proteins but not stick to their target
proteins. Unless we can stop the transfer process, the complex will not be stable. One
example is the complex structure of yeast copper chaperone yCCS and its partner
protein, superoxide dismutase (SOD1). His48, one of the ligand for copper was mutated
to Phe in SOD1; in this mutant transfer could not be completed. yCCS and this mutant
SOD1 form stable complex (Lamb et al., 2000) and can be co-crystallized (Lamb et al.,
2001).
Another complex structure was characterized by combination of NMR and in
silico modeling. The study was conducted with Atx1 and the first MBD of Ccc2. By
following the

15

N and 1H chemical shifts, a new species was detected. This species is in
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fast exchange with the parent species on the NMR time scale. Nuclear relaxation data
are consistent with the formation of an adduct (Arnesano et al., 2001). Based on NMR
chemical shift mapping information, a structure model of the transient complex was
proposed through in silico docking. The model shows that the interaction is mainly of an
electrostatic nature with hydrogen bonds stabilizing the complex (Arnesano et al.,
2004).
Crystallization and NMR are two major tools to get the details of structural
information. Dr. Abdul Ajees Abdul Salam in our laboratory is trying to get the crystal
structure of ArsA-ArsD complex, but with no success so far. Dr. Jun Ye and I tried NMR
study on ArsD in the hope of mapping interaction interface by following the

15

N and 1H

chemical shifts. However, the inhomogeneous nature of ArsD aggregation state at high
concentration such as 1 mM required for NMR study has delayed complete assignment.
Yeast two-hybrid has been used to show interaction between Atx1 and the Nterminal MBD of Ccc2 (Pufahl et al., 1997), between Atx1 and copper amine oxidase
Cao1 (Peter et al., 2008), between HAH1 and the 2nd or 4th MBD of ATP7B (van
Dongen et al., 2004), and also between HAH1 and 2nd-6th MBD of ATP7A (Larin et al.,
1999).
The yeast two-hybrid system is a genetic system engineered to study proteinprotein interaction (Fields and Song, 1989). It has been widely used to build proteinprotein interaction networks (Bruckner et al., 2009). Yeast two-hybrid analysis takes
advantage of the properties of yeast transcriptional factor such as GAL4. GAL4 is a
transcriptional activator required for expression of genes encoding enzymes for utilizing
galactose. It consists of two separate and essential domains. One is the N-terminal
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DNA binding domain (BD). The other is the C-terminal activation domain (AD). DNA
binding domain (BD) binds to a small DNA element (UAS, upstream activation
sequence), usually in the promoter region of the activated genes. The activation domain
(AD) recruits the transcriptase to initiate the transcription. By expressing bait protein
fused with BD and prey protein fused with AD separately from different plasmids, only
when bait protein and prey protein interact with each other, a functional GAL4
transcriptional activator can be reconstituted. Usually a reporter gene was engineered in
the yeast chromosome as a marker for selection. When two proteins interact, the
reporter gene will be expressed. Normal yeast two-hybrid analysis uses nutrition
synthetic genes such as his3, a histidine synthesis gene, as a reporter. So only when
two proteins interact with each other, can the yeast cells grow on media lacking
histidine. New systems have also been devised using a toxic gene such as ura3 as a
reporter gene. ura3 encodes orotidine 5-phosphate decarboxylase. It can metabolize 5FOA (5-fluoroorotic acid) to 5-fluorouridine, an analog of uridine, inhibiting cell growth.
Therefore it can be used to select for the mutants with weaker interaction or no
interaction by growing the yeast cells on the plate with 5-FOA. This is also called
reverse yeast two-hybrid analysis (Vidal et al., 1996). Mutations interfering with
interaction can give information about the protein-protein interaction interface. The
normal yeast two-hybrid analysis has been used to select for the mutants retaining the
interaction. The absence of interference of these mutation points was used to map the
protein-protein interaction interface (Dhayalan et al., 2008).
Using a yeast two-hybrid system based on the GAL4 transcriptional factor, ArsD
and ArsA were shown to interact with each other (Lin et al., 2006). Plasmid pACT2 was
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used to express ArsD or ArsA fused with GAL4 activation domain (GAL4-AD). Plasmid
pGBT9 was used to express ArsD or ArsA fused with GAL4 DNA binding domain
(GAL4-BD). Yeast strain AH109 with his3 as reporter gene was used to show ArsDArsA interaction. his3 encodes imidazole glycerol-phosphate dehydratase, catalyzing
the sixth step in histidine biosynthesis. ArsD-ArsA interaction is indicated by cell growth
on the plate lacking histidine.
Histidine synthesis by HIS3 enzyme is competitively inhibited by 3-AT (3-amino1,2,4-triazole) (Klopotowski and Wiater, 1965). If 3-AT was added to the medium, the
yeast cells need to synthesize more HIS3 to grow normally. 3-AT has been used in the
yeast three-hybrid system to select RNA with higher affinity to the protein (Cassiday and
Maher, 2003; Hook et al., 2005).
We did random mutagenesis by error-prone PCR induced with Mn2+ on both
ArsA and ArsD (Cadwell and Joyce, 1992). Then we selected for mutants that lose
interaction using reverse yeast two-hybrid analysis. 3-AT was used with the yeast twohybrid strain AH109 using his3 as a report gene to select for mutants showing stronger
interaction. In addition, we also did site-directed mutagenesis on lysine residues of ArsD
and obtained mutants losing function. All these mutants will give us information about
ArsA-ArsD interaction interface.
4.2

Materials and Methods

4.2.1 Reagents
3-AT (3-amino-1,2,4-triazole) was purchased from MP Biomedicals (Solon, OH).
5-FOA (5-Fluoroorotic Acid) was purchased from Fermentas (Burlington, Ontario).
Yeast minimal SD base, amino acid Drop-out supplements, -Leu/-Trp and -Leu/-Trp/-His
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were

purchased

from

Clontech

(Mountain

view,

CA).

Sulfo-NHS

Acetate

(Sulfosuccinimidyl Acetate) was purchased from Thermo Scientific (Rockford, IL).
Unless otherwise mentioned, all other chemicals were obtained from Sigma.
4.2.2 Strains, plasmids and media
E. coli strain JM109 [rcA1 supE44 endA1 hsdR17 gyrA96 relA1 thiΔ(lac-proAB)
F’ (traD36 proAB+ lacIq lacZΔM15)] was used for molecular cloning. E. coli strain
BL21(DE3) [hsdS gal(ΔcIts857 ind1 Sam7 nin5 lacUV5-T7 gene1)] was used for protein
expression and purification. ArsA with C-terminal His6 tag was cloned in the expression
vector pAlter-1 as pAlter-dAhB (Li and Rosen, 2000). Six histidines tagged ArsD1-109
truncation was cloned in the expression vector pET28a as pET28a-ArsD109 (Chapter 2).
E. coli cells were grown in Luria-Bertani (LB) medium (Sambrook et al., 1989) at 37°C.
Ampicillin

(100

µg/ml),

kanamycin

(40

µg/ml)

and

0.3

mM

isopropyl-ß-D-

thiogalactopyranoside were added as required. Plasmids pGBT9 and pACT2 were used
as S. cerevisiae/E. coli shuttle vectors for yeast two-hybrid assay (Lin et al., 2007b). S.
cerevisiae strains AH109 (MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4∆,
gal80∆,

LYS2::GAL1UAS-GAL1TATA-HIS3,

GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UAS-

MEL1TATA-lacZ) (Clontech, Mountain View, CA) and MAV203 (MATα; leu2-3,112; trp1901;

his3Δ200;

ade2-101;

cyh2R;

HIS3UASGAL1::HIS3@LYS2; SPAL10::URA)

can1R;

gal4Δ;

gal80Δ;

GAL1::lacZ;

(Invitrogen, Carlsbad, CA) were used for

yeast two-hybrid assay. Yeast cells were grown in complete yeast extract-peptonedextrose (YPD) or minimal synthetic dextrose (SD) media with the appropriate
supplements at 30°C (Adams et al., 1998). Growth in liquid culture was estimated from
the absorbance at 600 nm. The strains and plasmids are listed in Table 4-2.

74

4.2.3 DNA manipulation and mutagenesis
Plasmid extraction, DNA restriction endonuclease analysis, ligation and other
general molecular biological procedures were performed as described (Sambrook et al.,
1989). Transformation of E. coli cells was carried out using a BIO-RAD MicroPluser
(BIO-RAD, Hercules, CA). Transformation of Yeast cells was performed using Fast
Yeast Transformation™ kit from G-Biosciences (Maryland Heights, MO). DNA
purification kits were obtained from QIAGEN (Valencia, CA). Either a Qiaprep Spin
Miniprep kit or a Qiaquick gel extraction kit (QIAGEN) was used to prepare plasmid
DNA for restriction enzyme digestion, sequencing, and recovering DNA fragments from
agarose gels. Zymoprep II™ Yeast Plasmid Miniprep (Zymo Research, Orange, CA)
was used to extract plasmid from yeast cells. The sequence of new plasmid constructs
was confirmed by DNA sequencing of the entire gene. Site-directed mutagenesis was
performed using Quick-change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA)
and confirmed by sequencing. DNA sequencing was performed using a CEQ2000 DNA
sequencer (Beckman Coulter, Brea, CA). The primers used are listed in Table 4-3.
4.2.4 Generation of a random mutated library of PCR fragments
Random mutagenesis of ArsA or ArsD was performed using ep-PCR (Cadwell
and Joyce, 1992) by employing biased nucleotide composition of the PCR buffer, high
concentration of Mg2+ and addition of Mn2+. The ep-PCR reaction mixture (50 μl)
contained 20 mM Tris–HCl (pH 8.4), 50 mM KCl, 7 mM MgCl2, 0.2 mM each of dATP
and dGTP, 1 mM each of dCTP and dTTP, 25 pmol each of the oligonucleotide primers,
80 ng of template DNA, 2.5 U of Taq DNA polymerase (Invitrogen).
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For ArsA, pACT2-A plasmid DNA was used as template, and pACT2-s (CTA TTC
GAT GAT GAA GAT ACC CCA CCA AAC CC) and pACT2-a (AGG TTA CAT GGC
CAA GAT TGA AAC TTA GAG GAG) were used as primer, 0.1mM Mn2+ was added.
PCR condition was 1× 96 °C for 3 min, 30× 94 ° for 30 s, 1× 55 °C for 30 s, 1× 72 °C for
4 min, and, finally, 1× 72 °C for 10 min. For ArsD, pGBT9-D plasmid DNA was used as
template, and pGBT9-s (TAA AGA TGC CGT CAC AGA TAG ATT G) and pGBT9-a
(ACC TGA CCT ACA GGA AAG AGT TAC T) were used as primer. 0.5mM Mn2+ was
added. PCR condition was similar to the condition for ArsA, only extension time at 72°C
is changed to 100 s. The ep PCR product was analyzed by agarose gel, extracted from
gel and quantified by absorption at 260nm.
4.2.5 Yeast two-hybrid analysis
Two yeast stains, AH109 (Fields and Song, 1989) and MAV203 (Vidal et al.,
1996), were used. Both are GAL4-based yeast two-hybrid system. AH109 was used to
analyze protein-protein interaction or select the mutants that retaining capability of
interaction or showing stronger interaction in the presence of 3-AT (3-amino-1,2,4triazole) (Sigma-Aldrich, St. Louis, MO). MAV203 was used to select for the mutants
that lose the capability of interaction through counter-selection in the presence of 5-FOA
(5-Fluoroorotic Acid) (Fermentas, Burlington, Ontario). Yeast cells are co-transformed
with ars gene-fused pGBT9-X (BD-X) and pACT2-Y (AD-Y) plasmids. To determine
protein-protein interaction by growth of series of dilutions, the transformed cells were
cultured overnight in SD medium at 30°C and then washed, suspended and adjusted to
an absorbance of 1 at A600nm in 20 mM Tris-HCl pH 7.5. Portions of the cell suspensions
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(1 μl) were inoculated in serial 10-fold dilutions on SD agar plates lacking histidine or
with 3-AT at indicated concentration. The plates were incubated at 30°C for 3 days.
pGBT9 was modified to pGBT9-k as in Chapter 2. To select for ArsD mutants,
the ep-PCR fragment was mixed with pGBT9-k vector linearized by EcorI and BamHI,
and co-transformed with pACT2-A or pACT2-D into yeast-strains and selected on the
indicated plates. The PCR fragment will be ligated into the vector in vivo through
homology recombination (Hua et al., 1997). To select for ArsA mutants, the ep-PCR
fragment was mixed with pACT2 vector linearized by EcorI EcoRI and BamHI, and cotransformed with pGBT9-k-D into yeast-strains and selected on the indicated plates.
4.2.6 Sequencing of ArsD and ArsA mutant genes in yeast colonies
Each yeast colony was grown in corresponding liquid SD medium. The plasmids
were isolated from yeast by Zymoprep II™ Yeast Plasmid Miniprep Kit (Zymo Research
Cop. Orange, CA), transformed to E. coli JM109 and grown on LB plate with ampicillin
for ArsA and kanamycin for ArsD. Then the plasmids were extracted from E. coli JM109
and sequenced as the following. For ArsD, mutant genes on pGBT9-k vector were
sequenced with the GAL4-BD sequencing primer (GAG TAG TAA CAA AGG TCA A).
For ArsA, mutant genes on pACT2 vector were sequenced with five sets of primers
(GAL4-AD sequencing primer: AAT ACC ACT ACA ATG GAT; ArsA-100-s: GTC CTG
CCT GAT GAC GTT GTT TCC A; ArsA-220-s: GTC GCC CGG ACT CAT CTG GAA
CTT G; ArsA-420-s: AAG AGG ACT TAC GCT CAC CTT GCA C; ArsA-480-a: CGT
GAC CAG TAA CAC TTT AGT GCG).
4.2.7 Protein expression and purification
Cells bearing the indicated plasmids were grown in LB medium overnight at 37°C
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and then diluted 50-fold into 1 L of the same medium. Proteins were expressed by
induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6-0.8 for 3 hrs.
ArsA with a six histidine tag at the C-terminus was purified from cells of strain
BL21(DE3) expressing pAlter-1-dAhB plasmid, as described (Zhou and Rosen, 1997).
Cells were harvested by centrifugation and washed once with a buffer containing 50 mM
MOPS, pH 7.5, 0.5 M NaCl, 30 mM Imidazole and 10 mM 2-mercaptoethanol (Buffer A).
The cells were suspended in 5 ml of Buffer A per gram of wet cells and lysed by a single
passage through a French press at 20,000 psi. Diisopropyl fluorophosphate (DIFP)
(Sigma) was added at 2.5 μl/g wet cells immediately following French press. Unbroken
cells and membranes were removed by centrifugation at 150,000 x g for 1 hr at 4oC.
The supernatant was loaded to 10 ml Probond Ni-column (Invitrogen) pre-equilibrated
with Buffer A. Unbound proteins were washed by 60 ml of buffer A, and ArsA was
eluted with imidazole gradient generated by Buffer A and Buffer B(50 mM MOPS, pH
7.5, 0.5 M NaCl, 300 mM Imidazole and 10 mM 2-mercaptoethanol), followed by
addition of 0.25 mM EDTA and 5 mM DTT to each fraction. ArsA containing fractions
were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE), pooled, concentrated by Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-10
membrane (Millipore), mixed with 10% glycerol, aliquoted and stored at -80oC until used.
ArsD and its derivatives with a six histidine tag at the N-terminus were purified similarly.
Purified proteins were stored at -80°C until use, and their concentrations were
determined according to the method of Bradford (Bradford, 1976) or from the absorption
at 280 nm (Gill and von Hippel, 1989).
4.2.8 ATPase activity assays
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ATPase activity was estimated using a couple assay (Vogel and Steinhart, 1976),
as described (Hsu and Rosen, 1989). ArsA was added at a final concentration of 0.3 μM
into an assay mixture containing 5 mM ATP, 1.25 mM phosphoenolpyruvate, 0.25 mM
NADH, 10 units of pyruvate kinase and lactate dehydrogenase with or without the
indicated concentrations of sodium arsenite, in the buffer containing 50 mM MOPS-KOH,
pH 7.5, 0.25 mM EDTA. ArsD was added at the indicated concentrations. The mixture
was pre-warmed to 37°C, and the reaction was initiated by addition of 2.5 mM MgCl2
and measured at 340 nm. The linear steady state rate of ATP hydrolysis was used to
calculate specific activity. The reaction volume was 0.2 ml each in 96-well microplates,
and the reactions were monitored by microplate reader SPECTRA max 340PC
(Molecular Devices).
4.2.9 Acetylation of lysine by Sulfo-NHS acetate
The Buffer of purified ArsD or ArsD derivatives was exchanged with a buffer
containing 50 mM MOPS-KOH, 200mM NaCl, pH 7.8, 0.25 mM EDTA, 5mM TCEP and
5mM DTT. Dissolve Sulfo-NHS acetate in pure water to 100mM. Dilute protein to 1 mM
concentration. Add Sulfo-NHS acetate at 10 fold concentration of free amine in the
protein solution. It is like mixing 1 ml of 1 M protein solution with 0.7 ml of 100 mM
Sulfo-NHS acetate for ArsD109 or 0.3 ml of 100 mM Sulfo-NHS acetate for
ArsD109K2/104A-K37/62R and ArsD109K2/104A-K60/90A. Mixture was incubated for 60 min at
room temperature. 200 ul of 0.5 M Tris pH 6.8 was added to quench the reaction for 20
min. Then protein was diluted with 10ml buffer of 50 mM MOPS-KOH, pH 7.5, 200 mM
NaCl, 0.25 mM EDTA, 5 mM TCEP and 5 mM DTT and concentrated to 1ml with
Amicon Ultra-15 Centrifugal Filter Unit. Repeat dilution with buffer and concentrating for
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three more times to totally change protein buffer. Finally protein was concentrated,
mixed with 10% glycerol, aliquoted and stored at -80oC until used.
4.2.10 Metalloid binding assay
The buffer of purified ArsD was exchanged with a buffer containing 50 mM
MOPS-KOH, pH 7.5, 0.25 mM EDTA (ATPase assay buffer), using a Bio-Gel P-6 Micro
Bio-Spin column (Bio-Rad, Hercules, CA). Purified protein (100 μM) was incubated at
4oC with 300 μM potassium antimonyl tartrate. After 1 h, each sample was passed
through a Bio-Gel P-6 column pre-exchanged with the ATPase assay buffer. ArsA
protein concentration in the flow through was quantified from the absorption at 280 nm
(Gill and von Hippel, 1989) or according to the method of Bradford (Bradford, 1976).
Flow through were diluted with 2% HNO3, and the quantity of metalloid was measured
by inductively coupled mass spectrometry (ICP-MS) with a PerkinElmer ELAN 9000.
Antimony standard solutions in the range of 1-20 ppb in 2% HNO3 were obtained from
Ultra Scientific, Inc. (North Kingstown, RI). From the ratio of antimony concentration and
protein concentration in the flow through, the binding molar ratio is calculated.
4.3

Results

4.3.1 ArsD mutants showing stronger interaction with ArsA
AH109 uses his3 as the reporter gene. his3 will be transcribed when two proteins
interact with each other. Histidine synthesis by HIS3 enzyme is competitively inhibited
by 3-AT (3-amino-1,2,4-triazole) (Klopotowski and Wiater, 1965). If 3-AT was added to
the medium, the yeast cells need to synthesize more HIS3 to grow normally. Here 3-AT
was used in yeast two-hybrid analysis to qualitatively distinguish interaction strength
between two proteins and select for stronger interaction mutants. Using a pair of primer
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homologous to regions on pGBT9-D flanking the inserted arsD gene, error-prone PCR
was done on ArsD in the presence of Mn2+. The purified ep-PCR product was mixed
with pGBT9-k vector linearized by EcoRI and BamHI, co-transformed with pACT2-D into
AH109 and selected on SD-L-W-H plates with 10 mM 3-AT. The PCR fragment was
ligated into the vector in vivo through homology recombination (Hua et al., 1997).
Around 30 colonies grew on SD-L-W-H plates with 10 mM 3-AT. We sequenced the
ArsD gene in each colony. Some contained a single mutation, while others contained
multiple mutations. Some mutations occurred only once, but mutations such as S14R,
T20I, Q24L, D28V and Q34R were found in many mutants. These mutations were
reintroduced by site-directed mutagenesis as single mutation and tested to see whether
they increased the strength of interaction with ArsA, as shown in Figure 4-1 (only
mutants with stronger interaction are shown).
ArsDs with any of nine mutations at eight positions, including two at Asp 28,
D28V and D28V, exhibit stronger interaction with ArsA (Figure 4-1). AH109 yeast cells
co-transformed with pGBT9-k-D (encoding the GAL4 DNA binding domain fused with
wild-type ArsD, BD-ArsD) and pACT2-A (encoding the GAL4 activation domain fused
with wild-type ArsA, AD-ArsA) do not grow on SD-L-W-H plates with 10 mM 3-AT, while
AH109 yeast cell co-transformed with pGBT9-k-DS14R (encoding BD-ArsDS14R) and
pACT2-A grows normally on plates with 30mM 3-AT, and the mutation has no effect on
dimerization with wild-type ArsD when co-transformed with pACT2-D (encoding wildtype AD-ArsD) (Figure 4-1, right panel). ArsD mutants, T20I, Q24L, D28V, D28T, T31A,
Q34R and V61A behave similarly as the S14R mutant. Mutant Q38R only slightly
increases the strength of interaction with ArsA, as shown that cells grow on plates
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containing 10 mM 3-AT but not on plates containing 30 mM 3-AT. Ser 14 and Thr 20 are
in the loop containing the metal binding site formed by three cysteine residues Cys12,
Cys13 and Cys18. Four residues, Gln24, Asp28, Thr31 and Gln34, are located on the
same face of the first α-helix (Figure 4-7A). Q38R shows a slight effect on the
interaction with ArsA and is located just following the above four residues on the same
α-helix. These results suggest that a strip formed by these 5 residues on this α-helix
may be involved in direct contact of ArsD with ArsA.
4.3.2 Lys37 and Lys62 are involved in interaction with ArsA
One unsuccessful approach had been to attempt to crosslink the ArsD dimer
using amine-specific homofunctional crosslinker. As part of that, we made series of
ArsD lysine mutants to reduce nonspecific crosslinking. ArsD has 6 lysine residues,
Lys2, Lys 37, Lys60, Lys62, Lys90 and Lys104. One of the mutants, ArsD109K2/104AK37/62A,

was not able to stimulate ArsA ATPase activity (Figure 4-2A), suggesting that

one or more of those four lysine residues might be involved in ArsD metallochaperone
function, shown as increasing the apparent affinity of ArsA for As(III) in this assay. To
identify which lysine residue(s) is (are) involved, we examined more ArsD mutants
carrying fewer lysine mutations. ArsD109K2/104A stimulates ArsA ATPase activity as well
as the parental ArsD109. ArsD109 increases ArsA apparent affinity for As(III) from 535
μM to 15 μM, and ArsDK2/104A increases to 8 μM. However, ArsD109K37A and
ArsD109K62A individually only increase ArsA apparent affinity for As(III) to 126 μM and
289 μM respectively, suggesting that Lys37 and Lys62 together, but not Lys2 and
Lys104, may play roles during arsenic transfer from ArsD to ArsA. Thus, it appears that
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the two mutations at Lys37 and Lys62 are synergistic in their effect on ArsD
metallochaperone function.
We further examined lysine residues Lys60 and Lys90 to see whether they are
involved in the arsenic transfer. By mutating both of them to alanine, ArsD109K2/104AK60/90A

increases ArsA apparent affinity for As(III) to 21 μM (Figure 4-2B), almost same

as wild-type ArsD109, indicating that neither Lys60 nor Lys90 are required for arsenic
transfer from ArsD to ArsA.
To examine the requirement for a positive charge, Lys37 and Lys62 were
changed to arginine. ArsD109K2/104A-K37/62R increases the apparent affinity of ArsA for
As(III) to 15 μM, similar to ArsD109 (Figure 4-2B). Compared with ArsD109K2/104A-K37/62A,
which loses ability to stimulate ArsA ATPase activity, arginine mutant ArsD109K2/104AK37/62R

is still active, suggesting that a positive charge may be required for ArsD

metallochaperone function. This was further supported by chemical modification of
lysine residues with Sulfo-NHS acetate (sulfosuccinimidyl acetate), which acetylates
amine group and neutralizes the positive charge.

ArsD109 increases the apparent

affinity of ArsA for As(III) from 521 μM to 12 μM before acetylation, and 204 μM after
acetylation, consistent with the involvement of lysine residues in metallochaperone
activity. Acetylation decreases wild-type activity dramatically although not completely,
which might be due to partial acetylation (Figure 4-3). Mutant ArsD109K2/104A-K60/90A, with
only lysine residues Lys37 and Lys62 remaining, increases the apparent affinity of ArsA
for As(III) to 26 μM before acetylation, and 283 μM after acetylation. This suggests that
acetylation of Lys37 and Lys62 causes loss of ArsD metallochaperone function. Mutant
ArsD109K2/104A-K37/62R, with only lysine residues Lys60 and Lys90 left, increases ArsA
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apparent affinity for As(III) to 12 μM before acetylation, and 7 μM after acetylation. This
is consistent with the result above that Lys 60 and Lys 90 are not required for
stimulating ArsA ATPase activity. It also indicates that acetylation has no effect on other
non-lysine residues. It is not surprised that acetylation has no effect on ArsD109K2/104AK37/62R,

in which Lys37 and Lys62 were mutated to arginine, since acetylation by Sulfo-

NHS does not change the positive charge of arginine residues. All of these results
suggest that Lys37 and Lys62 are involved for the ArsD metallochaperone function and
that a positive charge at these positions is important.
The antimony binding capability of the mutant ArsD109K2/104A-K37/62A was
measured by gel-filtration and ICP-MS quantification. As expected, the parental
ArsD109 binds approximately one Sb(III) per monomer (Lin et al., 2007a).
ArsD109C12/13S-C18A, with no metalloid binding site, binds only a background level of
Sb(III) (Lin et al., 2007a). ArsD109K2/104A-K37/62A binds Sb(III) as well as ArsD109, about
one Sb(III) per monomer (Figure 4-4A). Interaction between ArsD lysine mutants and
ArsA was investigated using yeast two-hybrid analysis. All of the mutants interact with
wild-type ArsD, suggesting these mutants fold and dimerize (Figure 4-4B). This is also
supported by the fact that these mutants can be overexpressed in E. coli and purified
from the cytosolic soluble fraction. ArsDK2/104A-K37/62A does not interact with ArsA, while
ArsDK2/104A-K37/62R and ArsDK2/104A-K60/90A interacts with ArsA as well as wild-type ArsD.
This is consistent with above results that ArsD109K2/104A-K37/62A does not stimulate ArsA
ATPase activity, but ArsD109K2/104A-K37/62R and ArsD109K2/104A-K60/90A do stimulate. K37A
and K62A mutations were separated, and their individual effects on ArsA interaction
was examined by yeast two-hybrid analysis. ArsD109K2/104A-K37A interacts with ArsA
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poorly compared with wild-type ArsD, while ArsD109K2/104A-K62A interacts with ArsA
almost same as wild-type, indicating that Lys37 may be more important than Lys62 in
terms of interaction with ArsA.
All these results suggest that mutating Lys37 and Lys62 to alanine does not
affect metal binding ability of ArsD but causes loss of interaction with ArsA, leading to
inability of transfer As(III) to ArsA and to stimulate ArsA ATPase activity. In the crystal
structure, Lys37 is in the same first α-helix as residues Gln24, Asp28, Thr31, Gln34 and
Gln38 (Fig. 4-7A). This is consistent with our hypothesis that this helix is involved in
interaction with ArsA. On the other hand Lys62 is adjacent to Val61, located in the third
α-helix, which is on the other side of the ArsD structure compared with the first α-helix
(Figure 4-7A). The above results show that a V61A mutant interacts more strongly with
ArsA, suggesting that the third α-helix, in which Val61 and Lys62 are located, may be
another point of interaction with ArsA.
4.3.3 ArsD mutants showing weaker interaction with ArsA
Yeast strain MAV203 has the reporter gene ura3, which encodes an enzyme that
metabolizes 5-FOA (5-fluoroorotic acid) to 5-fluorouridine, a toxic analogue of uridine
that inhibits cell growth. Therefore MAV203 can be used to select for mutants with
weaker or no interaction by selecting for growth on plates with 5-FOA (Vidal et al., 1996).
ArsA and ArsD have been shown to interact with each other in GAL4 yeast two-hybrid
system AH109 (Lin et al., 2007b). We confirmed that ArsA and ArsD also interact with
each other in strain MAV203 and determined that MAV203 co-transformed with pACT2A (encoding AD-ArsA) and pGBT9-D (encoding wild-type BD-ArsD) cannot grow on SD-
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L-W plates with 0.2 % 5-FOA. So we use 0.2 % 5-FOA to select for ArsD mutants that
cannot interact with ArsA or interact more weakly.
Using a pair of primer homologous to regions on pGBT9-D (encoding BD-ArsD)
flanking the inserted arsD gene, error-prone PCR was done as described under
‘Materials and Methods’. The purified PCR product was mixed with pGBT9-k vector
linearized by EcoRI and BamHI, and co-transformed with pACT2-A (encoding AD-ArsA)
into MAV203 and selected on SD-L-W plates with 0.2 % 5-FOA. 70 colonies were
isolated from 5-FOA plates, 7% of the 1000 clones on plates without 5-FOA. Of these
mutants, some will be ArsD mutants that interact more weakly with ArsA, but others
may be prematurely chain terminating ArsD mutants, unfolded ArsD mutants, or even
empty pGBT9 vector. Since ArsD forms a dimer in yeast two-hybrid AH109 (Lin et al.,
2007b), we further screened for those mutants that could still dimerize with wild-type
ArsD, with the assumption that these should fold normally. We pooled all 70 colonies,
and used the same primer, homologous to regions on pGBT9-D flanking the inserted
arsD gene, for colony PCR. The purified PCR products were mixed with plasmid
pGBT9-k that had been linearized with EcoRI and BamHI, co-transformed with plasmid
pACT2-D (encoding AD-ArsD) into AH109 and selected on SD-L-W-H plates. 300
colonies grew on SD-L-W-H plates, 7% of the 4000 colonies that grew on SD-L-W
plates. 30 colonies were purified and sequenced. Finally we isolated 5 ArsD mutants
showing weaker or no interaction with ArsA but still dimerizing with wild-type ArsD
(Figure 4-5A). These mutants are ArsDV17A, ArsDV22A, ArsDV27D, ArsDQ51H, and ArsDF55L.
Residues Val17 and Val22 are in the loop containing the metalloid binding site (Cys12,
Cys13 and Cys18). Val27 is in the first α-helix, in which residues Gln24, Asp28, Thr31,
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Gln34, Lys37 and Gln38 have been shown above to be important for the interaction with
ArsA (Figure 4-7A). This supports our hypothesis that this first α-helix is involved in the
interaction with ArsA.
4.3.4 ArsA mutants restoring interaction with ArsD mutants
To select for mutants that restored the ability of ArsD mutants to interact with
ArsA, we used random mutagenesis of ArsA in plasmid pACT2-A. Using a pair of primer
homologous to regions on pACT2 flanking the multiple cloning sites, error-prone PCR
was done on ArsA, as described under ‘Materials and Methods’. The purified PCR
product was mixed with the plasmid pACT2 linearized with EcoRI and BamHI, cotransformed with ArsD mutants in the plasmid pGBT9-k into strain AH109 and selected
on SD-L-W-H plates. Five ArsA mutants, ArsAP9L,L74H,D121G,F123L,E425A, ArsAD121E,
ArsAG111C,E400V,L530H,Q557L, ArsAL179R,H219L, and ArsAA29S,R88G,D121N,V215A,T401A, restored
interaction with ArsDV22A but also retained ability of interaction with wild-type ArsD
(Figure 4-5B). Three ArsA mutants, ArsAD121E, ArsAE425K,L564H, and ArsAD417N, restored
interaction with ArsDF55L (Figure 4-5C).

Six ArsA mutants, ArsAL152R,F162L,D513Y,S560C,

ArsAD121E,L207P, ArsAI65T,Q84L,D121E,H453L, ArsAV101A,R151H,S570T, ArsAT149A,I150H,E438D, and
ArsAD121G,E405V,E415V,H558R, restored interaction with ArsDQ51H (Figure 4-5D). All of the
ArsA mutants retained the ability to interact with wild-type ArsD, and one mutant
ArsAD121E, restored interaction with both ArsDV22A and ArsDF55L. This suggests that the
compensation of mutation on ArsA is not specific for the particular mutation in ArsD but
increase interactions from another site in ArsD, since an extensive interaction interface
was identified on ArsD.
4.3.5 ArsA mutants showing stronger interaction with ArsD
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Using a pair of primer homologous to regions on pACT2 flanking the multiple
cloning sites, error-prone PCR was done on ArsA. The purified PCR product was mixed
with vector pACT2 linearized by EcoRI and BamHI, co-transformed with pGBT9-D into
AH109 and selected on SD-L-W-H plates with 20 mM 3-AT. Six ArsA mutants show
stronger interaction with wild-type ArsD (Figure 4-6). AH109 yeast cells co-transformed
with pACT2-A or other ArsA mutants and pGBT9-k-D (encoding wild-type ArsD) were
spotted on SD-L-W-H plates with different concentrations of 3-AT. Cells with wild-type
ArsA cannot grow on plates with 10 mM 3-AT. ArsAI117M,E425G and ArsAH368L,E425k confer
resistance to 60 mM 3-AT, and both have Glu425 mutation. ArsAF120L,L193S and
ArsAF54L,F120L,H219R,E254V,F443L,K475R,A533T confer resistance to 120 mM 3-AT, and both have
mutations at Phe120. ArsAD121E and ArsAD121N confer resistance to 30 mM 3-AT, and
both have mutation at Asp121 position. These results suggest that ArsA residues
Glu425, Phe120 and Asp121 may be involved in interaction with ArsD.
Another Asp121 mutant, ArsAD121G,E405V,E415V,H558R, which was isolated as
complementing mutation Q51H in ArsD, also confers resistance to 60 mM 3-AT.
ArsAP9L,L74H,D121G,F123L,E425A was isolated by ability to complement mutation V22A in ArsD.
This multiple mutant contains changes at Asp121 and Glu425 and confers resistance to
90 mM 3-AT (Figure 4-6).
4.4

Discussion
ArsD transfers As(III) to ArsA in the presence of Mg2+ and ATP (Lin et al., 2006).

In vitro experiments suggest that ArsD and ArsA interact through their metal binding
sites. ArsA and ArsD crystal structures have been solved individually, but the details of
their interactions are still unknown. In this study, yeast forward and reverse two-hybrid
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selections were used to isolate mutants with stronger or weaker interactions, providing
information about the physical interface between ArsA and ArsD. Totally 16 mutations
in ArsD were identified to affect ArsA-ArsD interaction (Table 4-4).
Using 3-AT and strain AH109 with his3 as report gene, nine ArsD mutants were
found to increase the strength of interaction with ArsA. They include ArsDS14R, ArsDT20I,
ArsDQ24L, ArsDD28V, ArsDD28T, ArsDT31A, ArsDQ34R, ArsDQ38R and ArsDV61A. Using reverse
yeast two-hybrid selection, five ArsD mutants were isolated that show loss of or weaker
interaction with ArsA. These mutants still dimerize with wild-type ArsD, indicating that
the mutations do not cause protein misfolding. These five mutants are ArsDV17A,
ArsDV22A, ArsDV27D, ArsDQ51H and ArsDF55L.
Through site-directed mutagenesis, Lys37 and Lys62 were found to be significant
for ArsD metallochaperone function. If mutated Lys37 or Lys62 to alanine individually,
the resulting ArsD proteins partially lose the ability to stimulate ArsA ATPase activity. If
mutated to alanine together, the resulting protein was unable to stimulate ArsA,
suggesting a synergistic effect of these two lysines. However, if mutated to arginines,
the resulting protein is still active, indicating that a requirement for positively charged
residues. The effect of acetylation of lysine residues with Sulfo-NHS acetate further
supported the requirement for positive charge. When both Lys37 and Lys62 were
mutated to alanines, the resulting protein retains the ability to bind antimony but loses
interaction with ArsA in yeast two-hybrid analysis.
In total, 16 mutations of 15 amino residues show either stronger or weaker
interactions with ArsA. They are at amino acid residues, Ser14, Val17, Thr20, Val22,
Gln24, Val27, Asp28, Thr31, Gln34, Lys37, Gln38, Gln51, Phe55, Val61 and Lys62
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(Table 4-4). These residues were mapped on the structure of ArsD (Figure 4-7). The
ArsD monomer has a thioredoxin fold of four β-strands flanked by four α-helices.
Residues 12 to 22 are mostly disordered in this structure. To show all the mutations, an
ArsD structural model with residues 12 to 22 inserted was constructed by homology
modeling (Ye et al., 2010). ArsD helices α1 and α4 are on one side of the ß-strands; α2
and α3 are on the other side. α2 is almost perpendicular to α3, with only one residue
between them. ß1 is between ß2 and ß3, parallel to ß2 and anti-parallel to ß3. ß3 and
ß4 form a ß-hairpin. Residues 70 to 72 form a short 310 helix.
Four residues, Ser14, Val17, Thr20 and Val22, are in the same loop as Cys12Cys13-Cys18. This is consistent with our model that the region near metal binding site
is involved in direct contact with ArsA. Seven residues, Gln24, Val27, Asp28, Thr31,
Gln34, Lys37 and Gln38, are in helix α1 just following the loop containing the metal
binding site. They are aligned on one side of the helix and solvent exposed, suggesting
that this surface is directly involved in interaction, or, alternatively, that the helix helps to
position the metalloid binding loop in correct orientation to interact with ArsA. Another
four residues Gln51, Phe55, Val61 and Lys62, are on helices α2 and α3. This region
could also be involved in interaction with ArsA or, again, may also serve to position the
loop for interaction with ArsA.
Metallated ArsD interacts with and transfers As(III) to ArsA during catalysis, when
the ATPase cycles between open to closed conformations (Lin et al., 2007a; Ruan et
al., 2006). The x-ray crystal structure of ArsA has been solved in the closed form (Zhou
et al., 2000, 2001). A yeast homologue termed Arr4p or Get3 (Auld et al., 2006) is
involved in targeting tail-anchored proteins in the endoplasmic reticulum (Bozkurt et al.,
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2009). Recently crystal structures of Get3 were solved in the open (nucleotide free) and
closed (ADP-AlF4-) conformations (Mateja et al., 2009). ArsA has two homologous
halves, A1 and A2, each with a nucleotide binding domain (NBD) connected by a short
linker, while Get3 is a dimer of two identical monomers, each homologous to either A1
or A2. In the open Get3 conformation there is a large conformational change, and the
two monomers are separated by approximately 37º rotation of one subunit towards the
other relative to their orientation in the closed form, which is more compact. The ADPAlF4- closed ArsA structure can be superimposed with Get3 closed structure with an
RMSD of 3.4 Å for 420 Cα atoms (Figure 4-9A). ArsA NBD1 (residue 1-297) and NBD2
(298-583) can be superimposed with the two monomers in the Get3 open structure, with
RMSD of 2.3 Å and 3.0 Å, respectively (Figure 4-9B). An open model of the ArsA
structure based on the open Get3 structure was generated for analysis of ArsA-ArsD
interactions and docking studies (Figure 4-9C) (Ye et al., 2010).
The open ArsA and metallated ArsD models were docked by using the fully
automated, web-based program ClusPro Version 2.0 with balanced coefficients and
default parameters (Ye et al., 2010). The ClusPro docking server yielded several topscoring solutions. One of the solutions with relative good score was consistent with
biochemical analysis indicating that the three cysteines of ArsD and the three cysteines
of ArsA must be in proximity for transfer (Figure 4-10). According to this model, most
likely ArsA and ArsD interact with each other at multiple points. It is consistent with
yeast two-hybrid results that the loop containing Cys12-Cys13-Cys18 metal binding site
and helix α1 are directly involved in protein contact.
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Six

ArsA

mutants,

ArsAI117M,E425G,

ArsAF54L,F120L,H219R,E254V,F443L,K475R,A533T,

ArsAD121E

ArsAH368L,E425k,
and

ArsAD121N,

ArsAF120L,L193S,
show

stronger

interaction with wild-type ArsD. Mutations at Glu425, Phe120 and Asp121 occurred
twice in different mutants, and they are spatially closing to ArsA MBS (metalloid binding
site) (Figure 4-8). These mutations might change the local conformation of the MBS to
increase the strength of interaction with ArsD, or they are possibly located in the
interaction interface. Whichever it is, that all these mutations are located close to the
ArsA MBS supports the model that ArsA and ArsD interacts at their metal binding sites.
ArsA mutants were isolated that restore interaction with ArsDV22A, ArsDQ51H or
ArsDF55L. One common feature of all ArsA complementary mutants is that they all have
one mutation spatially closing to the ArsA MBS, while most other mutations are
scattered around all over the protein. The mutations near the MBS could slightly change
the local conformation of MBS and restore the interaction with ArsD mutants. Among all
14 ArsA mutants, seven contain mutations at Asp121, and two have mutations at
Glu425. These two positions were shown to increase the interaction strength when they
are mutated. These results suggest that restoration of interaction with ArsD mutants is
not site-specific, but more likely ArsD and ArsA have multi-point contact sites,
considering the extensive interaction interface on ArsD was identified. The loss of
interaction at one point can be compensated by stronger interaction at another site.
Currently, the effect of mutation F120L, D121E, D121G, E425K and E425A on
ArsA and on ArsA-ArsD interaction is being studied. By changing these residues to
other residues, more mutants will be constructed and studied. These ArsA mutants
could be useful for co-crystallization with ArsD since they show stronger interaction with

92

ArsD. Probably these mutants could lock ArsA to the open conformation therefore
interacting with ArsD better. All ArsD mutants showing stronger interaction with ArsA in
yeast two-hybrid analysis will also be tried to co-crystallize with ArsA.
In addition, methods quantitatively measuring ArsA-ArsD interaction will be very
helpful to understand not only the effect of the mutations but also the basic mechanism
of arsenic transfer. Some preliminary work using SPR (surface plasmon resonance) has
been done. By immobilizing ArsD on the chip and flowing ArsA solution through the
surface, ArsA-ArsD interaction could be watched. The result until now looks promising
but stricter negative control is needed. ArsD109K2/104A-K37/62A could be a good negative
control. This mutant has been shown not to stimulate ArsA ATPase activity and not to
interact with ArsA in yeast two-hybrid analysis. Single molecule fluorescence resonance
energy transfer could also be used to study ArsA-ArsD interaction. It has been
successfully used to study transient interaction between copper chaperone HAH1 and
Wilson disease protein (Benitez et al., 2008). This method has advantage not only to
study ArsA-ArsD interaction in simulated pre-hydrolysis state, intermediate or posthydrolysis state but also to watch interaction change between single ArsA-ArsD
molecule pair during ATP hydrolysis.
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Table 2-1
Strains and plasmids used in CHAPTER 2
Strains/Plasmids

Genotype/description

Reference

JM109

endA1, recA1, gyrA96, thi, hsdR17 (rk-,
mk+), relA1, supE44, λ-, Δ(lac-proAB), [F’,
traD36, proAB, lacIqZΔM15]

(Sambrook et al.,
1989)

BL21(DE3)

[F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI
lacUV5-T7 gene1 ind1 Sam7 nin5])

(Sambrook et al.,
1989)

pAlter-dAhB

Six histidine codons added to the 3’-end of
arsA gene (Apr)

(Li and Rosen,
2000)

pMAL-ArsD109

arsD1-109 truncation was fused to the Cterminal of MBP (Apr)

(Lin et al.,
2007a)

pET28a

For expression of his-tagged protein
controlled by T7 promoter (Kanar)

Novagen

pET28a-ArsD109

arsD1-109 truncation was inserted into
pET28a through EcoRI and SalI sites
(Kanar)

This study

pET28a-ArsD109

Trp35 and Trp97 were mutated to Tyr by
site directed mutagenesis on pET28aArsD109 (Kanar)

This study

Thr15 was mutated to Trp by site directed
mutagenesis on pET28a-ArsD109 W35/97Y
(Kanar)

This study

Val17 was mutated to Trp by site directed
mutagenesis on pET28a-ArsD109 W35/97Y
(Kanar)

This study

Cys12 was mutated to Gly by site directed
mutagenesis on pET28a-ArsD109 (Kanar)

This study

Strains

Plasmids

W35/97Y

pET28a-ArsD109
T15W

pET28a-ArsD109
V17W

pET28a-ArsD109
C12G
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Table 2-1
Strains and plasmids used in CHAPTER 2 (continued)
Strains/Plasmids

Genotype/description

Reference

Plasmids
pET28a-ArsD109
C13G

pET28a-ArsD109
C18G

pET28a-ArsD109
C12G,T15W

pET28a-ArsD109
C13G,T15W

pET28a-ArsD109
C18G,T15W

Cys13 was mutated to Gly by site directed
mutagenesis on pET28a-ArsD109 (Kanar)

This study

Cys18 was mutated to Gly by site directed
mutagenesis on pET28a-ArsD109 (Kanar)

This study

Cys12 was mutated to Gly by site directed
mutagenesis on pET28a-ArsD109 T15W
(Kanar)

This study

Cys13 was mutated to Gly by site directed
mutagenesis on pET28a-ArsD109 T15W
(Kanar)

This study

Cys18 was mutated to Gly by site directed
mutagenesis on pET28a-ArsD109 T15W
(Kanar)

This study
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Table 2-2
Oligonucleotide primers used in CHAPTER 2
Primer

Sequence (5’–3’)

Target / Direction

T7 promoter
sequencing primer

TAATACGACTCACTATAGGG

pET28a forward sequencing
primer

T7 terminator
sequencing primer

GCTAGTTATTGCTCAGCGG

pET28a reverse sequencing
primer

ArsD-T15W-s

GCGATGTGTTGCAGCTGGGGC
GTCTGCGGTACAG

Mutate ArsD Thr15 to Trp,
sense

ArsD-T15W-a

CTGTACCGCAGACGCCCCAGC
TGCAACACATCGC

Mutate ArsD Thr15 to Trp,
antisense

ArsD-V17W-s

GTGTTGCAGCACCGGCTGGTG
CGGTACAGATGTTG

Mutate ArsD Val17 to Trp,
sense

ArsD-V17W-a

CAACATCTGTACCGCACCAGCC
GGTGCTGCAACAC

Mutate ArsD Val17 to Trp,
antisense

ArsD-C12G-s

GGTATTTGACCCGGCGATGGGT Mutate ArsD Cys12 to Gly,
TGCAGCACCGGCGTC
sense

ArsD-C12G-a

GACGCCGGTGCTGCAACCCAT
CGCCGGGTCAAATACC

Mutate ArsD Cys12 to Gly,
antisense

ArsD-C13G-s

GTATTTGACCCGGCGATGTGTG
GCAGCACCGGCGTCTGC

Mutate ArsD Cys13 to Gly,
sense

ArsD-C13G-a

GCAGACGCCGGTGCTGCCACA
CATCGCCGGGTCAAATAC

Mutate ArsD Cys13 to Gly,
antisense

ArsD-C18G-s

GTTGCAGCACCGGCGTCGGCG
GTACAGATGTTGATC

Mutate ArsD Cys18 to Gly,
sense

ArsD-C18G-a

GATCAACATCTGTACCGCCGAC
GCCGGTGCTGCAAC

Mutate ArsD Cys18 to Gly,
antisense

ArsD-12G15W-s

GGTATTTGACCCGGCGATGGGT Mutate ArsD Cys12 to Gly
TGCAGCTGGGGCGTC
and Thr15 to Trp, sense

ArsD-12G15W-a

GACGCCCCAGCTGCAACCCAT
CGCCGGGTCAAATACC

Mutate ArsD Cys12 to Gly
and Thr15 to Trp, antisense
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Table 2-2
Oligonucleotide primers used in CHAPTER 2 (continued)
Primer

Sequence (5’–3’)

Target / Direction

ArsD-13G15W-s

GTATTTGACCCGGCGATGTGTG
GCAGCTGGGGCGTCTGC

Mutate ArsD Cys13 to Gly
and Thr15 to Trp, sense

ArsD-13G15W-a

GCAGACGCCCCAGCTGCCACA
CATCGCCGGGTCAAATAC

Mutate ArsD Cys13 to Gly
and Thr15 to Trp, antisense

ArsD-18G15W-s

GTTGCAGCTGGGGCGTCGGCG
GTACAGATGTTGATC

Mutate ArsD Cys18 to Gly
and Thr15 to Trp, sense

ArsD-18G15W-a

GATCAACATCTGTACCGCCGAC
GCCCCAGCTGCAAC

Mutate ArsD Cys18 to Gly
and Thr15 to Trp, antisense
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Table 2-3
Summary of the best-fit parameters from the ArsD1-109-As EXAFS fitting analysisa.
Fits in bold are the best fit for each sample.

Sample
ArsD1-109,C18G

ArsD1-109,C13G

ArsD1-109,C12G

ArsD1-109

Ligand Environmentb
Å2f
Atomc R(Å)d C.N.e

Ligand Environmentb
Å2f
R(Å)d
C.N.e
Atomc

F’ g

O/N

1.79

3.0

5.53

0.58

S

2.5

1

12.6

4.6

O/N

1.79

2.0

3.2

O/N

2.28

1.0

16.5

0.96

O/N

1.79

2.0

3.2

S

2.48

0.5

10.2

0.93

O/N

1.79

2.0

3.0

0.79

S

1.97

1

3.02

1.98

O/N

1.79

2.5

4.37

O/N

2.13

1.0

3.63

0.67

O/N

1.79

2.0

4.8

S

1.96

1.0

8.8

0.66

O/N

1.79

2.0

4.50

1.6

S

2.5

1

20.4

4.1

O/N

1.79

2.0

4.86

O/N

2.16

1.5

4.16

1.58

O/N

1.79

2.0

4.87

S

2.41

1.0

24.3

1.56

O/N

2.08

3

0.9

3.86

S

2.24

3

2.4

0.89

O/N

2.01

2

-4.1

O/N

2.13

1

-7.8

6.01

O/N

2.06

0.5

4.4

S

2.24

3

2.6

0.84

a

Data were fit over a k range of 1 to 13 Å-1.

b

Independent metal-ligand scattering environment

c

Scattering atoms: O (oxygen), N (nitrogen), S (sulfur) and C (carbon), Cu (Copper)

d

Average metal-ligand bond length from three independent samples

e

Average metal-ligand coordination number from three independent samples

f

Average Debye-Waller factor in Å2 x 103 from three independent samples
g

Number of degrees of freedom weighted mean square deviation between data and fit.

98

Table 3-1
Strains and plasmids used in CHAPTER 3
Strains/Plasmids

Genotype/description

Reference

E.coli strains
JM109

endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), (Sambrook et al.,
1989)
relA1, supE44, λ-, Δ(lac-proAB), [F’,
q
traD36, proAB, lacI ZΔM15]

BL21(DE3)

[F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI
lacUV5-T7 gene1 ind1 Sam7 nin5])

(Sambrook et al.,
1989)

S. cerevisiae strains
AH109

MATa, trp1-901, leu2-3, 112, ura3-52, his3-200,
gal4∆, gal80∆, LYS2::GAL1UAS-GAL1TATA-HIS3,
GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UASMEL1TATA-lacZ

Clontech

MAV203

MATα; leu2-3,112; trp1-901; his3Δ200; ade2-101;
cyh2R; can1R; gal4Δ; gal80Δ; GAL1::lacZ;
HIS3UASGAL1::HIS3@LYS2; SPAL10::URA3.

Invitrogen

pGBT9

GAL4(1-147) DNA-binding domain, TRP1 (Apr)

Clontech

pACT2

GAL4(768-881) activation domain, LEU2 (Apr)

Clontech

pACT2-A

arsA gene cloned in pACT2 (Apr)

(Lin et al., 2006)

pACT2-D

arsD gene cloned in pACT2 (Apr)

(Lin et al., 2006)

pGBT9-D

arsD gene cloned in pGBT9 (Apr)

(Lin et al., 2006)

pGBT9-k

Kanamycin resistance gene is amplified from
pET28a and inserted into pGBT9 at AatII site
(Kanar)

This study

pGBT9-k-D

Kanamycin resistance gene is amplified from
pET28a and inserted into pGBT9-D at AatII
site (Kanar)

This study

pGBT9-k-D G86E

Selected by yeast two-hybrid (Kanar)

This study

Plasmids
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Table 3-1
Strains and plasmids used in CHAPTER 3 (continued)
Strains/Plasmids

Genotype/description

Reference

Plasmids
pAlter-dAhB

Six histidine codons added to the 3’end of arsA gene (Apr)

(Li and Rosen,
2000)

pET28a

For expression of his-tagged protein
controlled by T7 promoter (Kanar)

Novagen

pET28a-ArsD109

arsD1-109 truncation was inserted into
pET28a through EcoRI and SalI sites
(Kanar)

Chapter 2

pET28a-ArsD109

Gly86 was mutated to Glu by site
directed mutagenesis on pET28aArsD109 (Kanar)

This study

Ser68, Arg87 and Arg96 were
mutated to Ala by site directed
mutagenesis on pET28a-ArsD109
(Kanar)

This study

Ser68, Arg87, Arg96, Glu81, Thr82,
Val83 and Met84 were mutated to Ala
by site directed mutagenesis on
pET28a-ArsD109 (Kanar)

This study

arsD1-109 truncation was fused to the
C-terminal of MBP (Apr)

(Lin et al.,
2007a)

G86E

pET28a-ArsD109
S68A/R87A/R96A

pET28a-ArsD109
S68A/R87A/R96A/E81A/T8
2A/V83A/M84A

pMAL-ArsD109
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Table 3-2
Oligonucleotide primers used in CHAPTER 3
Primer

Sequence (5’–3’)

Target / Direction

GAL4-BD
sequencing primer

GAGTAGTAACAAAGGTCAA

pGBT9 Forward sequencing
primer

T7 promoter
sequencing primer

TAATACGACTCACTATAGGG

pET28a forward sequencing
primer

T7 terminator
sequencing primer

GCTAGTTATTGCTCAGCGG

pET28a reverse sequencing
primer

pET28a-3600AatII

CTATGACGTCCAACCCGGTAA
GACACGACTTATC

Sense primer for amplifying
kanamycin resistance gene
from pET28a

pET28a-5300AatII

CTATGACGTCCGCCCGCTCCT
TTCGCTTTCTTCC

Antisense primer for
amplifying kanamycin
resistance gene from
pET28a

pGBT9-s

TAAAGATGCCGTCACAGATAGA Sense primer for ep-PCR of
TTG
ArsD on pGBT9-k-D

pGBT9-a

ACCTGACCTACAGGAAAGAGTT Antisense primer for epACT
PCR of ArsD on pGBT9-k-D

D109-XhoI

CAGCTCGAGTTAAGGCGCTAA
TCCCACTTTATCCAG

Using with pGBT9-s to
amplify ArsD mutant gene
from pGBT-k-DX vector to
put into pET28 vector
between EcoRI and XhoI

ArsD-S68A-s

GTTTATTGAAGCTGCCGGGGC
AGAAGGTC

Mutate ArsD Ser68 to Ala,
sense

ArsD-S68A-a

GACCTTCTGCCCCGGCAGCTT
CAATAAAC

Mutate ArsD Ser68 to Ala,
antisense

ArsD-R87A-s

GAAACAGTGATGGCCGGGGCT Mutate ArsD Arg87 to Ala,
TACCCGAAACGCGC
sense

ArsD-R87A-a

GCGCGTTTCGGGTAAGCCCCG Mutate ArsD Arg87 to Ala,
GCCATCACTGTTTC
antisense
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Table 3-2
Oligonucleotide primers used in CHAPTER 3 (continued)
Primer

Sequence (5’–3’)

Target / Direction

ArsD-R96A-s

CGCGCTGAGCTGGCTGCCTGG
TTTGGCATTCCACTG

Mutate ArsD Arg96 to Ala,
sense

ArsD-R96A-a

CAGTGGAATGCCAAACCAGGC
AGCCAGCTCAGCGCG

Mutate ArsD Arg96 to Ala,
antisense

ArsD-81-84A-s

CATTGTTGTTACTGGATGGCGC Mutate ArsD residues from
AGCAGCGGCAGCCGGGGCTTA 81 to 84 to Ala, sense
CCCGAAACG

ArsD-81-84A-a

CGTTTCGGGTAAGCCCCGGCT
GCCGCTGCTGCGCCATCCAGT
AACAACAATG

Mutate ArsD residues from
81 to 84 to Ala, antisense

Table 4-1
Summary of study of interaction between copper-chaperone proteins and their targets

Species

Chaperone

Target protein

Enterococcus
hirae

CopZ

CopY

Yeast-2-hybrid

HAH1

Ccc2

(Pufahl et al.,
1997)

CAOs

(Peter et al.,
2008)

MNK

WLN

(Larin et al.,
1999)

(van Dongen et
al., 2004)

Complex detected
(Arnesano et al.,
2001)

Co-IP
(Hamza et al.,
1999)
Pull-down, Co-IP
(Hamza et al.,
1999)

Complex Notdetected
(Banci et al.,
2005)
Lower ratio of
complex
(Achila et al.,
2006)
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human

Atx1

NMR

SPR (Multhaup et
al., 2001)

CopA

Yeast

In vitro binding
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Table 4-2
Strains and plasmids used in CHAPTER 4
Strains/Plasmids

Genotype/description

Reference

E.coli strains
JM109

endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), (Sambrook et al.,
1989)
relA1, supE44, λ-, Δ(lac-proAB), [F’,
q
traD36, proAB, lacI ZΔM15]

BL21(DE3)

[F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI
lacUV5-T7 gene1 ind1 Sam7 nin5])

(Sambrook et al.,
1989)

S. cerevisiae strains
AH109

MATa, trp1-901, leu2-3, 112, ura3-52, his3-200,
gal4∆, gal80∆, LYS2::GAL1UAS-GAL1TATA-HIS3,
GAL2UAS-GAL2TATA-ADE2,URA3::MEL1UASMEL1TATA-lacZ

Clontech

MAV203

MATα; leu2-3,112; trp1-901; his3Δ200; ade2-101;
cyh2R; can1R; gal4Δ; gal80Δ; GAL1::lacZ;
HIS3UASGAL1::HIS3@LYS2; SPAL10::URA3.

Invitrogen

pGBT9

GAL4(1-147) DNA-binding domain, TRP1 (Apr)

Clontech

pACT2

GAL4(768-881) activation domain, LEU2 (Apr)

Clontech

pACT2-A

arsA gene cloned in pACT2 (Apr)

(Lin et al., 2006)

pACT2-D

arsD gene cloned in pACT2 (Apr)

(Lin et al., 2006)

pGBT9-A

arsA gene cloned in pGBT9 (Apr)

(Lin et al., 2006)

pGBT9-D

arsD gene cloned in pGBT9 (Apr)

(Lin et al., 2006)

pGBT9-k

Kanamycin resistance gene is amplified
from pET28a and inserted into pGBT9 at
AatII site (Kanar)

Chapter 3

pGBT9-k-D

Kanamycin resistance gene is amplified
from pET28a and inserted into pGBT9-D at
AatII site (Kanar)

Chapter 3

Plasmids
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Table 4-2
Strains and plasmids used in CHAPTER 4 (continued)
Strains/Plasmids

Genotype/description

Reference

Plasmids
pGBT9-k-D S14R

Ser14 was mutated to Arg by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D T20I

Thr20 was mutated to Ile by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D Q24L

Gln24 was mutated to Leu by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D D28V

Asp28 was mutated to Val by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D D28T

Asp28 was mutated to Thr by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D T31A

Thr31 was mutated to Ala by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D Q34R

Gln34 was mutated to Arg by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D Q38R

Gln38 was mutated to Arg by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D V61A

Val61 was mutated to Ala by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D F55L

Selected by yeast two-hybrid (Kanar)

This study

pGBT9-k-D Q51H

Selected by yeast two-hybrid (Kanar)

This study

pGBT9-k-D V22A

Val22 was mutated to Ala by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D V17A

Val17 was mutated to Ala by site directed
mutagenesis on pGBT9-k-D (Kanar)

This study

pGBT9-k-D V27D

Selected by yeast two-hybrid (Kanar)

This study
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Table 4-2
Strains and plasmids used in CHAPTER 4 (continued)
Strains/Plasmids

Genotype/description

Reference

Plasmids
pAlter-dAhB

Six histidine codons added to the 3’-end of
arsA gene (Apr)

(Li and Rosen,
2000)

pET28a

For expression of his-tagged protein
controlled by T7 promoter (Kanar)

Novagen

pET28a-ArsD109

arsD1-109 truncation was inserted into
pET28a through EcoRI and SalI sites
(Kanar)

Chapter 2

pET28a-ArsD109

Lys2 and Lys104 were mutated to Ala by
site directed mutagenesis on pET28aArsD109 (Kanar)

This study

Lys37 and Lys62 were mutated to Ala by
site directed mutagenesis on pET28aArsD109 K2/104A (Kanar)

This study

Lys37 and Lys62 were mutated to Arg by
site directed mutagenesis on pET28aArsD109 K2/104A (Kanar)

This study

Lys60 and Lys90 were mutated to Ala by
site directed mutagenesis on pET28aArsD109 K60/90A (Kanar)

This study

arsD K2/104A-K37/62A inserted into pGBT9-k
(Kanar) between EcoRI and BamHI

This study

arsD K2/104A-K37/62R inserted into pGBT9-k
(Kanar) between EcoRI and BamHI

This study

arsD K2/104A-K60/90A inserted into pGBT9-k
(Kanar) between EcoRI and BamHI

This study

arsD K2/104A-K37A inserted into pGBT9-k
(Kanar) between EcoRI and BamHI

This study

arsD K2/104A-K62A inserted into pGBT9-k
(Kanar) between EcoRI and BamHI

This study

K2/104A

pET28a-ArsD109
K2/104A-K37/62A

pET28a-ArsD109
K2/104A-K37/62R

pET28a-ArsD109
K2/104A-K60/90A

pGBT9-k-D K2/104AK37/62A

pGBT9-k-D K2/104AK37/62R

pGBT9-k-D K2/104AK60/90A

pGBT9-k-D K2/104AK37A

pGBT9-k-D K2/104AK62A
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Table 4-3
Oligonucleotide primers used in CHAPTER 4
Primer

Sequence (5’–3’)

Target / Direction

GAL4-BD
sequencing primer

GAGTAGTAACAAAGGTCAA

pGBT9 Forward sequencing
primer

GAL4-AD
sequencing primer

AATACCACTACAATGGAT

pACT2 Forward sequencing
primer

ArsA-100-s

GTCCTGCCTGATGACGTTGTTT
CCA

ArsA forwarding sequencing
primer from 100th residue

ArsA-220-s

GTCGCCCGGACTCATCTGGAA
CTTG

ArsA forwarding sequencing
primer from 220th residue

ArsA-420-s

AAGAGGACTTACGCTCACCTTG ArsA forwarding sequencing
CAC
primer from 420th residue

ArsA-480-a

CGTGACCAGTAACACTTTAGTG
CG

ArsA reversing sequencing
primer from 480th residue

pET28a-3600AatII

CTATGACGTCCAACCCGGTAA
GACACGACTTATC

Sense primer for amplifying
kanamycin resistance gene
from pET28a

pET28a-5300AatII

CTATGACGTCCGCCCGCTCCT
TTCGCTTTCTTCC

Antisense primer for
amplifying kanamycin
resistance gene from
pET28a

pGBT9-s

TAAAGATGCCGTCACAGATAGA Sense primer for ep-PCR of
TTG
ArsD on pGBT9-k-D

pGBT9-a

ACCTGACCTACAGGAAAGAGTT Antisense primer for epACT
PCR of ArsD on pGBT9-k-D

pACT2-s

CTATTCGATGATGAAGATACCC
CACCAAACCC

pACT2-a

AGGTTACATGGCCAAGATTGAA Antisense primer for epACTTAGAGGAG
PCR of ArsA on pACT2-A

Sense primer for ep-PCR of
ArsA on pACT2-A
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Table 4-3
Oligonucleotide primers used in CHAPTER 4 (continued)
Primer

Sequence (5’–3’)

Target / Direction

ArsD-S14R-s

ACCCGGCGATGTGTTGCAGAAC Mutate ArsD Ser14 to Arg,
CGGCGTCTGCGGTACAG
sense

ArsD-S14R-a

CTGTACCGCAGACGCCGGTTCT Mutate ArsD Ser14 to Arg,
GCAACACATCGCCGGGT
antisense

ArsD-T20I-s

CACCGGCGTCTGCGGTATAGAT Mutate ArsD Thr20 to Ile,
GTTGATCAGGCTCT
sense

ArsD-T20I-a

AGAGCCTGATCAACATCTATAC
CGCAGACGCCGGTG

Mutate ArsD Thr20 to Ile,
antisense

ArsD-Q24L-s

GCGGTACAGATGTTGATCTGGC
TCTGGTCGATTTTTC

Mutate ArsD Gln24 to Leu,
sense

ArsD-Q24L-a

GAAAAATCGACCAGAGCCAGAT
CAACATCTGTACCGC

Mutate ArsD Gln24 to Leu,
antisense

ArsD-D28V-s

GTTGATCAGGCTCTGGTCGTTT
TTTCTACAGATGTGCAAT

Mutate ArsD Asp28 to Val,
sense

ArsD-D28V-a

ATTGCACATCTGTAGAAAAAAC
GACCAGAGCCTGATCAAC

Mutate ArsD Asp28 to Val,
antisense

ArsD-D28T-s

TGATCAGGCTCTGGTCACTTTT
TCTACAGATGTGC

Mutate ArsD Asp28 to Thr,
sense

ArsD-D28T-a

GCACATCTGTAGAAAAAGTGAC
CAGAGCCTGATCA

Mutate ArsD Asp28 to Thr,
antisense

ArsD-T31A-s

GGCTCTGGTCGATTTTTCTGCA
GATGTGCAATGGCTCAA

Mutate ArsD Thr31 to Ala,
sense

ArsD-T31A-a

TTGAGCCATTGCACATCTGCAG
AAAAATCGACCAGAGCC

Mutate ArsD Thr31 to Ala,
antisense

ArsD-Q34R-s

CGATTTTTCTACAGATGTGCGA
TGGCTCAAACAATGCGG

Mutate ArsD Gln34 to Arg,
sense

ArsD-Q34R-a

CCGCATTGTTTGAGCCATCGCA
CATCTGTAGAAAAATCG

Mutate ArsD Gln34 to Arg,
antisense
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Table 4-3
Oligonucleotide primers used in CHAPTER 4 (continued)
Primer

Sequence (5’–3’)

Target / Direction

ArsD-Q38R-s

GATGTGCAATGGCTCAAACGAT
GCGGTGTACAAATTGAG

Mutate ArsD Gln38 to Arg,
sense

ArsD-Q38R-a

CTCAATTTGTACACCGCATCGT
TTGAGCCATTGCACATC

Mutate ArsD Gln38 to Arg,
antisense

ArsD-V61A-s

CTTTGTACAGAACGAGAAGGCC
AAAGCGTTTATTGAAGCTT

Mutate ArsD Val61 to AIa,
sense

ArsD-V61A-a

AAGCTTCAATAAACGCTTTGGC
CTTCTCGTTCTGTACAAAG

Mutate ArsD Val61 to AIa,
antisense

ArsD-K2A-s

ATCCGAATTCCCGGGGGCAAC
GTTAATGGTATTTGA

Mutate ArsD Lys2 to Ala on
pET28a-ArsD109, sense

ArsD-K2A-a

TCAAATACCATTAACGTTGCCC
CCGGGAATTCGGAT

Mutate ArsD Lys2 to Ala on
pET28a-ArsD109, antisense

ArsD-K37A-s

ACAGATGTGCAATGGCTCGCAC
AATGCGGTGTACAAAT

Mutate ArsD Lys37 to Ala,
sense

ArsD-K37A-a

ATTTGTACACCGCATTGTGCGA
GCCATTGCACATCTGT

Mutate ArsD Lys37 to Ala,
antisense

ArsD-K62A-s

TACAGAACGAGAAGGTCGCAG
CGTTTATTGAAGCTTC

Mutate ArsD Lys62 to Ala,
sense

ArsD-K62A-a

GAAGCTTCAATAAACGCTGCGA
CCTTCTCGTTCTGTA

Mutate ArsD Lys62 to Ala,
antisense

ArsD-K104A-s

TTGGCATTCCACTGGATGCAGT
GGGATTAGCGCCTT

Mutate ArsD Lys104 to Ala,
sense

ArsD-K104A-a

AAGGCGCTAATCCCACTGCATC
CAGTGGAATGCCAA

Mutate ArsD Lys104 to Ala,
antisense

ArsD-K60A-s

AGCTTTGTACAGAACGAGGCGG Mutate ArsD Lys60 to Ala,
TCAAAGCGTTTATTGA
sense

ArsD-K60A-a

TCAATAAACGCTTTGACCGCCT
CGTTCTGTACAAAGCT

Mutate ArsD Lys60 to Ala,
antisense
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Table 4-3
Oligonucleotide primers used in CHAPTER 4 (continued)
Primer

Sequence (5’–3’)

Target / Direction

ArsD-K90A-s

ATGGCCGGGCGTTACCCGGCA
CGCGCTGAGCTGGCTCGC

Mutate ArsD Lys90 to Ala,
sense

ArsD-K90A-a

GCGAGCCAGCTCAGCGCGTGC
CGGGTAACGCCCGGCCAT

Mutate ArsD Lys90 to Ala,
antisense

ArsD-K37R-s

ACAGATGTGCAATGGCTCAGAC
AATGCGGTGTACAAAT

Mutate ArsD Lys37 to Arg,
sense

ArsD-K37R-a

ATTTGTACACCGCATTGTCTGA
GCCATTGCACATCTGT

Mutate ArsD Lys37 to Arg,
antisense

ArsD-K62R-s

TACAGAACGAGAAGGTCAGAGC Mutate ArsD Lys62 to Arg,
GTTTATTGAAGCTTC
sense

ArsD-K62R-a

GAAGCTTCAATAAACGCTCTGA
CCTTCTCGTTCTGTA

Mutate ArsD Lys62 to Arg,
antisense

Ec-N-ArsD-K2A-s

TCCGGAATTCATGGCAACGTTA
ATGGTATTTG

Sense primer for amplifying
ArsD K2/104A mutants to put
into pGBT9-k between
EcoRI and BamHI

Bm-D109-K104A-a

CGCGGATCCTTAAGGCGCTAAT
CCCACTGCATCCAG

Antisense primer for
amplifying ArsD K2/104A
mutants to put into pGBT9-k
between EcoRI and BamHI

T7 promoter
sequencing primer

TAATACGACTCACTATAGGG

pET28a forward sequencing
primer

T7 terminator
sequencing primer

GCTAGTTATTGCTCAGCGG

pET28a reverse sequencing
primer
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Table 4-4
ArsD mutations increasing or decreasing ArsA-ArsD interaction
method

effect

mutations

yeast two-hybrid

stronger interaction with ArsA

S14R, T20I, Q24L, D28T,
D28V, T31A, Q34R, Q38R,
V61A

yeast two-hybrid

weaker interaction with ArsA

V17A, V22A, V27D, Q51H,
F55L

site-directed
mutagenesis

weaker interaction with ArsA

K37A, K62A
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Figure 1-1. Structure of R773 ArsA ATPase (Lin et al., 2007b).
(A): The overall structure of ArsA is shown as a ribbon diagram. Mg2+-ADP is bound to
each of the two NBDs in the A1 and A2 halves of ArsA, while three Sb(III) are bound at
the single MBD.
(B) The metalloid binding domain composed of three 3-coordinate As(III)/Sb(III) binding
sites. Each site has two protein ligands, one from A1 and one from A2, plus a nonprotein ligand that appears to be a chloride in the crystal structure but could be a
hydroxyl in the native protein. The high affinity site is composed of Cys-113 from A1
and Cys-422 from A2. The other two sites are composed of His-148 from A1 and Ser420 from A2 and Cys-172 from A1 and His-453 from A2. The two histidines come from
the signal transduction domains (D142/447TAPTGH148/453) that connect the two nucleotide
binding domains, NBD1 and NBD2, to the MBD. Binding of metalloid acts like
molecular glue to hold A1 and A2 in a conformation in which residues from both
contribute to the formation of NBD1 and NBD2. Thus metalloid binding increases the
affinity of NBD1 and NBD2 and activates catalysis.
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Figure 2-1. Normalized XANES spectra of ArsD and its derivatives.
Spectra from top to bottom include: C18G (A), C13G (B), C12G (C) and wild type
ArsD109 (D). Spectra were offset for clarity.
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Figure 2-2. ArsD EXAFS data and simulations.
Raw EXAFS data and phase shifted Fourier Transforms of As bound to C18G (A, B),
C13G (C, D), C12G (E, F) and wild type ArsD109 (G, H). Raw unfiltered data is given as
solid lines, while the best-fit simulated data are shown as dotted lines.
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Figure 2-3. ArsD109 tryptophan mutants fold normally and have same activity as
wild type.
(A) Circular CD spectra were collected with (●) 10 μM ArsD109, (Δ) tryptophan-free
ArsD109-W35Y/W97Y, (■) T15W and (◊) V17W.
(B) ArsA ATPase activity was assayed at the indicated concentrations of sodium
arsenite in the presence or absence of ArsD derivatives. ArsA ATPase activity was
assayed as described under “Materials and Methods”. (●), no addition; (○), ArsD109;
(▼), tryptophan-free ArsD109-W35Y/W97Y; , T15W. The curves were fitted using
SigmaPlot 9.0, with error bars represent standard deviation.
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Figure 2-4. Protein fluorescence of single tryptophan derivatives T15W and
V17W reports metalloid binding.
Emission scans were performed with excitation at 295 nm, as described under Materials
and Methods.
(A) (▼), 1 µM tryptophan; (●), tryptophan-free W35Y/97Y; (■), T15W; (▲), V17W; (○),
W35Y/97Y + 6 M guanidine-HCl; (□), T15W + 6 M guanidine-HCl; (Δ), V17W + 6 M
guanidine-HCl.
(B) (○), T15W; (V), T15W + 5 mM As(III); (□), T15W + 0.1 mM Sb(III); (●), V17W; (▼),
V17W + 5 mM As(III); (■), V17W + 0.1 mM Sb(III); (◊), tryptophan-free W35Y/97Y.
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Figure 2-5. Binding of As(III) by single tryptophan derivatives T15W and V17W
and cysteine mutants.
(A) Time course of 1 µM V17W fluorescence quenched by different concentration of
As(III). The data were fitted using SigmaPlot 9.0 with function F=F0-Fm*(1-e-kobst), in
which Kobs is the binding rate used in Fig B.
(B) The rate of fluorescence quenching, Kobs, was determined as a function of arsenite
concentration with excitation and emission wavelengths of 295 and 345 nm,
respectively.
(●), T15W; (○), V17W; (■), T15W/C12G; (Δ), T15W/C13G; (▼),
T15W/C18G. The data were fitted using SigmaPlot 9.0, with error bars representing the
standard deviation from three assays.

118

0.10

0.08

-1

Kobs(s )

with 5mM GSH
0.06

0.04

0.02

without GSH
0.00
3

4

5

6

7

8

9

10

pH
Figure 2-6. GSH accelerates binding of As(III) binding by V17W.
The rate of fluorescence quenching, Kobs, was determined as a function of pH in the
presence (○) or absence (●) of 5 mM GSH.
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Figure 2-7. As(GS)3 is the metalloid donor to ArsD.
Fluorescence of V17W was measured with excitation and emission wavelengths of 295
and 345 nm, respectively.
(A) At the arrow the following additions were made: (▲), 50 µM As(III); (V), 0.2 mM
GSH followed by 50 µM As(III); (◊), 5 mM TCEP followed by 50 µM As(III); (●), 5 mM
GSH followed by 50 µM As(III); (■), 50 µM As(GS)3.
(B) At the arrow the following additions were made: (●), 50 µM As(III); (○), 5 mM Lcysteine followed by 50 µM As(III); (▼), 5 mM β-mercaptoethanol followed by 50 µM
As(III); (Δ), 2.5 µM Sb(III).
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Figure 2-8. As(GS)3 does not activate ArsA.
Activated ATPase activity of 0.3 µM ArsA was determined at the indicated
concentrations of sodium arsenite, as described under Materials and Methods. (●), no
addition; (○), 5 mM GSH; (■), 6 µM ArsD. The data were fitted using SigmaPlot 9.0,
with error bars representing the standard deviation from three assays.
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Figure 2-9. GSH helps cooperation of ArsA and ArsD.
(A) ATPase activity of 0.3 µM ArsA was determined at the indicated concentrations of
sodium arsenite in the presence of 3 µM ArsD in buffer with or without 5mM GSH. ArsA
ATPase activity was assayed as described under “Materials and Methods”. (●), no
addition; (○), 5 mM GSH. The curves were fitted using SigmaPlot 9.0, with error bars
representing standard deviation from three assays.
(B) The apparent affinity of ArsA for As(III), in ArsA ATPase activity assay, was
determined at different concentrations of ArsD in different buffers. The enhancement of
apparent affinity of ArsA for As(III) by ArsD was measured in buffers supplemented with
or without TCEP and GSH. (●), buffer alone; (▼), buffer supplemented with 5mM TCEP;
(○), buffer supplemented with 5mM glutathione.
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Figure 2-10. ArsD channels As(III) to ArsA.
The effect of the As(III) chelator DMSA on metalloid transfer from ArsD to ArsA was
estimated from the activation of ATPase activity of 0.3 μM ArsA, as described under
Materials and Methods. ATP hydrolysis was measured in the presence of the indicated
concentrations of DMSA with (●) ArsA alone, (V) ArsA + 0.5 mM sodium arsenite or (■)
ArsA + 0.5 mM sodium arsenite plus 6 μM ArsD. The error bars represent the standard
deviation from three assays.
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Figure 2-11. Metalloid transfer from ArsD occurs during ArsA catalysis.
As(III) transfer assays were performed as described under Materials and Methods.
MBP-ArsD was bound to an amylose resin, following the column was charged with
sodium arsenite to saturate ArsD. Next purified ArsA or BSA were applied to the
columns with the indicated nucleotides (5 mM) at room temperature unless otherwise
noted. Experiments were done at room temperature, except experiment in F was done
at 4ºC. (A), 10 fractions were collected and analyzed by SDS PAGE. Nearly all of the
BSA or ArsA eluted in fraction 2, and fraction 9 contained nearly all of the MBP–ArsD.
Nucleotides: (B), ArsA + MgATP; (C), BSA + MgATP, (D), ArsA + MgADP; (E), ArsA +
MgATP-γ-S; (F), ArsA + MgATP at 4ºC. The concentration of protein (open bar) and
As(III) (●) was quantified in each fraction. The error bars represent the standard
deviation from three assays.
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Figure 2-12. Model of transfer from As(GS)3 to ArsD to ArsA.
In the first step As(OH)3 forms As(GS)3 with intracellular GSH. In the next step ArsD
extracts As(III) from As(GS)3 by thiol exchange with residues Cys12, Cys13 and Cys18.
In a step-wise series of thol exchanges (with an unknown order), the bound As(III) is
transferred to the thiolates Cys113, Cys172 and Cys422 of ArsA when the two
nucleotide binding domains, NBD1 and NBD2, hydrolyze ATP. Binding of As(III) and
ATP induces a series of conformational changes in ArsA resulting in activation of
catalysis, with final extrusion of the metalloid out of the cells.
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Figure 3-1. MBP-ArsD109 and His6-ArsD109 both stimulate ArsA ATPase activity.
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as
described under “Materials and Methods”. (●), no addition; (○), MBP-ArsD109; (▼),
His6-ArsD109. The curves were fitted using SigmaPlot 9.0, with error bars representing
standard deviation from three assays.
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Figure 3-2. Dimerization equilibrium states of MBP-ArsD109 and His6-ArsD109.
(A) 2.4 mg of MBP-ArsD109 in 1 ml of buffer was loaded to a 1.5 cm diameter column
filled with 165 ml Sephacryl-200 gel-filtration column on a Bio-rad Biological LP
chromatography system as described under “Materials and Methods”. 1.5 mg aldolase,
1.5 mg conalbumin, and 1.5 mg albumine were used as internal standards. The column
was washed with 200 ml of column buffer. Elutions were collected as 1.5 ml each
fraction. Fractions 59-83 were analyzed by 12 % SDS-PAGE.
(B) 2 mg of His6-ArsD109 in 1 ml of buffer was separated by Superdex-75
chromatography as above. 1.5mg ovalbumin, 1.5mg carbonic anhydrase and 1.5mg
ribonuclease were used as internal standards. The column was washed with 200ml of
column buffer. Elutions were collected as 1.5ml each fraction. Fractions 66-102 were
analyzed by 16 % SDS-PAGE.
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Figure 3-3. ArsD dimerization interface in crystal structure.
The ArsD dimerization interface was rendered with Pymol software. Subunit A is colored
in green and subunit B is colored in cyan. The residues involved in potential hydrogen
and salt bridge were shown in stick form and labeled. The distances of hydrogen bond
and the salt bridge was measured, with distances labeled in blue. The unit for distance
is Å.
(A) Cartoon view.
(B) Ribbon view.
(C) Ribbon view of magnified dimerization interface.
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Figure 3-4. His6-ArsD109S68A/R87A/R96A shifts equilibrium to monomer and still
activates ArsA ATPase activity.
(A) 2 mg His6-ArsD109S68A/R87A/R96A in 1 ml of buffer was separated by Superdex-75 gel
chromatography, as described above. Fractions 66-102 were analyzed by 16% SDSPAGE.
(B) 2 mg His6-ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A in 1 ml of buffer was separated by
Superdex-75 gel chromatography, as described above. Fractions 66-105 were analyzed
by 16 % SDS-PAGE.
(C) ArsA ATPase activity was assayed at the indicated concentrations of sodium
arsenite in the presence or absence of ArsD derivatives. ArsA ATPase activity was
assayed as described under “Materials and Methods”. (●), no addition; (Δ), His6ArsD109; (■), His6-ArsD109S68A/R87A/R96A/E81A/T82A/V83A/M84A. The curves were fitted using
SigmaPlot 9.0, with error bars representing standard deviation from three assays.
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Figure 3-5. Dimerization equilibrium of His6-ArsD109G86E shifts to monomer.
(A) Yeast two-hybrid analysis was performed as described under “Materials and
Methods.” S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and
binding domain (BD) fusion plasmids was grown in SD medium overnight and
inoculated on agar plates with SD lacking histidine with 10-fold serial dilutions. The first
row was cells with the empty vector serving as control. ArsD and ArsD mutants were
fused to BD domain, as indicated on the left side. They are tested with ArsA fused to AD
(left panel) or ArsD fused to AD (right panel).
(B) 2 mg His6-ArsD109G86E in 1 ml of buffer was separated by Superdex-75 gel
chromatography, as described above.. Fractions 69-108 were analyzed by 16 % SDSPAGE.
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Figure 3-6. His6-ArsD109G86E activates ArsA ATPase.
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as
described under “Materials and Methods”. (●), no addition; (Δ), His6-ArsD109; (■), His6ArsD109G86E. The curves were fitted using SigmaPlot 9.0, with error bars representing
standard deviation from three assays.
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Figure 3-7. Comparison of R773 ArsD structure and Bacteroides vulgatus ATCC 8482 ArsD.
R773 ArsD structure (pdb: 3KGK) and Bacteroides vulgatus ATCC 8482 ArsD structure (pdb: 3KTB) were compared and
presented in cartoon view with Pymol software.
(A) R773 ArsD structure (pdb: 3KGK) in cartoon view.
(B) Alignment of chain A of R773 ArsD (3KGK) with chain A of Bacteroides vulgatus ATCC 8482 ArsD (3KTB) with
cysteine residues shown in stick.
(C) Bacteroides vulgatus ATCC 8482 ArsD structure (pdb: 3KTB) in cartoon view with cysteine residues shown in stick.
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Figure 3-8. ArsDP52L dimerize more strongly with wild type ArsD in yeast two-hybrid.
S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was
grown in SD medium overnight and inoculated with 10-fold serial dilutions on SD agar plates, lacking histidine and
supplemented with different concentrations of 3-AT. Top panel shows wild-type ArsD and ArsD P52L fused to BD cotransformed with wild-type ArsD fused to AD. Bottom panel shows wild-type ArsD and ArsD P52L fused with BD cotransformed with wild-type ArsA fused to AD.
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Figure 3-9. A hypothetic dimerization interface.
R773 ArsD structure (pdb: 3KGK) was rendered by Pymol, with backbone shown as cartoon. A patch of residues
including Leu48, Phe52, Met53, Phe55, Val56, Val61, Ile66 and Ala70 was shown with stick and labeled. These residues
are colored in magenta in one subunit and blue in another subunit.
(A) Full view of a second dimerization interface between subunits from different asymmetric units.
(B) Magnified view of the interface.
(C) and (D) view of the hydrophobic patch from the top.
(E) Interface shown with the surface of the hydrophobic patch.
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Figure 4-1. ArsD mutants showing stronger interaction with ArsA.
S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was
grown in SD medium overnight and inoculated with 10-fold serial dilutions on SD agar plates, lacking histidine and
supplemented with different concentrations of 3-AT. Left 4 strips show wild-type ArsD or ArsD mutants fused to BD cotransformed with wild-type ArsA fused to AD. Right 4 strips show wild-type or ArsD mutants fused with BD co-transformed
with wild-type ArsD fused to AD. The ArsD mutants were indicated on the left.
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Figure 4-2. Mutating Lys37 and Lys62 to alanine abolishes ArsD function as an
arsenic chaperone.
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as
described under “Materials and Methods”. The curves were fitted using SigmaPlot 9.0,
with error bars represent standard deviation.
(A) (○), no addition; (●), ArsD109; (▼), ArsD109K2/104A-K37/62A; (Δ), ArsD109K2/104A; (□),
ArsD109K37A; (■), ArsD109K62A.
(B) (●), no addition; (○), ArsD109; (▲), ArsD109K2/104A-K60/90A; (Δ), ArsD109K2/104A-K37/62A;
(▼), ArsD109K2/104A-K37/62R.
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Figure 4-3. Acetylation of Lys37 and Lys62 sabotages ArsD metallochaperone
function.
ArsA ATPase activity was assayed at the indicated concentrations of sodium arsenite in
the presence or absence of ArsD derivatives. ArsA ATPase activity was assayed as
described under “Materials and Methods”. (●), no addition; (□), ArsD109; (■), acetylated
ArsD109; (▲), ArsD109K2/104A-K60/90A; (Δ), acetylated ArsD109K2/104A-K60/90A; (▼),
ArsD109K2/104A-K37/62R; (▼), acetylated ArsD109K2/104A-K37/62R. The curves were fitted
using SigmaPlot 9.0, with error bars represent standard deviation.
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Figure 4-4. ArsD K2/104A-K37/62A still binds As(III) but does not interact with ArsA.
(A) The antimony binding ability of ArsD and ArsD mutants was measured by mixing
100 μM of ArsD and 300 μM of potassium antimonyl tartrate. After incubation, the
mixture was passed through gel-filtration column to remove free antimony. Then protein
concentration and antimony concentration was determined to get the antimony binding
molar ratio. Details were described under “Materials and Methods”, and error bars
represent standard deviation.
(B) Yeast two-hybrid analysis was performed as described under “Materials and
Methods.” S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and
binding domain (BD) fusion plasmids was grown in SD medium overnight and
inoculated on agar plates with SD lacking histidine with 10-fold serial dilutions. The first
row was cells with the vector serving as control. ArsD and ArsD mutants were fused to
BD domain, as indicated on the left side. They are tested with ArsA fused to AD (left
panel) or ArsD fused to AD (right panel).
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Figure 4-5. ArsD mutants showing weaker interaction with ArsA and the corresponding complementary ArsA
mutants.
Yeast two-hybrid analysis was performed as described under “Materials and Methods.” S. cerevisiae strain AH109
bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was grown in SD medium overnight
and inoculated on agar plates with SD lacking histidine with 10-fold serial dilutions.

(A) wild-type ArsD or ArsD mutants fused with BD domain were co-transformed with AD-ArsA (ArsA fused with AD) or
AD-ArsD (ArsD fused with AD). As a negative control, AD vector (pACT2) and BD vector (pGBT9) were co-transformed.
(B) ArsA complementary mutants restore interaction with ArsDV22A. Wild-type ArsA or ArsA mutants fused with AD domain
were co-transformed with BD-ArsD (ArsD fused with BD) or BD-ArsDV22A (ArsDV22A fused with BD).
(C) ArsA complementary mutants restore interaction with ArsDF55L. Wild-type ArsA or ArsA mutants fused with AD domain
were co-transformed with BD-ArsD (ArsD fused with BD) or BD-ArsDF55L (ArsDF55L fused with BD).
(D) ArsA complementary mutants restore interaction with ArsDQ51H. Wild-type ArsA or ArsA mutants fused with AD domain
were co-transformed with BD-ArsD (ArsD fused with BD) or BD-ArsDQ51H (ArsDQ51H fused with BD).
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Figure 4-6. ArsA mutants showing stronger interaction with ArsD.
S. cerevisiae strain AH109 bearing both GAL4 activation domain (AD) and binding domain (BD) fusion plasmids was
grown in SD medium overnight and inoculated with 10-fold serial dilutions on SD agar plates, lacking histidine and
supplemented with different concentrations of 3-AT. Wild-type ArsA and ArsA mutants fused with AD domain were cotransformed with BD-ArsD (ArsD fused with BD domain).

Thr20

A

B

Val17

Gln24
Val22
Ser14

Asp28
Val27

Phe55

Thr31
Gln34
Gln38

Lys62

Val61
Gln51

Figure 4-7. Mapping mutations on ArsD structure.
An ArsD structure model based on R773 ArsD structure (pdb: 3KGK) was used to show all mutations with effect on ArsAArsD interaction (Ye et al., 2010). The figures are generated with Pymol software. Three cysteine residues Cys12, Cys13
and Cys18 are colored in magenta. Residues Val17, Val22, Val27, Lys37, Gln51, Phe55 and Lys62, lowing down the
interaction strength, are colored in red. Residues Ser14, Thr20, Gln24, Asp28, Thr31, Gln34, Gln38 and Val61, increasing
interaction strength, are colored in blue. All these residues are shown with stick.
(A) in cartoon view.
(B) in cartoon view with surface.
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Figure 4-8. Mapping mutations on ArsA structure.
ArsA structure (pdb: 1F48) was used to show all mutations with effect on ArsA-ArsD interaction. The figures are
generated with Pymol software. ArsA-A1 part (residues 1-297) is shown in green. ArsA-A2 part (residues 308-586) is
shown in orange. Three cysteine residues Cys113, Cys172 and Cys422 are colored in magenta. Residues Phe120,
Asp121 and Glu425, increasing interaction strength, are colored in blue. All these residues are shown with stick.
(A) front view.
(B) bottom view.
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Figure 4-9. Comparison of ArsA and Get3 structure (Ye et al., 2010).
ArsA was superimposed with closed and open Get3.
(A) Superimposition of ArsA (PDB ID: 1IHU) with Get3 closed structure (PDB ID: 2WOJ). ArsA-A1 (green), ArsA-A2
(orange), Get3 monomer-1 (Blue) and Get3 monomer-2 (light-blue) are shown as cartoon.
(B) Superimposition of ArsA-A1 (residues 1-297) and ArsA-A2 (residues 298-583) with Get3 open structure
(2WOO). ArsA-A1 (green), ArsA-A2 (orange), Get3 monomer-1 (Blue) and Get3 monomer-2 (gray) are shown as
cartoon.
(C) ArsA open structure was modeled based on the Get3 open structure. ArsA-A1 (green) and ArsA-A2 (orange) are
shown as a cartoon representation. Cysteine residues are shown in ball and stick with yellow color.
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Figure 4-10. Structure model of ArsA-ArsD complex (Ye et al., 2010).
ArsA-ArsD model was calculated with Cluspro docking server. One of the best models is shown here. ArsA is rendered
as cartoon with green and orange color. ArsD model is shown in cyan. As(III)/Sb(III) atom is shown as solid sphere in
magenta color and cysteines (yellow) are shown as ball and stick.
(A) In cartoon view.
(B) Figure 8A is shown in surface representation with 40% transparency.
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Arsenic is a metalloid toxicant that is widely distributed throughout the earth’s
crust and causes a variety of health and environment problems. As an adaptation to
arsenic-contaminated environments, organisms have developed resistance systems. In
bacteria and archaea various ars operons encode ArsAB ATPases that pump the
trivalent metalloids As(III) or Sb(III) out of cells. In these operons, an arsD gene is
almost always adjacent to the arsA gene, suggesting a related function. ArsA is the
catalytic subunit of the pump that hydrolyzes ATP in the presence of arsenite or
antimonite. ArsB is a membrane protein which containing arsenite-conducting pathway.
ArsA forms complex with ArsB, therefore ATP hydrolysis is coupled to extrusion of As(III)
or Sb(III) through ArsB.
Most transition and heavy metal ions do not exist as free ions in the cytosol but
are sequestered by a variety of proteins called metal ion chaperones, scaffolds or
intracellular carriers. ArsD was recently shown to be a chaperone for transfer of
cytosolic As(III) to the 583-residue ArsA ATPase, the catalytic subunit of the efflux pump.
ArsD is a 120-residue protein with three conserved cysteine residues, Cys12, Cys13
and Cys18 required for chaperone activity. ArsA exhibits a low, basal rate of ATPase
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activity in the absence of As(III) or Sb(III) and a higher, activated rate in their presence.
ArsA has a high affinity metalloid binding site composed of Cys113 and Cys422 and a
third residue, Cys172, which participates in high affinity binding and activation of ATP
hydrolysis. By directly transferring As(III) to ArsA, ArsD also increased ArsA ATPase
activity at environmental concentrations of arsenic. Therefore, ArsAB pump efficiency is
increased and less As(III) will be accumulated in the cells. In analogy with the
mechanism of copper transfer from chaperones to copper pumps or enzymes, a stepwise transfer of As(III) from the cysteines of ArsD to the cysteines of ArsA, was
proposed.
The properties of As(III) binding by ArsD and subsequent transfer to ArsA were
examined. X-ray absorption spectroscopy was used to show that As(III) is coordinated
with three sulfur atoms, consistent with Cys12, Cys13 and Cys18 forming the As(III)
binding site. An assay using intrinsic protein fluorescence was developed as a probe of
metalloid binding to ArsD. Two single tryptophan derivatives of ArsD were constructed
by changing either Thr15 or Val17 to tryptophan in a tryptophan-free background. Both
exhibited quenching of fluorescence upon binding of As(III) or Sb(III), from which the
apparent affinity for metalloid could be estimated. Since it is likely that cytosolic As(III) is
bound to reduced glutathione (GSH), the effect of GSH on binding to ArsD was
examined. GSH greatly increased the rate of binding As(III) to ArsD, suggesting that
ArsD accepts metalloid from the As(GS)3 complex. In contrast, GSH did not affect the
As(III)-stimulated ArsA ATPase activity, suggesting that As(III) is directly transferred
from ArsD to ArsA, as opposed to release from ArsD, binding to GSH and then
interaction of ArsA with the As(GS)3 complex.

To differentiate between these two
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possibilities, the effect of the As(III) chelator dimercaptosuccinic acid (DMSA) was
examined. The chelator did not affect transfer, indicating channeling of As(III) from ArsD
to ArsA. Transfer occurs only under conditions where ArsA hydrolyzes ATP, suggesting
that ArsD transfer As(III) to an ArsA conformation transiently formed during catalysis
and not simply to the closed conformation that ArsA adopts when As(III) and MgATP
are bound.
R773 ArsD was shown to be a dimer in crystal structure. Whether the
dimerization form is a physiological one existing in the solution, was studied by
mutagenesis. Residues, Ser68, Arg87 and Arg96, involved in dimerization were
mutated to alanine. ArsD dimerization equilibrium was shifted to the monomer direction
by mutating these residues to alanine, but not totally a monomeric form. One mutant
ArsDG86E was selected from reverse yeast two-hybrid analysis, showing no dimerization
with wild-type ArsD. Gel-filtration chromatography confirmed mutation G86E shifts ArsD
dimerization equilibrium to the monomer direction, but not totally change ArsD to a
monomeric form. Since Gly86 sits on the dimerization interface in the crystal structure, it
is most likely the crystallographic ArsD dimer forms in the solution. All these mutants
still retain the ability to stimulate ArsA ATPase activity, suggesting dimerization is not
strictly required for ArsD metallochaperone function.
ArsA and ArsD crystal structure have been solved individually. But little is known
about ArsA-ArsD interaction interface. Yeast two-hybrid and reverse yeast two-hybrid
are combined to select for totally 14 ArsD mutants with weaker or stronger interaction
with ArsA. Additionally, Lys37 and Lys62 were shown to be important for ArsD function
by site-directed mutagenesis. ArsD loses function when Lys37 and Lys62 were mutated
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to alanine as well as acetylated by Sulfo-NHS acetate. The charge carried by Lys37 and
Lys6 was shown to be important since protein is still active when they are mutated to
arginine. Yeast two-hybrid confirmed mutating Lys37 and Lys62 to alanine has effect on
ArsA-ArsD interaction. Mapping all the mutations on ArsD structure gives us information
on ArsA-ArsD interaction interface. Four residues, Ser14, Val17, Thr20 and Val22, are
in the loop containing the important metal binding site Cys12-Cys13-Cys18. This
suggests the metal binding site may be directly involved in the interaction with ArsA.
Seven residues, Gln24, Val27, Asp28, Thr31, Gln34, Lys37 and Gln38 are located on
helix α1. They are aligned at one side of helix α1 and solvent exposed, suggesting this
region might be directly involved in interaction. A structure model of ArsA-ArsD complex
was generated by docking. The model suggested an extensive interaction interface at
multiple directions, consistent with most of the yeast two-hybrid results.
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